Index to Volume 55—1987

AUTHOR INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), book reviews (B), reprinted articles (R), and Workshop on Experimental Chemotherapy of Leprosy supplement (S).

ABALOS, R. M., (C) 718
ABE, M., (A) 742, 774
ABUD-MENDOZA, C., (O) 651
ACHENBACH, R., (A) 587
ADAMS, L. M., (A) 593
AGARWAL, S., (A) 583
AGUADO SANCHEZ, G., (A) 743
AHRENS, E. M., (A) 607
AIT-KHALED, A., (A) 393
AIZER, F., (A) 609
AKIMOV, V. G., (A) 375
AKUFFO, H., (A) 595
ALBERICI, F., (A) 393
ALCOCER-VARELA, J., (O) 651
ALLEN, J. L., (A) 182
ALMEIDA, J. G., (C) 726
ALTYNOVA, M. P., (A) 763
ALVARENGA, A. E., (A) 576
AMEZCUA, M. E., (O) 286
ANANDADASAN, P. K., (C) 555
ANANDAN, D., (A) 174
ANANDARAJ, H., (A) 375
ANDAVOLU, R. H., (A) 186
ANDERSEN, B. R., (A) 784
ANDERSON, D. C., (A) 406, 594, 743, 745
ANDERSON U., (A) 382
ANDRADE, V. L. G., (O) 435
ANTIA, N. H., (A) 173, 176, 381, 592
APPA RAO, A. V. N., (A) 372
ARANZAZU, N., (C) 351, (O) 646
ARCE, P., (A) 391
ARDEN JONES, M. P., (A) 185
ARNOLD, J. J., (A) 784
ARORA, S. K., (A) 577
ARRUDA, W. O., (A) 378
ASENSIO, A. S., (C) 357
ASHMALLA, L., (A) 590
ASHWORTH, M., (A) 176
ASPINALL, G. O., (A) 380
ASSELINEAU, C., (A) 180
AUSINA, V., (A) 607
AVELLEIRA, J. R., (O) 435
AVERBAKH, M. M., (A) 761
AYTEKIN, A. H., (A) 183
AZULAY, R. D., (O) 450

BABU, T. S., (A) 395
BACCHI, C. E., (O) 338
BACH, M.-A., (O) 305, (A) 390, (O) 626, (A) 757
BACIEWICZ, A. M., (A) 577
BADELON, I., (A) 378
BAESS, I., (A) 180
BAIRD, B., (A) 396
BAJAJ, A. K., (A) 174
BALACHANDRAN, C., (C) 559
BALAKRISHNAN, S., (A) 174, 371, 577
BALDWIN, B., (A) 403
BALTA, Y. E., (A) 763
BALYBIN, E. S., (A) 742
BAND, A. H., (A) 178
BAND, H., (C) 563
BANSAL, R., (O) 499
BAQUILLON, G., (A) 387, 739
BARANDA, L., (O) 651
BARBOSA, J., (A) 378
BARNASS, S., (A) 379
BASKIN, G. B., (O) 109, (A) 417, 418
BASSI, F., (A) 393
BASTEN, A., (O) 277, (A) 379, 744
BATES, J. H., (A) 608
BAZUROV, G. I., (A) 375
BECK, J. S., (A) 381, 747, 748
BECX-BLEUMINK, M., (A) 578
BEIGUELMAN, B., (C) 357
BEKEMEYER, W. B., (A) 577
BELL-KROTOSKI, J., (A) 394, 414
BENNAN, P. J., (A) 409
BENNEDSEN, J., *et al.*, (A) 176
BEOHAR, P. C., (A) 179
BERCOUVIER, H., (A) 388
BERCOVIER, H., (A) 609
BEREZOUSKY, B. A., (A) 761
BERGSVIK, H., (O) 617
BERKELEY, J. S., (A) 583
BERLIN, O. G., (A) 765
BEUERMAN, R. W., (A) 418
BHAGARIA, A., (A) 583
BHAGAT, N., (A) 607
BHALERAO, V. R., (A) 582
BHARADWAJ, V. P., (O) 328, (A) 373
BHAT, K. S., (C) 559
BHATE, R. D., (A) 172, 376, 590
BHATIA, V. N., (A) 173, 174, (C) 555, (A) 582
BIAN, J., (A) 370
BINFORD, C. H., (O) 109, (A) 181, 417, 418, 788
BIRKE, J. A., (A) 184, 415, 416
BJUNE, G., (O) 261
BJUNE, G. J., (C) 548

Black, J. R., (A) 175
Blake, L. A., (A) 758
Bliss, L., (O) 454
Bloom, B. R., (A) 179, 594, 745, 750, 782
Bobhate, S. K., (A) 590
Bobin, P., (O) 672
Bodian, M., (A) 584
Boerrigter, G., (A) 182, 183, 578
Bona, S. H., (A) 605
Bose, S., (O) 667
Bottasso, O. A., (A) 593
Boucher, P., (A) 584
Bourland, J., (A) 586
Bourrel, P., (A) 184
Bousquet, J. C., (A) 371
Bouvry, M., (A) 373
Bovornkitti, S., (A) 610
Bradley, A. K., (A) 580
Brand, P. W., (A) 607, 607, 607
Brandsma, J. W., (A) 394
Breger, D., (A) 414
Brennan, P. J., (A) 179, 380, 408, 594, 596, 597, (O) 617, (A) 755, 775, 782
Brett, S. J., (A) 389, 743
Brightmer, I., (A) 605
Britton, S., (A) 382, 596
Britton, W. J., (A) 379, 594, 744, 745
Brown, A., (C) 551
Brown, A. E., (A) 379
Brown, W. B., (A) 744
Brucker, G., (O) 672
Bucci, F., Jr., (A) 742
Buchanan, T. M., (A) 406, 594, 603, 743, 745
Budhraja, B. K., (A) 174
Bulakh, P. M., (A) 766
Bullen, M. G., (A) 188
Bullock, W., (C) 551
Busharnamath, S. A., (O) 499
Bussell, A., (A) 592
Butler, R., (A) 389

Cabane, J., (A) 378
Cai, Z., (A) 392
Callen, J. P., (A) 607
Camara, M., (A) 584
Cardama, J. E., (A) 385
Cartel, J.-L., (A) 392, (O) 626, 672
Cassidy, J. J., (N) 165
Caticha-Alfonso, O. S., (C) 357
Cazares, J. V., (O) 286
Celona, R. V., (C) 718
Centers for Disease Control, (A) 608
Chacko, C. J. G., (O) 515
Chae, G. T., (A) 782
Chakrabarty, A. N., (A) 755
Chakraborti, C. K., (A) 375
Chakravarti, R. N., (A) 391, (O) 499
Chandi, S. M., (O) 515
Chang, W.-C., (A) 179
Chanteau, S., (O) 626
Chapon, F., (A) 579
Char, G., (A) 375
Chatterjee, B. D., (A) 375
Chatterjee, D., (A) 380
Chattopadhyay, S. P., (A) 172, 173, 376
Chaturvedi, R. M., (O) 657
Chaudhuri, S., (A) 375
Chauhan, V. S., (A) 605
Chawhan, R. N., (A) 766
Chehl, S. K., (A) 410, (C) 722
Cheikh, F., (A) 393
Chen, D., (A) 371
Chen, J., (A) 373, 740
Chen, L., (A) 750
Chen, Q., (A) 760
Chevallard, A. J., (O) 16, (C) 160
Ching, C. Y., (A) 746
Chiplunkar, S., (A) 380, 748
Chirmule, N. B., (O) 657
Cho, S.-N., (A) 380
Choi, I. H., (A) 183
Chopra, N. K., (O) 316
Chukanov, V. I., (A) 763
Clark-Curtiss, J. E., (A) 405, 788, 789
Clavel-Seres, S., (A) 185
Clavijo, P., (A) 752
Clement, F., (A) 185
Closs, O., (A) 388, 594, 745
Coates, A. R. M., (A) 185, 763
Cocito, C., (A) 600
Coddi, Z., (A) 173
Cohn, Z. A., (A) 177, 178, 596, 747, 748, 785
Coleman, W. C., (A) 415, 607
Collins, C. H., (A) 185
Collins, F. M., (A) 413
Colston, M. J., (A) 180, 743, (S) 819, 836, 859, 885, 896
Conant, R., (A) 745
Condom, M. J., (A) 607
Constant-Desportes, M., (O) 672
Converse, P. J., (O) 261, (C) 548, (A) 779
Convit, J., (C) 351, (O) 646
Cooper, C. L., (A) 750
Cordoliani, G., (O) 16
Cortez, A., (A) 371
Cottenot, F., (A) 592
Courrege, M. L., (A) 383
Crawford, J. T., (A) 608
Cree, I. A., (A) 381
Cremer, A. W. F., (A) 186
Cross, J. N., (A) 375
Crowle, A. J., (A) 186
Cruz, N., (A) 610
Curet, P., (A) 371
Curtis, J., (A) 383, 595, 595
Curtiss, R., III, (A) 789
Cutler, E., (O) 267

da Costa, R. J., (A) 605
da Cunha, L. H. V., (O) 435

DA FONSECA, A. DEP. M., (A) 605
DA SILVA, D. C., (A) 579
DAFFE, M., (A) 180
DAHIYA, R., (C) 162
DAID, H. L., (A) 187
DALUZ, W., (A) 376
DARBRE, A., (A) 756
DAS, S., (A) 755
DASTIDAR, S. G., (A) 755
DATTA, A. K., (O) 680
DAUMERIE, D., (A) 376, 576
DAVID, H. L., (A) 185, 186, 762
DAVY, C., (A) 371
DAYAON, E., (A) 746
DE BEAUMONT, W., (A) 750
DE BRACCO, M. M. DE E., (A) 385
DE CARLI, E. I., (C) 560
DE JONG, N., (A) 394
DE LA BARRERA, S., (A) 385
DE LEY, M., (A) 382
DE LIBERO, G., (A) 380, 748
DE VRIES, R. R. P., (O) 261, (A) 384, (O) 521, (A) 609, 745, 779
DE WIT, M. Y. L., (A) 580, 749
DECAZES, J. M., (A) 739
DEI CAS, A., (A) 393
DEL PORTILLO, P., (A) 752
DELVILLE, J., (A) 600
DENG, Y., (A) 739
DEO, M. G., (O) 657
DEPASQUALE, G., (A) 579
DERIDDER, K., (A) 788
DESCHAMPS, P., (A) 579
DESIKAN, K. V., (O) 1
DETOEUF, G., (A) 738
DEWAR, C. A., (C) 565
DHARIWAL, K. R., (A) 387, 755
DHERMY, P., (A) 378
DHIR, R., (A) 579
DHOPAVKAR, P. V., (A) 173
DHOPLE, A. M., (A) 172, 179, 402, 588, 601, 778
DIETERLE, W., (O) 9
DIETRICH, M., (A) 579
DIIORO, L., (O) 305
DIOP MAR, I., (A) 605
DIOUF, B., (A) 738
DISCAMPS, G., (A) 393
DITTRICH, M., (A) 173
DIXON, J. F. P., (A) 386
DOBSON, G., (A) 180
DOEHRING, E., (A) 173
DOGA, J., (A) 761
DOI, E., (A) 378
DONG, X., (A) 754
DONINI, P., (Ob) 713
DOROZHKOVA, I. R., (A) 763
DOUGLAS, J. T., (A) 383, (C) 718
DOUSSET-FAURE, I., (A) 739
DOUVAS, G. S., (A) 186
DOWD, P. M., (A) 175
DRAPER, P., (A) 180, 755, 756, 756, 781
DRESSEL, L., (A) 416
DROGARI, P., (O) 463
DROSOS, A. A., (A) 594
DU, J., (A) 758
DUARTE, I., (A) 177
DUBEY, A. L., (A) 591
DUBOIS, J.-P., (O) 9
DUFFUS, P., (A) 583
DUNCAN, M. E., (A) 174
DUPUY, B., (A) 579
DWIVEDI, M. P., (A) 605

EGGELTE, T. A., (A) 580
EHRENBERG, J. P., (A) 779
EISENACH, K. D., (A) 608
EJIMOVA, A. A., (A) 765
ELFERINK, D. G., (A) 384
ELISAF, M. S., (A) 594
ELL, S. R., (E) 345, (A) 401
ELLNER, J. J., (A) 188
ELVERS, U., (A) 178
EMMERSON, A. M., (A) 186
EMMRICH, F., (A) 594
ENGERS, H. D., (A) 176, 743
ENGLEMAN, E. G., (A) 383
EREMEEV, V. V., (A) 761
ESCOBAR-GUTIERREZ, A., (O) 286
ESSER, R. E., (A) 789
ESTRADA-PARRA, S., (C) 716

FADEEVA, N. I., (A) 763
FAFUTIS-MORRIS, M., (C) 566
FAJARDO, T., (C) 718
FALES, H. M., (A) 387, 755
FAN, H.-X., (A) 378
FARINA, M. H., (C) 560
FAUCHI, A. S., (A) 396
FERNANDEZ, R., (A) 609
FINDLAY, G. H., (A) 738
FINE, P. E. M., (O) 88, 454, (A) 745
FISHBEIN, D. B., (A) 597
FLAGEUL, B., (O) 672
FLESCH, I., (A) 748
FLEURY, R. N., (O) 338
FONTAINE, M., (A) 378
FORGET, A., (O) 63
FOSTER, F., (A) 403
FOSTER, R., (A) 403
FOX, W., (A) 762
FRANKLIN, R. M., (A) 418
FRANZBLAU, S. G., (B) 369, (A) 402, 403, 412, 602, 783
FREERKSEN, E., (A) 182
FREHEL, C., (A) 762
FRIED, P., (A) 775
FU, Q., (A) 377
FUCHS, D., (A) 599
FUJIMIYA, Y., (A) 179
FUJIWARA, H., (A) 188

FUJIWARA, T., (A) 790
FUKUNISHI, Y., (A) 181, 384
FUKUSHIMA, N., (A) 599
FUSCO, F., (A) 409

GALLAIS, J. J., (A) 392
GALLINOTTO, M. E., (O) 646
GANAPATI, R., (A) 585, 587, 603
GANDHI, I. S., (A) 584
GANDHI, R. R., (A) 596
GANGULY, N. K., (C) 162, 358, (A) 390, 391, 597, 604
GARCIA, R., (O) 651
GARDNER, I. D., (A) 181
GARSIA, R. J., (A) 379, 744
GATTI, J. C., (A) 385, (C) 560, (N) 731
GAUTAM, R. K., (A) 179, 386
GAYLORD, H., (A) 179
GEARY, N. P. J., (A) 606
GELBER, R. H., (O) 78, (C) 353, (A) 383, 390, (C) 554, (A) 580, 776, (S) 872, 879
GEORGE, J., (A) 174, 371
GERASIMOVA, E. V., (A) 763
GERSUK, G. M., (A) 750
GERVASONI, B., (A) 379
GIARDINA-BECKET, M., (A) 409
GIBBELS, E., (O) 333
GIDEL, R., (A) 396
GIGG, J., (A) 745
GIGG, R., (A) 745
GILL, H. K., (O) 30, (A) 177, 746, 750
GILL, V., (A) 396
GILLILAND, B. C., (A) 590
GILLIS, T. P., (O) 54, (A) 381, 405, 408, 410, 419, 594, 745
GIRDHAR, A., (A) 739
GIRDHAR, B. K., (A) 373, 739
GIROIR, A.-M., (O) 70
GODAL, T., (O) 30, (A) 177, 187, 746, 750
GOGIYA, P., (O) 316
GONZALEZ, A. B., (A) 371
GONZALEZ-ABREU, E., (A) 371
GONZALEZ-AMARO, R., (O) 651
GONZALEZ-MENDOZA, A., (C) 566
GOOD, R. C., (O) 322
GOPALAKRISHNAN, S., (A) 371
GORDER, D., (O) 633
GOREN, M. B., (A) 387, 755
GORMUS, B. J., (O) 109, (A) 384, 416, 417, 417, 418, 751
GOTTLIEB, M. S., (A) 765
GRANGE, J. M., (C) 565, (A) 753
GREEN, K. J., (A) 172, 601
GREENWOOD, A. M., (A) 580
GREENWOOD, B. M., (A) 580
GREER, W. E., (A) 417
GREGORY, D., (A) 180
GRELLET, J., (A) 371
GRIFFITHS, D., (A) 595
GRILLONE, S., (A) 586, 739
GRIMES, G., (A) 396

GROSSET, J., (A) 581, 584, (S) 807
GROSSET, J. H., (O) 70, (A) 392, (O) 672, (S) 847, 852, 889, 899
GROSSETETE, G., (A) 376
GROVER, S., (A) 173, 590
GRUNEBERG, R. N., (A) 186
GU, G., (A) 754
GUELPA-LAURAS, C.-C., (O) 70, 672, (S) 847, 889
GUHA, P. K., (A) 182, 579, 590
GUHA, S. K., (A) 175
GUIDI, C., (O) 626, 672
GUILLAUME, J.-C., (O) 672
GULL, K., (A) 595
GUMARAES PROENCA, N., (A) 177
GUNICH, L. A., (A) 762
GUNTER, J. R., (O) 494, (A) 750
GUPTA, A. K., (A) 591
GUPTA, C. M., (A) 172, 173, 174, 376, 590, 598
GUPTA, H. P., (A) 604
GUPTA, O. P., (A) 175, 590
GUPTA, S. C., (A) 174
GUPTA, S. K., (O) 42, (A) 178

HA, D. K. K., (A) 181
HACBARTH, E., (A) 378
HACHTEL, G., (A) 588
HADLEY, W. K., (A) 765
HALL, R. M., (A) 180, 387
HALLER, R., (A) 588
HANLY, W. C., (A) 597
HAQ, G., (A) 370
HARBOE, M., (A) 384, (B) 574, (A) 594, 610, (O) 617, (A) 746, 746
HAREGEWOIN, A., (A) 750
HARGRAVE, J. C., (O) 277
HARIKRISHNAN, S., (A) 173, 174
HARNISCH, J. P., (O) 441, (A) 590, (O) 633
HARRIS, D., (O) 267
HARRIS, E. B., (A) 181, 182, 402, 403, 419, 587, 740
HARSHAN, K. V., (O) 316
HARTSKEERL, R. A., (A) 749
HASTINGS, R. C., (E) 140, (B) 170, (A) 181, 182, (O) 299, (A) 391, 403, 407, 410, 419, 419, 420, (B) 574, (A) 587, 603, (O) 685, (C) 722, (A) 781
HAUBENSTOCK, H., (O) 267
HAUPT, W. F., (O) 333
HAUSEN, A., (A) 599
HE, S., (C) 556
HELLQVIST, L., (A) 379, 744
HENKE, U., (O) 333
HERNANDEZ, O., (A) 371
HERVIO, P., (A) 373
HIBINO, T., (A) 381
HILBERS-MODDERMAN, E. S. M., (A) 374
HINRICHSEN, L., (A) 593
HIRATA, M., (A) 188
HIRAYAMA, K., (A) 749
HOFFENBACH, A., (O) 305, (A) 390, 757
HOFMAN, F. M., (O) 494
HOKAMA, Y., (A) 746

HOLOSHITZ, J., (A) 188
HOLZER, T. J., (A) 784
HONG, D., (A) 392
HORWITZ, D. A., (A) 179
HOUBA, V., (A) 176
HOUSE, P. H., (A) 174
HOWARD, M. K., (A) 595
HSU, P.-S., (A) 381
HU, Y., *et al.*, (A) 758
HUANG, C. T., (A) 186
HUANG, H., (A) 182
HUGH-JONES, M. E., (A) 419, 420
HUI, D., (A) 739
HUIKESHOVEN, H., (A) 580
HUNT, R., (O) 685
HUNTER, S. W., (A) 179, 782
HUSER, J. A., (A) 739
HUSSEIN, S., (A) 595, 595
HUSSEIN, Y. M., (A) 747, 748
HUSSER, J. A., (A) 376, 576, 586, 587, 740
HUSSON, R. N., (A) 595

IKEDA, M., (A) 790
IMAEDA, T., (A) 180
INDERLIED, C. B., (A) 765
IRGENS, L. M., (A) 603
ISERSON, K. V., (A) 581
ISLAS-RODRIGUEZ, A. E., (C) 566
ITO, T., (A) 778, (S) 807, 885, 889, 899
ITTY, B. M., (A) 381
IVANYI, J., (A) 594, 594, 600, 745, 746, 747, 749
IWAMOTO, L., (A) 746
IZAKI, M., (A) 381
IZAKI, S., (A) 381
IZUMI, S., (A) 790

JACOBSON, R. R., (A) 372
JAGADHA, V., (A) 186
JAGANNATH, K., (A) 389
JAGANNATHAN, R., (A) 583
JAGIRDAR, P. C., (A) 185, 590
JAIN, A. P., (A) 175, 590
JAIN, G. L., (A) 175
JAJOO, U. N., (A) 175, 590
JALED, M. M., (C) 560
JAMUMDAR, S., (C) 162
JANSSENS, L., (A) 586, 587
JAYALAKSHMI, P., (O) 510
JENA, S. K., (A) 395
JENKINS, P. A., (A) 180
JENNER, P. J., (A) 581
JESSEN, K. R., (A) 753
JESUDASAN, K., (A) 583
JI, B., (S) 807, 830, 836, 899
JIANG, C., *et al.*, (A) 758
JIMENEZ, C., (A) 752
JING, X., (A) 760
JOB, C. K., (O) 54, (A) 182, (O) 299, (A) 391, 410, 419, 420, 420, (O) 507, 685, (C) 722
JOHNSTONE, P. A. S., (E) 535
JOPLING, W. H., (A) 582
JOSHI, A. V., (A) 591
JUSCENKO, A. A., (N) 736, (A) 757

KAJDACSY-BALLA, A. A., (A) 378
KAKLAMANI, E. P., (O) 463
KALDANY R.-R. J., (A) 596, 747
KALTER, D. C., (A) 376
KALTHOFF, P. G., (A) 582
KALYANKAR, S. D., (A) 605
KANA, B., (A) 751
KANDLER, O., (A) 756
KANEDA, S., (A) 189
KANSY, M., (A) 588
KAPLAN, G., (A) 177, 178, 596, 747, 748, 785
KAPOOR, K. K., (A) 591
KAR, H. K., (A) 582
KARACHUNSKY, M. A., (A) 763
KARALIS, D. T., (O) 463
KARP, W. B., (A) 172
KARTIKEYAN, S., (A) 582
KATARIYA, S., (O) 499
KATO, L., (C) 157, (A) 361, 602
KATOCH, K., (O) 1, 680
KATOCH, V. M., (O) 680
KATSOUYANNI, K. M., (O) 463
KAUFMANN, S. H. E., (A) 380, 594, 748
KAUR, H., (A) 391, 604
KAUR, P., (A) 182, 377, 590
KAUR, S., (C) 162, (O) 273, (C) 358, (A) 390, 391, (O) 499, (A) 597, 604
KAZACHKOVA, T. E., (A) 765
KAZDA, J., (A) 587, 603
KEDAR, G. P., (A) 590
KEE, T. S., (A) 762
KERR, M. A., (A) 747, 748
KHER, A. V., (A) 173, 590
KHERA, V. R., (A) 405
KHERDEKAR, M., (A) 173
KHODZITSKAYA, V. K., (A) 766
KHOMENKO, I. S., (A) 761
KHOR, M., (A) 763
KIESSLING, R., (A) 779
KIKUCHI, I., (A) 749
KIM, D. I., (A) 597
KIM, H. B., (A) 596
KIM, J. D., (A) 183
KIM, M. Y., (A) 596
KIM, P. S., (A) 744
KIM, S. J., (A) 183
KING, R., (A) 576
KINGSTON, A. E., (A) 743
KLATSER, P. R., (A) 749
KLENERMAN, L., (A) 606
KLENERMAN, P., (E) 702
KLIEMANN, T. A. E., (A) 177
KLINGMULLER, G., (O) 333, (Ob) 714
KLYUEV, B. V., (A) 763
KOCH, P., (A) 592
KOGAN, E. S., (A) 765

KOHSAKA, K., (A) 778, (S) 885, 889
KOLK, A. H. J., (A) 594, 745, 749
KORANNE, R. V., (A) 179
KORONELLI, T. V., (A) 763
KOSTER, F. T., (A) 597
KOSTINA, Z. I., (A) 763
KOTAMBE, D. S., (A) 605
KOTENKO, T. V., (A) 763
KOUMANTAKI, I. G., (O) 463
KRAHENBUHL, J. L., (A) 386, 407, 411, 412, 603, 781, 782, 783
KRISHNA, D. R., (A) 372
KROTOSKI, W. A., (A) 383
KRUPASHANKAR, D. S. R., (C) 159
KULKARNI, S. S., (A) 591
KUMAR, A., (A) 577, 591
KUMAR, B., (C) 162, (O) 273, (C) 358, (A) 390, 391, (O) 499, (A) 597, 604
KUMAR, J., (A) 590
KUMAR, K., (A) 175
KUMAR, N. S., (A) 377
KUMAR, S., (A) 178
KUSAKA, T., (A) 387
KUSHAWAHA, S. S., (A) 605
KVACH, J. T., (A) 609
KYAZIMOVA, L. M., (A) 763

LAAL, S., (A) 178, (O) 481
LABIDI, A., (A) 186, 187
LAKSHMI, V., (A) 377
LAL, B. B., (A) 761
LALITHA, V. S., (O) 23
LAMB, J. R., (A) 189, 600, 749
LAMBA, P. A., (A) 175, (O) 667
LAMBERT, P. H., (A) 743
LAMBERT, W. C., (A) 742
LANE, H. C., (A) 396
LANEELLE, M. A., (A) 180
LANGHORNE, P., (A) 583
LANGUILLON, J., (A) 739
LARRABEE, W. A., (A) 744
LARRICK, J., (O) 249
LARSSON, L., (A) 180
LARY, C. H., (A) 758
LAU, B. H. S., (A) 403
LAWRENCE, K., (A) 416
LAWTON, J. W. M., (A) 181
LE HOANG, P., (A) 378
LEBEDEVA, L. V., (A) 763
LECHEVALIER, B., (A) 579
LEE, C. W., (A) 597
LEE, H. Y., (A) 597
LEE, Y. N., (A) 180
LEFFORD, M. J., (A) 596
LEI, G., (A) 392
LEIKER, D. L., (A) 583
LELE, V. R., (A) 173
LEVI, D. T., (A) 763, 765
LEVIS, W. R., (O) 267, (A) 381, 408, 409, 596, 775
LEVY, L., (A) 609, (S) 814, 819, 823, 843, 872, 896
LEVY, M. L., (A) 376
LI, F., (A) 388
LI, S., (A) 377
LI, S.-G., (A) 745
LI, W., (A) 187, 372
LI, W., *et al.*, (A) 372
LI, Z., (C) 556
LIEBER, E. B., (O) 468
LIEBER, M. D., (O) 468
LIM, K. J., (O) 510
LIMA DA SILVA, A. C., (A) 605
LIN, Z., (A) 757
LINDH, J., (A) 382
LINDNER, B., (A) 603
LITSEVA, O. A., (A) 765
LIU, J., (A) 182, 382
LIU, S., (A) 187
LIU, W., (A) 740
LIU, X., (A) 757
LIU, Z., (A) 373
LOCNISKAR, M., (O) 249
LOKO, S. D., (A) 584
LONGLEY, B. J., (A) 750
LOOI, L. M., (O) 510
LOOK, J. O., (A) 415
LOOKER, D. L., (A) 186
LOU, H., (A) 754
LOVIK, M., (E) 689
LOWRIE, D. B., (A) 763
LU, J., (A) 392, 394
LU, S., (A) 378
LU, W., (A) 182
LU, W. F., (A) 742
LU, W.-Q., (A) 378
LU, Z., (A) 759
LUCAS, D. C., (O) 249
LUDERSCHMIDT, C., (O) 83
LYGREN, S. T., (A) 388
LYONS, N. F., (A) 591, (O) 637

MA, S., (C) 556
MAASHO, K., (A) 596
MACE, J., (A) 379
MACKWORTH-YOUNG, C., (A) 598
MADARANG, M. C., (C) 718
MADOMBI, L., (A) 591
MAEDA, M., (A) 598
MAGNA, L. A., (C) 357
MAGNUSSON, M., (A) 180
MAHADEVAN, P. R., (A) 389, 405, 583, 587, 757
MAIER, M., (E) 116
MAINE, N. P., (A) 745
MAKONKAWKEYOON, S., (A) 379
MALAMA, I. M., (O) 463
MALATY, R., (O) 109, (A) 418, 788
MALIK, A., (A) 743
MANIAR, J. K., (N) 570
MARINO, L. J., JR., (A) 381
MARQUES, A. B., (O) 435
MARTIN, L. N., (O) 109, (A) 384, 417, 418, 751

Masur, H., (A) 396
Matangkasombut, P., (A) 610
Matemera, B. O., (A) 591
Mathur, A., (A) 373
Mathur, I. S., (A) 604
Matsuo, Y., (S) 836
Matzner, P., (A) 753
Maxwell, B. A., (B) 170
Mayama, A., (A) 576
Mayen, E., (O) 286
McAdam, K. P. W. J., (O) 249
McCormick, G. T., (O) 299, (C) 722
McDermott-Lancaster, R. D., (S) 885, 889
McDougall, A. C., (O) 88
McEniry, D. W., (O) 249
McGavran, M. H., (A) 376
McNeil, G., (A) 742
McNeil, M., (A) 782
Meckler, R. J., (A) 607
Meeker, H. C., (O) 267, (A) 381, 408, 409, 775
Mehra, V., (A) 179, 382, 594, 745
Mehta, J., (A) 584
Melancon-Kaplan, J., (A) 782
Mendez, P., (A) 391
Menigistu, G., (A) 751
Menon, S. K., (C) 159, 355
Menzel, S., (O) 617
Merkus, F. W. H. M., (A) 374
Mesa, M., (A) 742
Mester de Parajd, L., (A) 584
Mester de Parajd, M., (A) 584
Meyers, W. M., (O) 109, (A) 181, 416, 417, 418, 788
Miao, Z., (A) 740
Micks, J. E., (A) 607
Mikami, R., (A) 610
Mikhei, L. V., (A) 761
Miles, M. A., (A) 595
Millan, J., (A) 584, 605, (O) 672, (A) 738, 739
Miller, J. A., (A) 175
Miller, R. A., (O) 441, (A) 590, (O) 633
Millikan, L. E., (A) 383
Minagawa, F., (A) 742
Minnikin, D. E., (A) 180
Mirelis, B., (A) 607
Mirsky, R., (A) 753
Mishra, B., (A) 605
Mishra, R. S., (O) 316, (A) 385, (O) 481
Misra, S. N., (A) 761
Mitchison, D. A., (A) 763
Mitinskaya, L. A., (A) 765
Miyaji, I., (A) 742
Miyata, Y., (A) 778
Modderman, E. S. M., (A) 585
Modlin, R. L., (A) 179, 384, 386, (O) 494, (A) 750, 782, 786
Mohagheghpour, N., (C) 353, (A) 383
Moncada, B., (O) 651
Montreewasuwat, N., (A) 383
Mor, N., (A) 609
Morales-Ortiz, R., (C) 566
Moreira-Diop, T., (A) 584
Mori, T., (A) 387, 786
Morini, J. C., (A) 593
Mosco, W., (C) 351
Moses, V., (A) 379
Mostovoi, Y. M., (A) 761
Motwani, B. K., (C) 559
Moudgil, K. D., (A) 178
Mounts, P., (A) 609
Moutsopoulos, H. M., (A) 594
Mroczkowski, T. F., (A) 383
Mshana, R. N., (A) 407, 407, 419, (C) 548, (A) 751, 781
Mudd, D. W., (O) 249
Mukherjee, A., (A) 416
Mukherjee, R., (A) 176, 381
Mukhija, R. D., (A) 591
Murphey-Corb, M., (O) 109
Murray, L. P., (A) 776
Mustafa, A. S., (O) 30, (A) 187, 746, 750
Muthukkaruppan, V. R., (A) 383

Naafs, B., (A) 591, (O) 637
Nagai, S., (A) 610
Naik, R. P. C., (C) 159, 355
Naik, S., (O) 273
Nair, N. G. K., (O) 425
Nakamura, K., (A) 787
Nakamura, M., (A) 602
Nakanishi, M., (A) 396
Narayanan, P. R., (A) 178, 608
Narayanan, R. B., (A) 598
Narayanan, S., (A) 608
Narita, M., (A) 598
Nassos, P. S., (A) 765
Nath, I., (A) 178, (O) 316, (A) 385, (O) 481, (A) 748, 751
Natvig, I., (A) 750
Naudillon, Y., (A) 392
Naudin, J. C., (A) 584, 738
Nawoczenski, D., (A) 415
Nebout, M., (O) 16, (A) 376, 576
Neelan, P. N., (A) 183, (C) 555
Negesse, Y., (A) 751
Nelson, E. E., (A) 384
Nelson, K. E., (A) 379, (C) 551, (A) 597, 750, 753
Nesterenko, L. A., (A) 765
Neuteboom, S., (A) 384
Nevo, Z., *et al.*, (A) 188
Nigam, P., (A) 591
Nilsen, R., (A) 407, 751
Nishimura, Y., (A) 790
Nishiura, M., (O) 328
Nollet, E., (A) 587
Nomaguchi, H., (A) 594, 745
Nurlign, A., (A) 747
Nusrat, A., (A) 748

Obrosova, T. I., (A) 763
Ochiai, T., (A) 189

Oftung, F., (A) 750
Ogawa, K., (O) 328
Ohashi, D. K., (A) 404
Ohkawa, S., (A) 384, 417, 751
Ohman, R., (A) 596
Okhandiar, R. P., (A) 377
Okushita, T., (A) 742
Olcén, P., (A) 384
Oltra, A., (A) 391
Onsun, N., (A) 585
Oommen, P. K., (A) 395
Orme, A. M., (O) 293
Ortiz-Ortiz, L., (C) 566
Osborne, L. J., (A) 778
Ottenhoff, T. H. M., (O) 261, (A) 384, (O) 521, (A) 609, 745, 779, 779
Ottinger, M. L., (A) 175
Oughanem, M., (A) 393
Ozawa, T., (A) 749
Ozeretskovsky, N. A., (A) 765

Padhee, A., (C) 355
Padma, M. N., (A) 173
Palande, D. D., (A) 606, 606
Pan, R., (A) 759
Pan, X., *et al.*, (A) 760
Pan, Y., (A) 187
Pandey, S. S., (A) 182, 590
Pandya, S. S., (O) 23, (C) 562
Pankajam, R., (C) 555
Pant, K. C., (A) 591
Papadimitriou, C. S., (A) 594
Papaioannou, D. J., (O) 463
Paramasivan, C. N., (A) 608
Parikh, A. A., (A) 591
Parikh, D. A., (A) 585
Parkhe, S. M., (A) 184
Parra, C. A., (A) 752
Pasricha, J. S., (A) 175
Patarroyo, M. E., (A) 596, 610, 752
Patel, R., (A) 609
Pathak, R. G., (A) 591
Paties, C., (A) 393
Patil, K. M., (A) 395
Patil, S. A., (A) 175, 176
Patro, T. P., (A) 577
Pattengale, P. K., (A) 179, 750
Pattyn, S. R., (A) 180, 373, 585, 586, 586, 586, 587, 739, 739, 740
Pavithran, K., (A) 175
Payne, S., (A) 745
Pennec, J., (A) 592
Perani, E. G., (O) 70
Pericak-Vance, M. A., (A) 606
Petrashenko, A. I., (A) 764
Pfaltzgraff, R. E., (C) 553
Pfau, R., (A) 370
Pichet, C., (O) 672
Pinilla, C., (A) 752
Pisarenko, N. N., (A) 765

Piva, G., (A) 393
Plichart, R., (O) 626
Pokhodzei, I. V., (A) 763
Pol, J. T., (A) 766
Ponnighaus, J. M., (O) 88, (A) 182, 183, (O) 454, (A) 578, 745
Portaels, F., (A) 180, 788, 788
Potts, R. C., (A) 748
Prabhakar, M. C., (A) 372, (C) 561
Prabhakar, R., (A) 608
Prabhakaran, K., (A) 181, 389, 587, 740
Praputpittaya, K., (A) 747
Prasad, H. K., (A) 178, (O) 316, (A) 385
Pukhlik, B. M., (A) 761

Qian, A., (A) 739
Quesada-Pascual, F., (C) 716

Rabasa, S. L., (A) 593
Rada, E. M., (C) 351, (O) 646
Radhakrishna, S., (O) 425
Raffalli, M.-J., (O) 16
Rajasekaran, S., (A) 389
Rajagopalan, K., (O) 510
Rajendran, V., (C) 555
Ramachandran, A., (A) 591
Ramanathan, U., (O) 1
Ramanathan, V. D., (C) 721
Ramankar, T. V., (A) 372
Ramasesh, N., (A) 412, 603, 783
Ramesh, K., (C) 555
Ramirez, C., (A) 610
Ramnarayan, K., (C) 355
Ramu, G., (O) 1, (A) 175, 176, 598, 600, 605
Ramu, S. G., (A) 739
Rao, B. R., (A) 577
Rao, K. N., (A) 377, 377
Rao, P. R., (O) 36, (A) 599
Rao, P. S., (A) 393
Rao, P. T., (A) 395
Rao, S. N., (C) 559
Rao, T. D., (O) 36, (A) 599
Rastogi, N., (A) 762
Ratledge, C., (A) 387
Ravettini, B., (A) 587
Ravioli, R., (A) 379
Rawlinson, W. D., (O) 277
Rayfield, M. A., (A) 418
Rea, T. H., (A) 179, 384, 386, (O) 441, 494, (A) 750, 782, 786
Rees, A., (A) 749
Reibnegger, G., (A) 599
Reich, C. V., (A) 738
Reichert, E., (A) 746
Reider, F., (A) 173
Reitz-Vick, D., (A) 596
Remy, J.-C., (O) 672
Remy, J. G., (A) 392
Ren, X., (A) 393
Resnick, M., (A) 609

Revankar, C., (A) 603
Revankar, C. R., (A) 585, 587
Rey, J. L., (A) 396
Richard, L., (O) 63
Ridley, D. S., (O) 99, (A) 589, 752, 764, 764
Ridley, M. J., (O) 99, (A) 589, 764, 764
Riveau, E., (A) 371
Rivrain, Y., (A) 579
Roberts, C., (A) 765
Robertson, A. F., (A) 172
Rode, C. R., (A) 605
Rode, J., (A) 175
Rodriguez, J. E., (A) 371
Rohatgi, J., (A) 175, (O) 667
Rojas-Espinosa, O., (A) 391, (C) 716
Rook, G. A. W., (A) 379
Rose, P., (O) 249
Rosen, T., (A) 376
Rosenfeld, M., (A) 587, 588
Rotberg, A., (A) 599
Roulland-Dussoix, D., (A) 186, 187
Roux, G., (A) 584
Rowbotham, T. J., (C) 565
Roy, R. G., (A) 582
Rubin, L., (A) 753
Ruibal-Area, B., (A) 385
Russell, D. A., (A) 606
Ryter, A., (A) 762

Sabbaga, J., (A) 598
Saha, K., (A) 377, 377
Saikawa, K., (A) 742
Saint-André, P., (A) 387, 740
Sakaguchi, Y., (A) 610
Sakai, M., (O) 328
Sakamoto, Y., (A) 742
Salazar, L. M., (A) 752
Salazar-Gonzalez, J. F., (O) 651
Saliou, P., (A) 396
Samuel, N. M., (A) 385, 753
Sanchez, A., (A) 403
Sanchez, R. M., (O) 299, (A) 391, 420, 587, (O) 685
Sane, S. B., (A) 584
Santa-Maria, J. R., (A) 378
Santos Argumendo, L., (C) 716
Sarate, G. S., (A) 591
Sarno, E. N., (A) 178
Sasazuki, T., (A) 749
Sasiain, M. del C., (A) 385
Sathish, M., (A) 588, 789
Sato, D., (A) 746
Saxena, S. P., (A) 591
Saylan, T., (A) 183, 585
Schaad-Lanyi, Z., (O) 9
Schaper, K.-J., (A) 587, 588
Schauf, V., (A) 379, 753
Schena, C., (A) 393
Schmutzhard, E., (A) 599
Schonenberger, H., (A) 77
Schuller-Levis, G., (O) 267, (A) 381, 408, 409, 775
Schwartz, R. A., (A) 742
Schwartz, R. S., (A) 598
Scollard, D. M., (A) 379, 597, 753
Sebille, A., (O) 16
See, A., (A) 373
Sehgal, S., (O) 273
Sehgal, V. N., (A) 175, 179, 386
Self, T. H., (A) 577
Sen, P. C., (A) 577
Senba, M., (A) 599
Sengupta, U., (O) 42, (A) 175, 176, 598, 600
Sersen, E., (A) 409, 775
Seshadri, P. S., (A) 591
Seydel, J. K., (A) 587, 588, 778
Seydel, U., (A) 603
Shah, A., (A) 176, 607
Shah, B. H., (A) 591
Shaikh, S. U., (O) 657
Shannon, E. J., (A) 419
Shao, K., *et al.*, (A) 605
Sharma, A. K., (A) 178
Sharma, S. P., (A) 591
Sharma, V. D., (O) 680
Sharma, V. K., (A) 386, (O) 499
Shen, J.-Y., (O) 441, 494
Shenton, F. C., (A) 580
Shepard, C. C., (O) 322
Sheriff, D. S., (A) 592
Sheriff, M. M., (A) 748
Shi, Z.-R., (O) 507
Shields, E. D., (A) 606
Shinnick, T. M., (A) 753
Shirai, F., (A) 610
Shivannavar, C. T., (O) 680
Shorey, P., (A) 175
Shu, H., (A) 370
Shu, H., *et al.*, (A) 760
Shu, W., *et al.*, (A) 761
Sibley, L. D., (A) 386, 411, 782, 783
Silcox, V. A., (A) 188
Silva, M. T., (A) 788
Sims, D. S., (A) 184
Singh, G., (A) 182, 377, 577, 579, 590
Singh, I. P., (A) 172
Singh, K., (A) 592
Singh, K. G., (A) 377
Singh, M., (A) 176
Singh, N. B., (A) 609
Singh, P. A., (A) 174
Singh, R. G., (A) 377
Sinha, R. K., (A) 377, 377
Sinha, S., (O) 42, (A) 175, 176, 598, 600
Sirsat, A. M., (O) 23
Sirumban, P., (A) 173, 183, 582
Siu, P., (A) 776
Sivaprasad, N., (A) 183
Small, C. S., (A) 403
Smith, A. W., (A) 580
Smith, K. A., (A) 750
Smith, S. E., (A) 581

SMITH, T., (A) 753
SMITH, W. C. S., (A) 184
SNOW, R. W., (A) 580
SOKOLNIKOVA, G. M., (A) 763
SON, S. J., (A) 597
SOVIERO, D. J., (A) 370
SREEVATSA, (O) 42
SRINIVAS, C. R., (C) 159, 355, 559
SRINIVASAN, H., (A) 395
SRIVASTAVA, K., (A) 609
SRIVASTAVA, S. K., (A) 604
STALLKNECHT, D. E., (A) 420
STANFORD, J. L., (A) 385, 609
STEELE, J., (A) 379
STEFANOU, S. G., (A) 594
STEINMAN, R. M., (A) 178
STEWART, C., (A) 782
STOKES, R. W., (A) 413
STUYVESANT, W., (A) 403
SUAREZ, O., (A) 371
SUBCOMMITTEE ON CLINICAL TRIALS OF THE CHEMOTHERAPY OF LEPROSY (THELEP) SCIENTIFIC WORK'NG GROUP OF THE UNDP/WORLD BANK/ WHO SPECIAL PROGRAMME FOR RESEARCH AND TRAINING IN TROPICAL DISEASES, (A) 588, (S) 864
SUBRAMANYA, R., (C) 559
SUBRAMANYAM, S. B., (A) 172
SUGIYAMA, K., (A) 790
SURIYANOND, V., (A) 753
SUZUKI, T., (A) 188
SWARBRICK, J., (A) 741, 741
SWEETSER, D., (A) 382
SWENSON, J. M., (A) 188

TAKASHIMA, T., (A) 413
TAKEDA, T., (A) 602
TAKUMA, S., (A) 188
TALATI, S., (A) 389
TALWAR, G. P., (A) 178, (C) 563
TAN, D., (A) 761
TANG, M., (A) 742
TANG, M.-Y., (A) 378
TERENCIO DE LAS AGUAS, J., (A) 379, 609
TESTA, J., (A) 387
THEOBALD, W., (O) 9
THERIOT, S., (A) 416
THOLE, J., (A) 594
THOMAS, P. K., (A) 576
THOMPSON, D. E., (A) 607
TIKHOMIROV, A. F., (A) 763
TJEPKEMA, T., (A) 394
TODA, T., (A) 599
TODD, J. R., IV, (A) 758
TOIDA, I., (A) 188
TOMANCIK, E., (A) 394
TORRES, M. L., (A) 752
TORRES, P., (A) 379, 609
TOUGNE, C., (A) 743
TRAVERS, C., (A) 378
TRICHOPOULOS, D. V., (O) 463
TRIPATHI, A., (A) 174
TRUMAN, R. W., (A) 419, 420
TSANG, M., (A) 776
TSAREVA, O. I., (A) 763
TSCHEN, J. A., (A) 376
TSUTSUMI, S., (A) 740
TUAZON, C., (A) 396
TUNG, K. S. K., (A) 753
TURCOTTE, R., (O) 63
TURK, J. L., (A) 383, 595, 595
TUTAKNE, M. A., (A) 174, 590

ULRICH, M., (O) 646
UMLAND, E., (A) 753
UMLAND, E. T., (A) 597
UPLEKAR, M. W., (A) 173, 592
USHA, (A) 377
UTTLEY, H. C., (A) 185
UYEMURA, K., (A) 384, 386

VACHULA, M., (A) 784
VADIEE, R., (A) 419
VAISHNAVI, C., (A) 390, 391, 597, 604
VALDES-PORTELA, A., (A) 592
VAN EDEN, W., (A) 188, 609
VAN EMBDEN, J., (A) 594
VAN LANDINGHAM, R. M., (O) 322
VAN RENS, M. M., (A) 749
VAN SCHOOTEN, W. C. A., (A) 749
VASANTHAKUMARI, R., (A) 389
VATTER, A. E., (A) 186
VAYRE, P., (A) 371
VEJARE, S., (A) 583, 757
VENKATESAN, K., (A) 373
VIASHNAVI, C., (C) 358
VIDHIDHARM, A., (A) 610
VILLON, A., (A) 396
VINODKUMAR, C. H. D., (C) 555, (A) 582
VISCHER, W., (O) 9
VISHNEVETSKY, F. E., (A) 757
VISHNEVSKY, B. I., (A) 762
VITHAYASAI, P., (A) 753
VITHAYASAI, V., (A) 379, 753
VOLKON, V. M., (A) 762
VYAS, G. H., (A) 605

WABITSCH, R., (A) 579
WACHTER, H., (A) 599
WAGNER, D., (A) 753
WALKER, L. L., (O) 322
WALLACE, R. J., JR., (A) 188
WALLACH, D., (A) 592
WALLIS, R. S., (A) 188
WALSH, G. P., (O) 109, (A) 181, 416, 417, 418, 788, 788
WAMBURKAR, M. N., (A) 584
WANG, C., *et al.*, (A) 759
WANG, H., (A) 182
WANG, H.-Y., (A) 391
WANG, J., (C) 556

Wang, Q., (A) 373
Wang, Q., *et al.*, (A) 759
Wang, X., (C) 556
Wang, Z., (A) 740
Warndoff van Diepen, T., (A) 384
Waroyar, B., (A) 593
Warzok, V. R., (A) 576
Waters, M. F. R., (O) 99, (A) 379, 589
Watson, J. D., (A) 744
Wayne, L. G., (A) 388
Wei, A., (A) 759
Weinstein, D. E., (A) 596
Wener, M. H., (A) 590
West, B. C., (A) 758
Wheeler, P. R., (A) 180, 589
Wiese, M., (A) 588
Wieten, G., (A) 180
Wiker, H. G., (A) 610, 746
Wilkins, E. G. L., (A) 765
Williams, D. L., (A) 405
Williams, K., (A) 580
Wintsch, K., (A) 395
Witmer, M. D., (A) 178, 748
Wolf, R. H., (O) 109, (A) 417, 418
Wone, I., (A) 605
Wong, L., (A) 179, 384, 386
Worobec, S., (A) 753
Wu, Q., *et al.*, (A) 754
Wu, Y., (A) 741

Xia, M., (A) 382, 754
Xie, Y., (A) 754
Xie, Z., (A) 393
Xiong, D., *et al.*, (A) 760
Xu, R., *et al.*, (A) 741

Yablokova, T. B., (A) 763, 765
Yabu, K., (A) 189
Yajko, D. M., (A) 765
Yamamoto, S., (A) 188
Yanagisawa, R., (A) 746
Yang, T.-T., (A) 741, 741
Yang, X., (A) 393
Yang, Y.-M., (A) 387, 755
Ye, G., (N) 363
Ye, G.-Y., (N) 730
Ye, S., (A) 742
Ye, S.-H., (A) 378
Yellapurkar, M. V., (O) 657
Yogi, Y., (A) 787
Yoneda, T., (A) 610
Yoshino, Y., (A) 742
Young, D. B., (A) 189, 603, 749
Young, L. S., (A) 765
Young, R. A., (A) 382, 406, 594, 743, 745, 745, 749
Young, R. C., (A) 595
Ysmail-Dahlouk, M., (A) 393
Yu, L.-C., (A) 378

Zabriskie, J., (A) 381, 408
Zacharia, A. G., (C) 554
Zaitz, C., (A) 177
Zawar, P. B., (A) 766
Zeng, J., (A) 373
Zhang, J., (A) 378
Zhang, Y., (A) 182
Zhang, Y., *et al.*, (A) 372
Zhang, Z., (A) 761
Zheng, C., (A) 374
Zhong, H., (A) 373
Zhou, H.-M., (O) 507
Zhou, S., (A) 374
Zhou, T., (A) 394
Zhou, W.-Q., (A) 378
Zhu, S., (A) 374
Zhu, W., (A) 754
Zhu, Y., (A) 382
Zhukova, L. N., (A) 765
Zhuo, D., (A) 370
Ziong, S., (A) 740
Zosimov, A. N., (A) 766
Zuidema, J., (A) 374

SUBJECT INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), reprinted articles (R), abstracts (A), book reviews (B), and Workshop on Experimental Chemotherapy of Leprosy supplement (S).

Acid-fast,
A cold staining method for acid-fast bacilli. Vasanthakumari, R., *et al.* ....(A) 389
Acid-fast bacilli detected in umbilical cord and skin specimens. Mori, T. ....(A) 786
[Acid-fast bacilli in *Culex fatigans.*] Bona, S. H., *et al.* ....(A) 605
Influence of prior periodic acid oxidation on the acid-fastness of *M. leprae.* Dhople, A. M. ....(A) 179
[Modified method of counting acid-fast bacilli with agarose gel.] Li, F. ....(A) 388
The identification and characterization of acid-fast bacilli cultured on hyaluronic acid media and an evaluation of their etiologic role in leprosy. Ohashi, D. K. ....(A) 404

Acupuncture,
The usefulness of acupuncture in leprosy. Jagirdar, P. C. ....(A) 185, 590

Adenosine triphosphate (ATP),
An *in vitro* system using adenosine triphosphate and ^{3}H-thymidine to determine drug sensitivity of *M. leprae.* Dhople, A. M. and Green, K. J. ....(A) 172

Africa,
[Differential diagnosis of leprous lesions in Africans.] Akimov, V. G. ....(A) 375
[Epidemiological profile of leprosy in Algeria.] Oughanem, M., *et al.* ....(A) 393
Preliminary evaluation of the effect of WHO-MDT on disabilities in leprosy patients in Malawi (Central Africa). Boerrigter, G. and Ponnighaus, J. M. ....(A) 578
[Problems in applying the practice of multidrug therapy in leprosy in West Africa.] Nebout, M., *et al.* ....(A) 576
[Studies on the tuberculosis infection in a cattle breeding area in sahelian Africa.] Rey, J. L., *et al.* ....(A) 396
Teaching of Leprosy. Proceedings of a Symposium Held on the Occasion of the 20th Annual General Meeting of the All Africa Leprosy and Rehabilitation Training Centre (ALERT). Harboe, M., ed. ....(B) 574
Ten years' leprosy control work in Malawi (Central Africa)—I. Methods and outcome after treatment. Boerrigter, G. and Ponnighaus, J. M. ....(A) 182
Ten years' leprosy control work in Malawi (Central Africa)—II. Patterns of endemicity since 1973. Ponnighaus, J. M. and Boerrigter, G. ....(A) 183

Allergy,
The relation between allergy and immunity in leprosy. Maier, M. .... E 116

Amyloid,
Amyloid goiter—a case report. Dhopavkar, P. V., *et al.* ....(A) 173

Ansamycin,
Effect of combined clofazamine and ansamycin therapy on *M. avium-M. intracellulare* bacteremia in patients with AIDS. Masur, H., *et al.* ....(A) 396

Antibody(ies),
A dot enzyme immunoassay for detection of IgM antibodies against phenolic glycolipid-I in sera from leprosy patients. Kumar, S., *et al.* ....(A) 178
Analysis of a leprosy-specific antibody epitope. Brown, W. B., *et al.* ....(A) 744
Analysis of idiotypes expressed by anti-mycobacterial mouse monoclonal antibodies using rabbit antisera. Ivanyi, J. and Praputpittaya, K. ....(A) 747
Analysis of monoclonal antibodies to *M. leprae* by crossed immunoelectrophoresis. Harboe, M. and Ivanyi, J. ....(A) 594
Anti-mycobacterial antibodies in saliva. Abe, M., *et al.* ....(A) 742
Antibodies to a synthetic analog of phenolic glycolipid-I of *M. leprae* in healthy household contacts of patients with leprosy. Menzel, S., *et al.* ....(O) 617

Antibodies to phenolic glycolipid-I during long-term therapy; serial measurements in individual patients. Miller, R. A., *et al.* ..... (O) 633
Antibodies to tubulin in patients with parasitic infections. Howard, M. K., *et al.* ..... (A) 595
Antimycobacterial antibodies in *Dasypus novemcinctus* infected wtih *M. leprae* and their correlation with the serum levels of lactate dehydrogenase. Rojas-Espinosa, O., *et al.* ..... (A) 391
Antispermatozoal antibodies in leprosy with special reference to their morphological patterns. Gupta, S. C., *et al.* ..... (A) 174
Attempts to produce erythema nodosum leprosum in *M. leprae*-infected nude nu/nu mice with monoclonal antibodies. Chehl, S., *et al.* ..... (A) 410
Bacillary growth, interleukin-2 production defect, and specific antibody secretion governed by different genetical factors in mice infected subcutaneously with *M. lepraemurium*. Hoffenbach, A. and Bach, M.-A. ..... (A) 390
Characterization of antibody-reactive epitopes on the 65-kilodalton protein of *M. leprae*. Buchanan, T. M., *et al.* ..... (A) 594
Characterization of mycobacterial species specificity of 14 separate epitopes which reacted with monoclonal antibodies to the 65,000 molecular weight protein molecule of *M. leprae*. Buchanan, T. M., *et al.* ..... (A) 745
Cold reactive lymphocytotoxic antibodies in patients with tuberculoid and lepromatous leprosy. Naik, S., *et al.* ..... (O) 273
Dominant cell wall proteins of *M. leprae* recognized by monoclonal antibodies. Britton, W. J., *et al.* ..... (A) 379
Histochemical demonstration of mycobacterial antigen, specific antibody and complement in the lesions of tuberculosis. Ridley, M. J. and Ridley, D. S. ..... (A) 764
Idiotypic markers of polyclonal B cell activation; public idiotypes shared by monoclonal antibodies derived from patients with systemic lupus erythematosus or leprosy. Mackworth-Young, C., *et al.* ..... (A) 598
Influence of route of inoculation on anti-*M. lepraemurium* antibody isotopes in murine leprosy. Hoffenbach, A., *et al.* ..... (O) 305
Monitoring of leprosy patients for antibodies to mycobacterial protein, glycolipid and lipopolysaccharide antigens. Levis, W. R., *et al.* ..... (A) 408
Monitoring of leprosy patients with antibodies to *M. leprae* phenolic glycolipid-I and a synthetic glycoconjugate. Meeker, H. C., *et al.* ..... (A) 409
Results of a World Health Organization-sponsored workshop to characterize antigens recognized by mycobacterium-specific monoclonal antibodies. Engers, H. D., *et al.* ..... (A) 176
Serodiagnosis of leprosy; relationships between antibodies to *M. leprae* phenolic glycolipid-I and protein antigens. Levis, W. R., *et al.* ..... (A) 381
Solid phase peptide synthesis of epitopes that react with monoclonal antibodies to the 65,000 dalton protein of *M. leprae*. Anderson, D. C., *et al.* ..... (A) 743
Specific antigen and antibody to *M. leprae* in the cryoprecipitate of a patient with Lucio phenomenon. Drosos, A. A., *et al.* ..... (A) 594
Synthesis of epitopes of monoclonal antibodies to the 65 kD protein of *M. leprae*. Anderson, D. C., *et al.* ..... (A) 406
The allyl group for protection in carbohydrate chemistry. Part 19. The coupling of allyl 2, 3-di-*O*-methyl-4-*O*-(3, 6-di-*O*-methyl-β-D-glucopyranosyl)-α-L-rhamnopyranoside to bovine serum albumin. Preparation of a diagnostic reagent for antibodies to the major glycolipid of *M. leprae* (the leprosy bacillus) in human sera. Gigg, J., *et al.* ..... (A) 745
The evolution of IgG and IgM antibodies to phenolic glycolipid-I in armadillos inoculated with *M. leprae*. Vadiee, R., *et al.*, ... (A) 419
The limited spectrum of antinuclear antibodies in leprosy. Miller, R. A., *et al.* ..... (A) 590
Thyroglobulin autoantibodies in leprosy. George, J., *et al.* ..... (A) 174

Antigen(s),
A recombinant 64 kilodalton protein of *M. bovis* bacillus Calmette-Guérin specifically stimulates human T4 clones reactive to mycobacterial antigens. Emmrich, F., *et al.* ..... (A) 594
Ability of the phenolic glycolipid-I antigen of *M. leprae* to elicit a positive Mitsuda response in the armadillo (*Dasypus novemcinctus*). Job, C. K., *et al.* ..... (O) 299
Antigens of *M. leprae* in urine during treatment of patients with lepromatous leprosy. Olcén, P., *et al.* ..... (A) 384

Cellular and humoral immune response to a phenolic glycolipid antigen (PGL-I) in patients with leprosy. Koster, F. T., *et al.* ..... (A) 597
Characterization of the 36 K antigen of *M. leprae.* Klatser, P. R., *et al.* ..... (A) 749
Comparative study of immunizing and delayed hypersensitivity eliciting antigens of *M. leprae, M. tuberculosis, M. vaccae,* and *M. bovis* (BCG). Sinha, S., *et al.* ..... (O) 42
Detection and characterization of antigens of *M. leprae* reacting with sera from leprosy patients. Sathish, M., *et al.* ..... (A) 789
Development of a dot-ELISA for detection of leprosy antigenuria under field conditions. Kaldany, R.-R. J. and Nurlign, A. ..... (A) 747
Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. Wallis, R. S., *et al.* ..... (A) 188
Efficient mapping of protein antigenic determinants. Mehra, V., *et al.* ..... (A) 382
Expression of major histocompatibility complex class I and class II antigens in human Schwann cell cultures and effects of infection with *M. leprae.* Samuel, N. M., *et al.* ..(A) 753
Genes for the major protein antigens of *M. tuberculosis*: the etiologic agents of tuberculosis and leprosy share an immunodominant antigen. Husson, R. N. and Young, R. C. ..... (A) 595
Histochemical demonstration of mycobacterial antigen, specific antibody and complement in the lesions of tuberculosis. Ridley, M. J. and Ridley, D. S. ..... (A) 764
HLA antigens and neural reversal reactions in Ethiopian borderline tuberculoid leprosy patients. Ottenhoff, T. H. M., *et al.* ..... (O) 261
Immunological and biochemical characterization and classification of mycobacterial antigens. Harboe, M. and Wiker, H. G. ..... (A) 746
Interferon-gamma induces the expression of major histocompatibility complex antigens by *in vitro* cultured murine Schwann cells. Mshana, R. N., *et al.* ..... (A) 781
Leprosy neuropathy; cells expressing MHC class II antigens in the lesion. Mshana, R. N. and Nilsen, R. ..... (A) 407
Limiting dilution analysis of the human T cell response to mycobacterial antigens from BCG vaccinated individuals and leprosy patients. Brett, S. J., *et al.* ..... (A) 743
M. leprae antigen-induced suppression of T cell proliferation *in vitro.* Kaplan, G., *et al.* ..... (A) 596
Macrophages infected *in vitro* with live mycobacteria fail to express Ia antigen after stimulation with lymphokine. Mshana, R. N., *et al.* ..... (A) 407
[Method of immunization with BCG-M vaccine with reduced antigenic content.] Yablokova, T. B., *et al.* ..... (A) 765
Methods for the detection of a specific *M. leprae* antigen in the urine of leprosy patients. Kaldany, R.-R., *et al.* ..... (A) 596
Monitoring of leprosy patients for antibodies to mycobacterial protein, glycolipid and lipopolysaccharide antigens. Levis, W. R., *et al.* ..... (A) 408
MPB59, a widely crossreacting protein of *M. bovis* BCG. Wiker, H. G., *et al.* ..... (A) 610
Mycobacterial carbohydrate antigens for serologic testing of leprosy. Levis, W. R., *et al.* ..... (A) 775
Quantitative analysis of contrasuppressor T lymphocytes in leprosy; induction of Ia antigens with gamma interferon. Gonzalez-Amaro, R., *et al.* ..... (O) 651
Resistance to *M. lepraemurium* is correlated with the capacity to generate macrophage activating factor(s) in response to mycobacterial antigens *in vitro.* Brett, S. J. and Butler, R. ..... (A) 389
Results of a World Health Organization-sponsored workshop to characterize antigens recognized by mycobacterium-specific monoclonal antibodies. Engers, H. D., *et al.* ..... (A) 176
Serodiagnosis of leprosy: relationships between antibodies to *M. leprae* phenolic glycolipid-I and protein antigens. Levis, W. R., *et al.* ..... (A) 381
Seroepidemiological study on 724 household contacts of leprosy patients in French Polynesia using disaccharide-octyl-BSA as antigen. Chanteau, S., *et al.* ..... (O) 626
Simplification and standardization of serodiagnostic tests for leprosy of phenolic glycolipid-I (PGL-I) antigen. Aguado Sanchez, G., *et al.* ..... (A) 743
Solid phase peptide synthesis of epitopes that react with monoclonal antibodies to the 65,000 dalton protein of *M. leprae.* Anderson, D. C., *et al.* ..... (A) 743
Specific antigen and antibody to *M. leprae* in the cryoprecipitate of a patient with Lucio phenomenon. Drosos, A. A., *et al.* ..... (A) 594

Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli. Hunter, S. W., *et al.* ....(A) 179
Suppression of delayed hypersensitivity skin reactions to tuberculin by *M. leprae* antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., *et al.* ....(A) 600
T lymphocytes respond to solid-phase antigen: a novel approach to the molecular analysis of cellular immunity. Young, D. B. and Lamb, J. R. ....(A) 189
The carbohydrate-containing antigens of *M. leprae*. Brennan, P. J. ....(A) 755
The HLA antigens and leprosy in Korea. Kim, S. J., *et al.* ....(A) 183
The repertoire of mycobacterial antigens recognized by peripheral blood cells and sera of healthy leprosy patient contacts. Converse, P. J., *et al.* ....(A) 779

Argentina,
80th anniversary of Asociación Argentina de Dermatólogía. ....(N) 363

Armadillo(s),
A cooperative taxonomic study of mycobacteria isolated from armadillos infected with *M. leprae*. Portaels, F., *et al.* ....(A) 180
A Mexican armadillo (*Dasypus novemcinctus*) colony for leprosy research. Quesada-Pascual, F., *et al.* ....(C) 716
Ability of the phenolic glycolipid-I antigen of *M. leprae* to elicit a positive Mitsuda response in the armadillo (*Dasypus novemcinctus*). Job, C. K., *et al.* ....(O) 299
Antimycobacterial antibodies in *Dasypus novemcinctus* infected with *M. leprae* and their correlation with the serum levels of lactate dehydrogenase. Rojas-Espinosa, O., *et al.* ....(A) 391
Congenital transmission of leprosy in armadillos. Hastings, R. C., *et al.* ....(A) 420
Cultivable mycobacteria isolated from 32 newly captured armadillos (*Dasypus novemcinctus*) from Louisiana. (U.S.A.) Portaels, F., *et al.* ....(A) 788
Detection of trehalose monomycolate in *M. leprae* grown in armadillo tissues. Dhariwal, K. R., *et al.* ....(A) 387, 755
[Histochemical study of reverse reactions in *M. leprae*-infected armadillos.] Juscenko, A. A. and Vishnevetsky, F. E. ....(A) 757
Lepromatous placentitis and intrauterine fetal infection in lepromatous nine-banded armadillos (*Dasypus novemcinctus*). Job, C. K., *et al.* ....(A) 391
Naturally acquired leprosy in the nine-banded armadillo; a decade of experience 1975–1985. Walsh, G. P., *et al.* ....(A) 181
Prevalence and significance of positive Mitsuda reaction in the nine-banded armadillo (*Dasypus novemcinctus*). Job, C. K., *et al.* ....(O) 685
Seroepidemiology of leprosy in wild armadillos (*Dasypus novemcinctus*). Truman, R. W., *et al.* ....(A) 419
Surveillance for *M. leprae* infections in a community of nine-banded armadillos. Stallknecht, D. E., *et al.* ....(A) 420
The evolution of IgG and IgM antibodies to phenolic glycolipid-I in armadillos inoculated with *M. leprae*. Vadiee, R., *et al.* ....(A) 419
Thorns in armadillo ears and noses and their role in the transmission of leprosy. Job, C. K., *et al.* ....(A) 182

Arthritis,
Arthritis induced by a T-lymphocyte clone that responds to *M. tuberculosis* and to cartilage proteoglycans. van Eden, W., *et al.* ....(A) 188

Assay(s), (see also **ELISA**),
A single cell assay for the study of γ-interferon formation in leprosy patients. Lindh, J., *et al.* ....(A) 382
Comparison of radiometric macrophage assay and fluorescein diacetate/ethidium bromide staining for evaluation of *M. leprae* viability. Harshan, K. V., *et al.* ....(O) 316

Australia,
Australia's last leprosarium closed and Hansen's disease symposium at Perth. Cassidy, J. J. ....(N) 165

B663 (see **Clofazimine**)

Bacilli,
A cold staining method for acid-fast bacilli. Vasanthakumari, R., *et al.* ....(A) 389
Acid-fast bacilli detected in umbilical cord and skin specimens. Mori, T. ....(A) 786
[Acid-fast bacilli in *Culex fatigans.*] Bona, S. H., *et al.* ....(A) 605
An unusual case of untreated lepromatous leprosy with rare bacilli; an immunologic follow-up. Gelber, R. H. and Mohagheghpour, N. ....(C) 353
Bacillary growth, interleukin-2 production defect, and specific antibody secretion governed by different genetical factors in mice infected subcutaneously with *M. lepraemurium.* Hoffenbach, A. and Bach, M.-A. ....(A) 390
Exochelin-mediated iron acquisition by the leprosy bacillus *M. leprae.* Hall, R. M. and Ratledge, C. ....(A) 387
[Lysosomes and leprosy bacilli.] Fukunishi, Y. ....(A) 181
[Modified method of counting acid-fast bacilli with agarose gel.] Li, F. ....(A) 388
Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercule bacilli. Hunter, S. W., *et al.* ....(A) 179
The identification and characterization of acid-fast bacilli cultured on hyaluronic acid media and an evaluation of their etiologic role in leprosy. Ohashi, D. K. ....(A) 404

Bacteremia,
Effect of combined clofazamine and ansamycin therapy on *M. avium-M. intracellulare* bacteremia in patients with AIDS. Masur, H., *et al.* ....(A) 396
[Incidence of bacteremia in leprosy and a comparison of various detecting methods.] Ye, S.-H., *et al.* ....(A) 378

Bacterial index (BI),
[Staining of *M. leprae*: comparison between Lepeyssonie and Causse's technique and THELEP's technique to evaluate the bacteriological index.] Baquillon, G., *et al.* ....(A) 387

Bacteriology,
[Clinical and bacteriological evaluation 8 years after triple drug chemotherapy for multibacillary leprosy in Senegal.] Dousset-Faure, I., *et al.* ....(A) 739

BCG (bacille Calmette-Guérin),
A recombinant 64 kilodalton protein of *M. bovis* bacillus Calmette-Guérin specifically stimulates human T4 clones reactive to mycobacterial antigens. Emmrich, F., *et al.* ....(A) 594
BCG-induced suppressor T cells optimal conditions for *in vitro* induction and mode of action. Mustafa, A. S. and Godal, T. ....(A) 187
Characteristics of human T-cell clones from BCG and killed *M. leprae* vaccinated subjects and tuberculosis patients; recognition of recombinant mycobacterial antigens. Mustafa, A. S., *et al.* ....(A) 750
Comparative study of immunizing and delayed hypersensitivity eliciting antigens of *M. leprae, M. tuberculosis, M. vaccae,* and *M. bovis* (BCG). Sinha, S., *et al.* ....(O) 42
Effect of oral exposure of *M. avium intracellulare* on the protective immunity induced by BCG. Narayanan, S., *et al.* ....(A) 608
Immunization of mice with *M. leprae/M. bovis* BCG admixtures: modulation of the acquired response to BCG. Orme, A. M. ....(O) 293
Immunosuppression and cellular immunity reactions in leprosy patients treated with a mixture of *M. leprae* and BCG. Rada, E. M., *et al.* ....(O) 646
Limiting dilution analysis of the human T cell response to mycobacterial antigens from BCG vaccinated individuals and leprosy patients. Brett, S. J., *et al.* ....(A) 743
[Method of immunization with BCG-M vaccine with reduced antigenic content.] Yablokova, T. B., *et al.* ....(A) 765
MPB59, a widely cross-reacting protein of *M. bovis* BCG. Wiker, H. G., *et al.* ....(A) 610
Study of DTH and resistance in *M. lepraemurium* infection using a T-cell line isolated from mice infected with *M. bovis* (BCG). Hussein, S., *et al.* ....(A) 595
The characterization and immunoreactivity of a 70 kD protein common to *M. leprae* and *M. bovis* (BCG). Britton, W. J., *et al.* ....(A) 744

Biochemistry,
Biochemical studies on *M. leprae.* Prabhakaran, K., *et al.* ....(A) 389
Enzymes and other biochemically active components of mycobacteria. Draper, P. ....(A) 755

Immunological and biochemical characterization and classification of mycobacterial antigens. Harboe, M. and Wiker, H. G. ..... (A) 746
[Significance of certain biochemical and immunological indices in estimation of activity of limited tuberculosis of the lungs.] Kostina, Z. I., *et al.* ..... (A) 763

Biopsy,
Hansen's disease: a new endemic focus in the Piacenza Province (Italy)? A description of four diagnosed cases by cutaneous biopsy. Paties, C., *et al.* ..... (A) 393
Histopathological examination of skin biopsies from an epidemiological study of leprosy in Northern Malawi. McDougall, A. C., *et al.* ..... (O) 88
Myelinated and unmyelinated fibers in sural nerve biopsy of a case with lepromatous leprosy—a quantitative approach. Gibbels, E., *et al.* ..... (O) 333

Blood,
Blood dapsone levels in leprosy patients treated with acedapsone. George, J. and Balakrishnan, S. ..... (A) 371
The repertoire of mycobacterial antigens recognized by peripheral blood cells and sera of healthy leprosy patient contacts. Converse, P. J., *et al.* ..... (A) 779
Ultrastructural changes in the blood vessel in dermal lesions of leprosy. Mukherjee, A., *et al.* ..... (A) 416

Book reviews,
A Spot Test for Dapsone in Urine by Huikeshoven, Han. Hastings, R. C. ..... (B) 574
Proceedings of the Inauguration of China Leprosy Association, China Leprosy Foundation, China Leprosy Control and Research Centre and the First International Leprosy Symposium in China. ..... (B) 574
Questions and Answers on the Implementation of Multiple Drug Therapy (MDT) for Leprosy. ..... (B) 737
Research Activities of the National Institute for Leprosy Research. Abe, M., ed. ..... (B) 170
Studies on Leprosy in Bombay. Hastings, R. C. ..... (B) 170
Teaching of Leprosy. Proceedings of a Symposium Held on the Occasion of the 20th Annual General Meeting of the All Africa Leprosy and Rehabilitation Training Centre (ALERT). Harboe, M., ed. ..... (B) 574
The Mycobacteria: A Sourcebook (in two parts). Kubica, G. P. and Wayne, L. G., eds. Franzblau, S. G. ..... (B) 369
Tropical Disease Research: A Global Partnership. ..... (B) 737
World Health Statistics Quarterly, Vol. 39, No. 2, 1986. Maxwell, B. A. ..... (B) 170

Borderline leprosy,
An unusual bullous reaction in borderline leprosy. Singh, K. ..... (A) 592
HLA antigens and neural reversal reactions in Ethiopian borderline tuberculoid leprosy patients. Ottenhoff, T. H. M., *et al.* ..... (O) 261
Multiple relapses in borderline leprosy—a case report. Ramachandran, A. and Seshadri, P. S. ..... (A) 591
[Ultrastructure of Langerhans' cell in the skin of borderline leprosy patients.] Liu, J., *et al.* ..... (A) 382

Brazil,
Feasibility of multidrug therapy (MDT) in Hansen's disease in an urban population—Curupaiti State Hospital, Rio de Janeiro, Brazil. Andrade, V. L. G., *et al.* ..... (O) 435

Catalase,
Catalases, peroxidases, and superoxide dismutases in *M. leprae* and other mycobacteria studied by crossed immunoelectrophoresis and polyacrylamide gel electrophoresis. Lygren, S. T., *et al.* ..... (A) 388

Cell(s), (see also specific cells),
Accessory function of cells isolated from *M. leprae*-induced granulomas. Montreewasuwat, N., *et al.* ..... (A) 383
Dominant cell wall of *M. leprae* recognized by monoclonal antibodies. Britton, W. J., *et al.* ..... (A) 379
[*In situ* characterization of immune cells in the annular lesions of leprosy.] Lee, C. W., *et al.* ..... (A) 597

Leprosy neuropathy; cells expressing MHC class II antigens in the lesion. Mshana, R. N. and Nilsen, R. ..... (A) 407
[II. *M. lepraemurium* in cell culture, possibly useful for screening antileprosy drugs.] Ye, S., *et al.* ..... (A) 742
Single bacterial cell mass analysis: a rapid test method in leprosy therapy control. Seydel, U. and Lindner, B. ..... (A) 603
Suppressor response in lepromatous leprosy patients; role of Leu2a cells. Sasiain, M. del C., *et al.* ..... (A) 385
The cell wall of *M. leprae*; isolation, composition, and immunogenicity. Brennan, P. J., *et al.* ..... (A) 782
[The foamy cells in skin lesions of arrested lepromatous patients.] Zhu, W., *et al.* ..... (A) 754
The repertoire of mycobacterial antigens recognized by peripheral blood cells and sera of healthy patient contacts. Converse, P. J., *et al.* ..... (A) 779
Thymidine uptake as an indicator of cell ability and *in vitro* growth of *M. leprae*. Dhople, A. M. ..... (A) 402

Cells, B,
Idiotypic markers of polyclonal B cell activation; public idiotypes shared by monoclonal antibodies derived from patients with systemic lupus erythematosus or leprosy. Mackworth-Young, C., *et al.* ..... (A) 598

Cells, Langerhans',
Distribution and turnover of Langerhans' cells during delayed immune responses in human skin. Kaplan, G., *et al.* ..... (A) 748
[Ultrastructure of Langerhans' cells in the skin of borderline leprosy patients.] Liu, J., *et al.* ..... (A) 382

Cells, natural killer (NK),
The relationship between natural killer cell activity and delayed-type hypersensitivity reaction of 2,4-dinitrochlorbenzene in the spectrum of chronic, intractable pulmonary tuberculosis. Yoneda, T., *et al.* ..... (A) 610

Cells, Schwann,
Adherence of *M. leprae* to Schwann cells *in vitro*. Itty, B. M., *et al.* ..... (A) 381
Drs. Band and Talwar reply. Band, H. and Talwar, G. P. ..... (C) 563
Expression of major histocompatibility complex class I and class II antigens in human Schwann cell cultures and effects of infection with *M. leprae*. Samuel, N. M., *et al.* ..... (A) 753
Interferon-gamma induces the expression of major histocompatibility complex antigens by *in vitro* cultured murine Schwann cells. Mshana, R. N., *et al.* ..... (A) 781
Schwann cells and *M. leprae*. Pandya, S. S. ..... (C) 562

Cells, T,
An HLA-linked gene controls susceptibility to lepromatous leprosy through T cell regulation. Kikuchi, I., *et al.* ..... (A) 749
BCG-induced suppressor T cells optimal conditions for *in vitro* induction and mode of action. Mustafa, A. S. and Godal, T. ..... (A) 187
Characteristics of human T-cell clones from BCG and killed *M. leprae* vaccinated subjects and tuberculosis patients; recognition of recombinant mycobacterial antigens. Mustafa, A. S., *et al.* ..... (A) 750
Dissociation between delayed-type hypersensitivity and resistance to pathogenic mycobacteria demonstrated by T-cell clones. Hussein, S., *et al.* ..... (A) 595
Lepromin-induced suppressor cells in lepromatous leprosy. Nelson, E. E., *et al.* ..... (A) 384
Limiting dilution analysis of the human T cell response to mycobacterial antigens from BCG vaccinated individuals and leprosy patients. Brett, S. J., *et al.* ..... (A) 743
M. leprae antigen-induced suppression of T cell proliferation *in vitro*. Kaplan, G., *et al.* ..... (A) 596
Molecular localization and polymorphism of HLA class II restriction determinants defined by *M. leprae*-reactive helper T cell clones from leprosy patients. Ottenhoff, T. H. M., *et al.* ..... (A) 384
Possible role of helper and cytolytic T cells in mycobacterial infections. Kaufmann, S. H. E., *et al.* ..... (A) 748

Prevalence and specificity of the enhancing effect of three types of interleukin 2 on T-cell responsiveness in 97 lepromatous leprosy patients of mixed ethnic origin. Barnass, S., *et al.* ..... (A) 379
Reversal of T cell unresponsiveness in lepromatous leprosy. Nath, I. ..... (A) 751
Study of DTH and resistance in *M. lepraemurium* infection using a T-cell line isolated from mice infected with *M. bovis* (BCG). Hussein, S., *et al.* ..... (A) 595
Suppressor T cells for delayed-type hypersensitivity in susceptible mice infected with *M. lepraemurium*. Richard, L., *et al.* ..... (O) 63
T-cell defect in lepromatous leprosy is reversible *in vitro* in the absence of exogenous growth factors. Mohagheghpour, N., *et al.* ..... (A) 383
T-cell subpopulations in tuberculosis and the effects of rifampicin. Vidhidharm, A., *et al.* ..... (A) 610
The identification of T cell epitopes in *M. tuberculosis* using human T lymphocyte clones. Lamb, J. R., *et al.* ..... (A) 749
Type 1 reactions in leprosy–heterogeneity in T-cell functions related to the background leprosy type. Laal, S., *et al.* ..... (O) 481

Cell-mediated immunity (CMI),
Deficiency of cell mediated immunity in leprosy. Gill, H. K. and Godal, T. ..... (A) 177
Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy. Rao, T. D. and Rao, P. R. ..... (O) 36
Is neopterin—a marker of cell mediated immune response—helpful in classifying leprosy? Schmutzhard, E., *et al.* ..... (A) 599
Regulation of cell-mediated immunity in lepromatous leprosy. Kaplan, G. and Cohn, Z. A. ..... (A) 747
T lymphocytes respond to solid-phase antigen: a novel approach to the molecular analysis of cellular immunity. Young, D. B. and Lamb, J. R. ..... (A) 189

Chemotaxis,
Defective monocyte chemotaxis in active lepromatous leprosy. Schuller-Levis, G., *et al.* ..... (O) 267
Macrophage chemotaxis in *M. leprae* infected mice. Kumar, B., *et al.* ..... (A) 597

Chemotherapy, (see also **Therapy**),
A report on two follow-up investigations of the Malta Project. Jopling, W. H. ..... (A) 582
Characteristics of patients in the THELEP trials of chemotherapy of leprosy at Bamako and Chingleput. Subcommittee on Clinical Trials of the Chemotherapy of Leprosy (THELEP) SWG of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases ..... (A) 588
Chemotherapy trials in the neonatally thymectomized Lewis rat: a model for the study of the therapy of lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 776
[Clinical and bacteriological evaluation 8 years after triple drug chemotherapy for multibacillary leprosy in Senegal.] Dousset-Faure, I., *et al.* ..... (A) 739
Combined chemotherapy of multibacillary leprosy of 6 months' duration. Onsun, N., *et al.* ..... (A) 585
Comparison of DDS with two combined chemotherapy regimens for multibacillary leprosy. Results after 3 years of treatment. A prospective randomized multicentre study. Dietrich, M. and Wabitsch, R. ..... (A) 579
[Comparison of three therapeutic regimens for paucibacillary leprosy; preliminary note.] Huser, J. A., *et al.* ..... (A) 739
Development of new chemotherapeutic agents in leprosy. Dhople, A. M., *et al.* ..... (A) 778
Efficacy of different regimens in multibacillary leprosy. Pattyn, S. R. ..... (A) 586
Limited duration acedapsone prophylaxis in leprosy. Neelan, P. N., *et al.* ..... (A) 183
Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Fox, W. and Kee, T. S. ..... (A) 762
Recent developments in the field of multidrug therapy and future research in chemotherapy of leprosy. Grosset, J. ..... (A) 581
Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Khor, M., *et al.* ..... (A) 763
Short term chemotherapy of paucibacillary leprosy. Dhir, R., *et al.* ..... (A) 579

Teaching video on chemotherapy of leprosy available. ....(N) 736
The First Joint THELEP-Sasakawa Memorial Health Foundation Workshop on Experimental Chemotherapy of Leprosy. Grosset, J., *et al.* .... (S) 807
The normal mouse in experimental chemotherapy. Levy, L. .... (S) 843
[Treatment of 519 cases of leprosy with combined regimens.] Chen, D. ....(A) 371
Workshop on Experimental Chemotherapy of Leprosy, Osaka, Japan, 11–20 November 1986. .... (S) 797

China, People's Republic of,
[Economic benefits of leprosy control.] Shu, H., *et al.* ....(A) 370
[Effects of controlling leprosy in Wuhan City.] Lu, J. ....(A) 392
[Epidemic of leprosy and its control in Guangdong.] Yang, X. ....(A) 393
[Epidemic of leprosy and the effect of its control in the South Prefecture, Jiangxi Province.] Cai, Z. and Hong, D. ....(A) 392
[Epidemiological changes in Fujian Province, China.] Shao, K., *et al.* ....(A) 605
[Formation and origin of leprophobia.] Lu, J. ....(A) 394
National conference on MDT of leprosy held in Cheng-du. Ye, G. ....(N) 363
Proceedings of the Inauguration of China Leprosy Association, China Leprosy Foundation, China Leprosy Control and Research Centre and the First International Leprosy Symposium in China. ....(B) 574
[Relapse of leprosy in Jinju hospital for old-disabled persons.] Liu, W. ....(A) 740
Research work on social medicine of leprosy. Ye, G.-Y. ....(N) 730
[Review of leprosy control in Jiangsu Province.] Ren, X. and Xie, Z. ....(A) 393
[Survey of regular drug taking in leprosy patients in Guangdong.] Zeng, J., *et al.* ....(A) 373
[Survey on leprosy in Henan Province.] Lei, G. ....(A) 392
[Survey on leprosy in the Southwest Prefecture, Guizhou Province.] Zhou, T. ....(A) 394

Chromatography,
Pyrolysis gas chromatography—mass spectrometry of mycobacterial mycolic acid methyl esters and its application to the identification of *M. leprae.* Kusaka, T. and Mori, T. ....(A) 387

Cimetidine,
Cimetidine inhibits suppressor factor production in Ethiopian lepromatous leprosy patients. Converse, P. J., *et al.* ....(C) 548
Dr. Nelson *et al.*'s response. Nelson, K. E. ....(C) 551

Ciprofloxacin,
Activities of pefloxacin and ciprofloxacin against *M. leprae* in the mouse. Guelpa-Lauras, C.-C., *et al.* ....(O) 70
In vitro susceptibility of mycobacteria to ciprofloxacin. Collins, C. H. and Uttley, H. C. ....(A) 185

Clinic(s),
Factors influencing clinic attendance during the multidrug therapy of leprosy. Langhorne, P., *et al.* ....(A) 583
Treatment clinics for Hansen's disease. ....(N) 573

Clinical,
[A case of delayed diagnosis of leprosy.] Bazurov, G. I. ....(A) 375
Amniotic band syndrome. Pavithran, K. ....(A) 175
[An etiology of anterior segment diseases not to be ignored: leprosy.] Travers, C., *et al.* ....(A) 378
Anaesthetic complications in a leprosy patient. Sarate, G. S., *et al.* ....(A) 591
Application of the mouse food-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy. Levy, L. .... (S) 823
Certainty levels in the diagnosis of leprosy. Ponnighaus, J. M., *et al.* ....(O) 454
[Clinical and bacteriological evaluation 8 years after triple drug chemotherapy for multibacillary leprosy in Senegal.] Dousset-Faure, I., *et al.* ....(A) 739

Clinical and histopathologic findings in osteoarticular chronic hypertrophic neuritis and differentiation from leprosy. Li, Z., *et al.* ..... (C) 556
Clinical and histopathological observations in pure neuritic leprosy. Uplekar, M. W. and Antia, N. H. ..... (A) 592
[Clinical manifestations and biological perturbations in the course of erythema nodosum leprosum.] Daluz, W. ..... (A) 376
Clinical pharmacokinetics of dapsone. Zuidema, J., *et al.* ..... (A) 374
Clinical problems in the initiation and assessment of multidrug therapy. Waters, M. F. R., *et al.* ..... (A) 589
Clinical significance of changes in serum proteins, immunoglobulins, and autoantibodies in leprosy. Rawlinson, W. D., *et al.* ..... (O) 277
Clinico-histopathological evaluation of modified piloarpine test in early diagnosis of leprosy. Chattopadhyay, S. P., *et al.* ..... (A) 376
[Combined and supervised treatment of leprosy—two years of follow-up.] Ravettini, B. and Achenbach, R. ..... (A) 587
Hansen's disease following lymphoma. Levy, M. L., *et al.* ..... (A) 376
Hansen's disease (leprosy) revisited. Waroyar, B. and Adams, L. M. ..... (A) 593
Influence of environmental mycobacteria on the prevalence of leprosy clinical type. Lyons, N. F. and Naafs, B. ..... (O) 637
Isolation of a nocardia-like chemoautotroph from clinically proven multibacillary cases of leprosy. Chakrabarty, A. N., *et al.* ..... (A) 755
Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Fox, W. and Kee, T. S. ..... (A) 762
[Outpatient treatment of leprosy patients for 4 years in Luding County, Sichuan Province.] (China) Xiong, D., *et al.* ..... (A) 760
Pityriasis rubra pilaris with leprophobia. Pankajam, R., *et al.* ..... (C) 555
Semen analyses in Hansen's disease. Sheriff, D. S. ..... (A) 592
The biomechanics of the interphalangeal joints. Brand, P. W., *et al.* ..... (A) 607
The THELEP controlled clinical drug trials. Subcommittee on Clinical, etc. ..... (S) 864
Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission. Miller, R. A., *et al.* ..... (O) 441
[Treatment of leprosy with human metabolites.] Mester de Parajd, L. and Mester de Parajd, M. ..... (A) 584

Clofazimine,
Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Mehta, J., *et al.* ..... (A) 584
In vitro activity of clofazimine against rapidly growing nonchromogenic mycobacteria. Ausina, V., *et al.* ..... (A) 607
Pharmacokinetics of clofazimine in healthy volunteers. Schaad-Lanyi, Z., *et al.* ..... (O) 9
Response to Dr. Pfaltzgraff. Gelber, R. H. and Zacharia, A. G. ..... (C) 554
[Seven years' follow-up of multibacillary patients treated with RFP or B663 for a short time.] Li, W. and Zhang, Y., *et al.* ..... (A) 372
The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy. Venkatesan, K., *et al.* ..... (A) 373
[Therapeutic effects of rifampicin, clofazimine and dapsone in multibacillary leprosy in the fieldwork—results of a year's treatment.] Li, W., *et al.* ..... (A) 372
[Three cases of multibacillary leprosy treated with B663 in four-drug regimen for one year.] Wang, Q. and Chen, J. ..... (A) 373

Complement,
Histochemical demonstration of mycobacterial antigen, specific antibody and complement in the lesions of tuberculosis. Ridley, M. J. and Ridley, D. S. ..... (A) 764

Concanavalin A (ConA),
Phenolic glycolipid-1 of *M. leprae* induces general suppression of *in vitro* concanavalin A responses unrelated to leprosy type. Prasad, H. K., *et al.* ..... (A) 385

Congresses,
Amsterdam will host 1988 International Congress for Tropical Medicine and Malaria. ..... (N) 364

XI Ibero-Latin American Congress of Dermatology Leprosy Symposium. Gatti, J. C. (N) 731
The 13th International Leprosy Congress, tentative program. (N) 728
XII International Congress for Tropical Medicine and Malaria. (N) 571

Control of leprosy,
Disability assessment as a measure of progress in leprosy control. Smith, W. C. S. and Parkhe, S. M. (A) 184
Dropouts during treatment for leprosy. (A study in the ELEP Leprosy Control Project, Dharmapuri District, Tamil Nadu, during 1975–1977). (India) Gopalakrishnan, S. (A) 371
[Economic benefits of leprosy control.] (China) Shu, H., *et al.* (A) 370
[Effects of controlling leprosy in Wuhan City.] (China) Lu, J. (A) 392
[Effects of leprosy control in Yulin Prefecture.] (China) Wang, C., *et al.* (A) 759
[Epidemic of leprosy and its control in Guangdong.] (China) Yang, X. (A) 393
[Epidemic of leprosy and the effect of its control in the South Prefecture, Jiangxi Province.] (China) Cai, Z. and Hong, D. (A) 392
[Leprosy control in 30 years in Hechi Prefecture.] (China) Pan, R. (A) 759
[New plan of the war against leprosy in Anjouan; preliminary results.] Grillone, S. and Pattyn, S. R. (A) 739
Proceedings of the Inauguration of China Leprosy Association, China Leprosy Foundation, China Leprosy Control and Research Centre and the First International Leprosy Symposium in China. (B) 574
[Review of leprosy control in Jiangsu Province.] (China) Ren, X. and Xie, Z. (A) 393
Study of compliance of the patients in leprosy control programme in an urban slum. Kartikeyan, S. and Bhalerao, V. R. (A) 582
Ten years' leprosy control work in Malawi (Central Africa)—I. Methods and outcome after treatment. Boerrigter, G. and Ponnighaus, J. M. (A) 182
Ten years' leprosy control work in Malawi (Central Africa)—II. Patterns of endemicity since 1973. Ponnighaus, J. M. and Boerrigter, G. (A) 183

Corticosteroids,
Evaluation of nerve function deficit, its improvement by nerve decompression or corticosteroid therapy. Shah, A. (A) 176
Reversal reaction—management with tropical corticosteroids. Srinivas, C. R., *et al.* (C) 355

Cuba,
Survey for primary dapsone resistance in Cuba. Gonzalez, A. B., *et al.* (A) 371

Cultivation,
Cultivable mycobacteria isolated from 32 newly captured armadillos (*Dasypus novemcinctus*) from Louisiana. (U.S.A.) Portaels, F., *et al.* (A) 788
[Cultivation of tubercle and opportunistic mycobacteria on medium with *N*-alkanes.] Koronelli, T. V. and Fadeeva, N. I. (A) 763
Investigations into cultivation of *M. leprae* in a nasal mucus medium: a preliminary report. Prabhakar, M. C. (C) 561
Investigations into the cultivation of *M. leprae*; a multifactorial approach. Kato, L. (A) 602
Studies of *in vitro*-cultivated isolates of *M. leprae* from nodules of lepromatous leprosy patients. Khera, V. R. and Mahadevan, P. R. (A) 405

Cutaneous,
Dapsone in the treatment of cutaneous leishmaniasis. Doga, J., *et al.* (A) 761
Hansen's disease: a new endemic focus in the Piacenza Province (Italy)? A description of four diagnosed cases by cutaneous biopsy. Paties, C., *et al.* (A) 393
[Study of new method for the application of tuberculin ointment for cutaneous use in comparison with the Mantoux test.] Levi, D. T., *et al.* (A) 763

Cyclosporine,
Effect of cyclosporine A in erythema nodosum leprosum. Uyemura, K., *et al.* (A) 386
Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission. Miller, R. A., *et al.* (O) 441

Dapsone (DDS),
A Spot Test for Dapsone in Urine by Han Huikeshoven. Hastings, R. C. ..... (B) 574
Association between regularity in dapsone (DDS) treatment and development of deformity. Radhakrishna, S. and Nair, N. G. K. ..... (O) 425
Binding of dapsone and its analogues to human serum albumin. Karp, W. B., *et al.* ... (A) 172
Blood dapsone levels in leprosy patients treated with acedapsone. George, J. and Balakrishnan, S. ..... (A) 371
Clinical pharmacokinetics of dapsone. Zuidema, J., *et al.* ..... (A) 374
Comparison of DDS with two combined chemotherapy regimens for multibacillary leprosy. Results after 3 years of treatment. A prospective randomized multicentre study. Dietrich, M. and Wabitsch, R. ..... (A) 579
Dapsone dependent nodular panniculitis. Uplekar, M. W. and Antia, N. H. ..... (A) 173
Dapsone in the treatment of cutaneous leishmaniasis. Doga, J., *et al.* ..... (A) 761
Dapsone neuropathy—report of three cases and pathologic features of a motor nerve. Sirsat, A. M., *et al.* ..... (O) 23
Dapsone resistance in *M. leprae*: a genotypic change. Prabhakaran, K., *et al.* ..... (A) 181
Dapsone susceptibility of *M. leprae* before and after 1977. Almeida, J. G. ..... (C) 726
Dapsone-induced neuropathy compounds Hansen's disease nerve damage: an electrophysiological study in tuberculoid patients. Sebille, A., *et al.* ..... (O) 16
Dapsone-induced peripheral neuropathy. Ahrens, E. M., *et al.* ..... (A) 607
Diabetogenic effect of dapsone. Asensio, A. S., *et al.* ..... (C) 357
Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Mehta, J., *et al.* ..... (A) 584
ELISA tests for dapsone and pyrimethamine and their application in a malaria chemoprophylaxis programme. Greenwood, B. M., *et al.* ..... (A) 580
[Intramuscular administration of dapsone in leprosy: a new approach.] Modderman, E. S. M. ..... (A) 585
Methemoglobinemia from dapsone therapy for a suspected brown spider bite. Iserson, K. V. ..... (A) 581
Pharmacokinetic interaction between dapsone and rifampicin in leprosy patients. Krishna, D. R., *et al.* ..... (A) 372
Primary and secondary dapsone resistance of *M. leprae* in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., *et al.* ..... (O) 672
[Report on four cases with acute DDS intoxication.] Wang, Z. and Chen, J. ..... (A) 740
[Sixty-eight cases of multibacillary leprosy treated with RFP or RFP plus DDS.] Zhou, S. and Zhu, S. ..... (A) 374
[Study on DDS resistance using the mouse foot pad technique.] Liu, X and Lin, Z. ... (A) 757
Survey for primary dapsone resistance in Cuba. Gonzalez, A. B., *et al.* ..... (A) 371
Sustained-release delivery systems, I: Phase diagram studies of dapsone and selected derivatives. Yang, T.-T. and Swarbrick, J. ..... (A) 741
Sustained-release delivery systems, II: *In vitro* dissolution of 4, 4′-sulfonylbisbenzamine (dapsone)—*N*-dodecanoyl-4, 4′-sulfonylbisbenzamine comelts. Yang, T.-T. and Swarbrick, J. ..... (A) 741
The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy. Venkatesan, K., *et al.* ..... (A) 373
The killing of *M. leprae* in mice by various dietary concentrations of dapsone and rifampin. Gelber, R. H. ..... (A) 390
[Therapeutic effects of rifampicin, clofazimine and dapsone in multibacillary leprosy in the fieldwork—results of a year's treatment.] Li, W., *et al.* ..... (A) 372
[Treatment of 24 cases of multibacillary leprosy with DDS, RFP, and PTH.] Zheng, C. ..... (A) 374

Deformity(ies),
Association between regularity in dapsone (DDS) treatment and development of deformity. Radhakrishna, S. and Nair, N. G. K. ..... (O) 425
[Loss of labor ability and social economics from leprosy deformities.] Shu, W., *et al.* .. (A) 761
[Psychosis of leprosy patients from social discrimination and somatic deformities.] Pan, X., *et al.* ..... (A) 760

Dermal,
An ultrastructural study of dermal nerves in early human leprosy. Chandi, S. M. and Chacko, C. J. G. ..... (O) 515
Ultrastructural changes in the blood vessel in dermal lesions of leprosy. Mukherjee, A., *et al.* ..... (A) 416

Dermatoglyphics,
An evaluation of palmar flexion creases and dermatoglyphics in leprosy. Gupta, C. M. and Tutakne, M. A. ..... (A) 174
[Asymmetry of dermatoglyphical indices and topics of tuberculosis process in the lungs.] Zosimov, A. N. and Khodzitskaya, V. K. ..... (A) 766

Dermatology,
80th anniversary of Asociación Argentina de Dermatología. ..... (N) 363
XI Ibero-Latin American Congress of Dermatology Leprosy Symposium. Gatti, J. C. .(N) 731
Samuel Patton Impey, M. D. (Aberdeen) (1856–1928), Cape Town's primordial leprologist, dermatologist, radiotherapist and rock-art enthusiast. Findlay, G. H. ..... (A) 738

DNA,
Cloning and expression of mycobacterial plasmid DNA in *Escherichia coli.* Labidi, A., *et al.* ..... (A) 186
Genetic relatedness among strains of the *M. tuberculosis* complex. Analysis of restriction fragment heterogeneity using cloned DNA probes. Eisenach, K. D., *et al.* ..... (A) 608
Isolation and restriction endonuclease analysis of mycobacterial DNA. Patel, R., *et al.* ..... (A) 609
Use of recombinant DNA molecules in epidemiological studies of leprosy. Clark-Curtiss, J. E., *et al.* ..... (A) 788

Drugs (see also specific drugs),
Activities of pefloxacin and ciprofloxacin against *M. leprae* in the mouse. Guelpa-Lauras, C.-C., *et al.* ..... (O) 70
An *in vitro* system using adenosine triphosphate and ^{3}H-thymidine to determine drug sensitivity of *M. leprae.* Dhople, A. M. and Green, K. J. ..... (A) 172
Application of the mouse foot-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy. Levy, L. ..... (S) 823
Binding of dapsone and its analogues to human serum albumin. Karp, W. B., *et al.* ...(A) 172
Blood dapsone levels in leprosy patients treated with acedapsone. George, J. and Balakrishnan, S. ..... (A) 371
Cimetidine inhibits suppressor factor production in Ethiopian lepromatous leprosy patients. Converse, P. J., *et al.* ..... (C) 548
[Clinical and bacteriological evaluation 8 years after triple drug chemotherapy for multibacillary leprosy in Senegal.] Dousset-Faure, I., *et al.* ..... (A) 739
Clinical pharmacokinetics of dapsone. Zuidema, J., *et al.* ..... (A) 374
Comparison of DDS with two combined chemotherapy regimens for multibacillary leprosy. Results after 3 years of treatment. A prospective randomized multicentre study. Dietrich, M. and Wabitsch, R. ..... (A) 579
Dapsone dependent nodular panniculitis. Uplekar, M. W. and Antia, N. H. ..... (A) 173
Drug susceptibility testing of *M. leprae.* Ji, B. ..... (S) 830
Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Mehta, J., *et al.* ..... (A) 584
Effect of combined clofazimine and ansamycin therapy on *M. avium-M. intracellulare* bacteremia in patients with AIDS. Masur, H., *et al.* ..... (A) 396
Effect of cyclosporine A in erythema nodosum leprosum. Uyemura, K., *et al.* ..... (A) 386
Effect of prothionamide on the infectivity of lepromatous leprosy. Girdhar, A., *et al.* ..(A) 739
Evaluation of levamisole, an immunopotentiator, in the treatment of lepromatous leprosy. Kar, H. K, *et al.* ..... (A) 582
Evaluation of subdermal biodegradable implants incorporating rifampicin as a method of drug delivery in experimental tuberculosis of guinea pigs. Mathur, I. S., *et al.* ....(A) 604
[Hepatotoxicity of ethionamide—a current problem.] See, A., *et al.* ..... (A) 373
Host-pathogen interaction—new *in vitro* drug test systems against *M. leprae*; possibilities and limitations. Mahadevan, P. R., *et al.* ..... (A) 583

Implementation of tests for monitoring drug compliance of leprosy out-patients under multi-drug therapy. Balakrishnan, S., *et al.* ..... (A) 577
In vitro susceptibility of mycobacteria to ciprofloxacin. Collins, C. H. and Uttley, H. C. ..... (A) 185
[Laboratory studies on antituberculous activity of cyclopentylrifampicin. II. A long-acting antituberculotic cyclopentylrifampicin.] Pan, Y., *et al.* ..... (A) 187
[II. *M. lepraemurium* in cell culture, possibly useful for screening antileprosy drugs.] Ye, S., *et al.* ..... (A) 742
Metabolic analyses of *M. leprae*: use in evaluation of *in vitro* culture media and drug activity. Franzblau, S. G. and Harris, E. B. ..... (A) 402
Metabolism in *M. leprae*: possible targets for drug interaction. Wheeler, P. R. ..... (A) 589
Monitoring of patient neural status during drug therapy—preliminary study. Bell-Krotoski, J. ..... (A) 414
Pharmacokinetic interaction between dapsone and rifampicin in leprosy patients. Krishna, D. R., *et al.* ..... (A) 372
Pharmacokinetics in drug screening. Grosset, J. H. ..... (S) 852
Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages. Jenner, P. J. and Smith, S. E. ..... (A) 581
Psychosocial dimensions of drug default in leprosy. Anandaraj, H. ..... (A) 375
Questions and Answers on the Implementation of Multiple Drug Therapy (MDT) for Leprosy. ..... (B) 737
Rifabutin and rifapentine compared with rifampin against *M. leprae* in mice. Pattyn, S. R. ..... (A) 373
Screening of drugs for activity against *M. leprae*. Ji, B., *et al.* ..... (S) 836
[Seven years' follow-up of multibacillary patients treated with RFP or B663 for a short time.] Li, W. and Zhang, Y., *et al.* ..... (A) 372
Side effects of levamisole. Arora, S. K., *et al.* ..... (A) 577
[Sixty-eight cases of multibacillary leprosy treated with RFP or RFP plus DDS.] Zhou, S. and Zhu, S. ..... (A) 374
Strategies in the development of new drugs and drug combinations against leprosy, demonstrated on the example of folate and gyrase inhibitors. Seydel, J. K., *et al.* ..... (A) 588
[Survey of regular drug taking in leprosy patients in Guangdong.] (China) Zeng, J., *et al.* ..... (A) 373
Thalidomide in leprosy—study of 94 cases. Parikh, D. A., *et al.* ..... (A) 585
[Thalidomide induced neuropathy.] Chapon, F., *et al.* ..... (A) 579
The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy. Venkatesan, K., *et al.* ..... (A) 373
The Malta experience: isoprodian-rifampicin combination treatment for leprosy. Depasquale, G. ..... (A) 579
The THELEP controlled clinical drug trials. Subcommittee on Clinical, etc. ..... (S) 864
[Therapeutic effects of rifampicin, clofazimine and dapsone in multibacillary leprosy in the fieldwork—results of a year's treatment.] Li, W., *et al.* ..... (A) 372
[Three cases of multibacillary leprosy treated with B663 in four-drug regimen for one year.] Wang, Q. and Chen, J. ..... (A) 373
[Treatment of 24 cases of multibacillary leprosy with DDS, RFP, and PTH.] Zheng, C. ..... (A) 374
Update on rifampin drug interactions. Baciewicz, A. M., *et al.* ..... (A) 577

Electron microscopy, (see also **Ultrastructure**),
Electron microscopic study of the intracellular fate of *M. leprae* in normal and activated macrophages. Sibley, L. D. and Krahenbuhl, J. L. ..... (A) 411

ELISA (enzyme-linked immunosorbent assay) tests,
A dot enzyme immunoassay for detection of IgM antibodies against phenolic glycolipid-I in sera from leprosy patients. Kumar, S., *et al.* ..... (A) 178
Development of a dot-ELISA for detection of leprosy antigenuria under field conditions. Kaldany R.-R. J. and Nurlign, A. ..... (A) 747
ELISA tests for dapsone and pyrimethamine and their application in a malaria chemoprophylaxis programme. Greenwood, B. M., *et al.* ..... (A) 580

Enzymes,
Enzymes and other biochemically active components of mycobacteria. Draper, P. ....(A) 755

Epidemiology,
A molecular approach to epidemiological studies of leprosy. Clark-Curtiss, J. E. .....(A) 405
[Comprehensive study of household gathering of leprosy with probability model of negative binomial and Poisson distributions.] Jiang, C., *et al.* .....(A) 758
Environmental nonhuman sources of leprosy. Blake, L. A., *et al.* .....(A) 758
[Epidemic of leprosy and its control in Guangdong.] (China) Yang, X. .....(A) 393
[Epidemic of leprosy and the effect of its control in the South Prefecture, Jiangxi Province.] (China) Cai, Z. and Hong, D. .....(A) 392
[Epidemical state of leprosy in Shannan Prefecture of Tibet.] Wei, A. .....(A) 759
[Epidemiological changes in Fujian Province, China.] Shao, K., *et al.* .....(A) 605
[Epidemiological profile of leprosy in Algeria.] Oughanem, M., *et al.* .....(A) 393
[Epidemiological survey of leprosy in Ankang Prefecture, Shanxi Province.] Hu, Y., *et al.* .....(A) 758
Genetic epidemiology of the susceptibility to leprosy. Shields, E. D., *et al.* .....(A) 606
Histopathological examination of skin biopsies from an epidemiological study of leprosy in Northern Malawi. McDougall, A. C., *et al.* .....(O) 88
[Investigation and analysis of leprosy epidemiology in Lufeng County of Guangdong Province.] Wang, Q., *et al.* .....(A) 759
[Investigation of leprosy endemic foci in Nandan County.] Lu, Z., *et al.* .....(A) 759
On the epidemiology of leprosy in Malta. Leiker, D. L. .....(A) 583
Retrieval of "left the area leprosy cases" by cross-notification. Rao, P. S. .....(A) 393
Social and demographic aspects of a leprosy epidemic on a Polynesian atoll: implications of pattern. Lieber, M. D. and Lieber, E. B. .....(O) 468
[Survey of leprosy in Dali Bai Autonomous Prefecture, Yunnan.] Du, J. .....(A) 758
[The epidemiology of leprosy.] Diop Mar, I., *et al.* .....(A) 605
[The epidemiology of leprosy in Guadeloupe from 1970 to 1984.] Cartel, J.-L., *et al.* ..(A) 392
Use of recombinant DNA molecules in epidemiological studies of leprosy. Clark-Curtiss, J. E., *et al.* .....(A) 788

Erythema nodosum leprosum (ENL),
Attempts to produce erythema nodosum leprosum in *M. leprae*-infected nude nu/nu mice with monoclonal antibodies. Chehl, S., *et al.* .....(A) 410
[Clinical manifestations and biological perturbations in the course of erythema nodosum leprosum.] Daluz, W. .....(A) 376
Effect of cyclosporine A in erythema nodosum leprosum. Uyemura, K., *et al.* .....(A) 386
Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy. Rao, T. D. and Rao, P. R. .....(O) 36
[Erythema nodosum leprosum with necrotic development.] Husser, J. A., *et al.* .....(A) 376
Plasma exchange in severe erythema nodosum leprosum. Wallach, D., *et al.* .....(A) 592
Tγ, Tμ and B lymphocytes in erythema nodosum leprosum reactions of leprosy. Rao, T. D. and Rao, P. R. .....(A) 599
The histopathology of type I (lepra) and type II (ENL) reactions in leprosy. Sehgal, V. N., *et al.* .....(A) 179
Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission. Miller, R. A., *et al.* .....(O) 441

Ethionamide,
[Hepatotoxicity of ethionamide—a current problem.] See, A., *et al.* .....(A) 373
Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages. Jenner, P. J. and Smith, S. E. .....(A) 581

Ethiopia,
Cimetidine inhibits suppressor factor production in Ethiopian lepromatous leprosy patients. Converse, P. J., *et al.* .....(C) 548
HLA antigens and neural reversal reactions in Ethiopian borderline tuberculoid leprosy patients. Ottenhoff, T. H. M., *et al.* .....(O) 261
Operational aspects of implementation of multidrug therapy at ALERT, Ethiopia. Becx-Bleumink, M. .....(A) 578

Experimental leprosy,
Effect of ofloxacin on experimental leprosy. Ito, T., *et al.* ..... (A) 778
Experimental leprosy in a rhesus monkey: necropsy findings. Baskin, G. B., *et al.* ..... (O) 109
Lepromin-induced lymphoproliferative response of experimental leprosy monkeys: regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., *et al.* ..... (A) 751
M. leprae-induced lymphoproliferative response of experimental leprosy monkeys; regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., *et al.* ..... (A) 417
Multiplication of *M. leprae* in the nude mouse, and some applications of nude mice to experimental leprosy. McDermott-Lancaster, R. D., *et al.* ..... (S) 889
Sciatic nerve in experimental leprosy. Vaishnavi, C., *et al.* ..... (A) 391
The search for animal models of leprosy. Johnstone, P. A. S. ..... (E) 535

Eye(s),
Anterior leprotic retinitis of trantas; a case report. Singh, M. ..... (A) 176
[Effects of orthopedic and conservative therapies on paralytic lagophthalmus.] Chen, Q. and Jing, X. ..... (A) 760
Factors influencing corneal involvement in leprosy. Lamba, P. A., *et al.* ..... (O) 667
Ocular leprosy: a case report and discussion of the pathology. House, P. H. ..... (A) 174
Study of hydration of stratum corneum in leprosy. Okhandiar, R. P., *et al.* ..... (A) 377
[Survey of eye diseases in 527 leprosy patients.] Li, S. and Fu, Q. ..... (A) 377
Unusual histological lesions in the eye of a leprosy patient. Zhou, H.-M., *et al.* ..... (O) 507
Uveal changes in leprosy. Rohatgi, J., *et al.* ..... (A) 175

Family(ies),
An investigation of family size and birth order as risk factors in leprosy. Koumantaki, I. G., *et al.* ..... (O) 463
Family studies of leprosy cases. Guha, P. K., *et al.* ..... (A) 182, 590

FLA-ABS test,
Sensitivity and specificity of the FLA-ABS test for leprosy in Mexican populations. Amezcua, M. E., *et al.* ..... (O) 286

Foot,
A standard dorsal-plantar and lateral radiographic projections of the feet. Brand, P. W. and Coleman, W. C. ..... (A) 607
Effect of rocker sole design on plantar forefoot pressures. Nawoczenski, D., *et al.* ..... (A) 415
Foot pressure measurement in leprosy and footwear designs. Patil, K. M., *et al.* ..... (A) 395
Hansen's disease with pedal involvement; a case report. Ottinger, M. L. and Black, J. R. ..... (A) 175
Microflora in the trophic ulcers of the foot in leprosy. Chatterjee, B. D., *et al.* ..... (A) 375
Plantar sensory threshold in the ulcerative foot. Birke, J. A. and Sims, D. S. ..... (A) 184
The insensitive foot; Northwick Park experience. Geary, N. P. J. and Klenerman, L. ..... (A) 606

Foot pad(s),
Application of the mouse foot-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy. Levy, L. ..... (S) 823
[Study on DDS resistance using the mouse foot pad technique.] Liu, X. and Lin, Z. ..... (A) 757
The effect of diet on the growth of *M. leprae* in mouse foot pads. Foster, R., *et al.* ..... (A) 403

France,
Primary and secondary dapsone resistance of *M. leprae* in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., *et al.* ..... (O) 672

Genetics,
Bacillary growth, interleukin-2 production defect, and specific antibody secretion governed by different genetical factors in mice infected subcutaneously with *M. lepraemurium*. Hoffenbach, A. and Bach, M.-A. ..... (A) 390
[Genetic component of the immune response to *M. leprae* in healthy individuals.] Bottasso, O. A., *et al.* ..... (A) 593
Genetic epidemiology of the susceptibility to leprosy. Shields, E. D., *et al.* ..... (A) 606

Genetic relatedness among strains of the *M. tuberculosis* complex. Analysis of restriction fragment heterogeneity using cloned DNA probes. Eisenach, K. D., *et al.* ..... (A) 608
The "Hansen-anergic fringe." Rotberg, A. ..... (A) 599

Germany,
Foundation of the Hansen Institute, Wurzburg. ..... (N) 363

Granuloma(s),
Accessory cell function of cells isolated from *M. leprae*-induced granulomas. Montree-wasuwat, N., *et al.* ..... (A) 383
Characterization of CD4-positive T-lymphocyte subsets in leprosy granulomas. Rea, T. H. and Modlin, R. L. ..... (A) 786
Elastase activity in granulomatous inflammation in experimental murine leprosy. Hsu, P.-S., *et al.* ..... (A) 381
Granulomatous inflammation in the acquired immune deficiency syndrome. Jagadha, V., *et al.* ..... (A) 186

Guadeloupe,
Primary and secondary dapsone resistance of *M. leprae* in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., *et al.* ..... (O) 672
[The epidemiology of leprosy in Guadeloupe from 1970 to 1984.] Cartel, J. L., *et al.* ..(A) 392

Hand(s),
A study of palmar ridge malformation in leprosy. Gupta, C. M., *et al.* ..... (A) 590
Simplified surgical technique for flexible clawed hand rehabilitation. Chevallard, A. J. ..... (C) 160
The repeatability of testing with Semmes-Weinstein monofilaments. Bell-Krotoski, J. and Tomancik, E. ..... (A) 394

Heiser Program, The,
The Heiser Program for Research in Leprosy 1988. ..... (N) 572

Histology,
A rapid silver staining method for identification of *M. leprae* in histologic sections. Senba, M., *et al.* ..... (A) 599
[Histologic evolution of paucibacillary leprosy during treatment with various therapeutic regimens.] Pattyn, S. R., *et al.* ..... (A) 587
Rationale for the histological spectrum of tuberculosis; a basis for classification. Ridley, D. S. and Ridley, M. J. ..... (A) 764
Unusual histological lesions in the eye of a leprosy patient. Zhou, H.-M., *et al.* ..... (O) 507

Histopathology,
[A study of the histopathologic changes of the nasal mucosa in patients with leprosy.] Kim, H. B. and Kim, M. Y. ..... (A) 596
Clinical and histopathologic findings in osteoarticular chronic hypertrophic neuritis and differentiation from leprosy. Li, Z., *et al.* ..... (C) 556
Clinical and histopathological observations in pure neuritic leprosy. Uplekar, M. W. and Antia, N. H. ..... (A) 592
Clinico-histopathological evaluation of modified piloarpine test in early diagnosis of leprosy. Chattopadhyay, S. P., *et al.* ..... (A) 376
Histopathological examination of skin biopsies from an epidemiological study of leprosy in Northern Malawi. McDougall, A. C., *et al.* ..... (O) 88
S-100 Protein and immunoperoxidase technique as an aid in the histopathologic di-agnosis of leprosy. Fleury, R. N. and Bacchi, C. E. ..... (O) 338
The histopathology of type I (lepra) and type II (ENL) reactions in leprosy. Sehgal, V. N., *et al.* ..... (A) 179
Venous involvement in leprosy: a venographic and histopathological correlation. Bansal, R., *et al.* ..... (O) 499

History of leprosy,
Early tractata on leprosy. Kato, L. ..... (C) 157
Plague and leprosy in the Middle Ages: a paradoxical cross-immunity? Ell, S. R. ..... (E) 345
..... (A) 401

HLA,
An HLA-DR3 immune response gene for *M. leprae* predisposes to tuberculoid leprosy. Ottenhoff, T. H. M. and de Vries, R. R. P. ..... (A) 779
An HLA-linked gene controls susceptibility to lepromatous leprosy through T cell regulation. Kikuchi, I., *et al.* ..... (A) 749
Evidence for an HLA-DR4-associated immune-response gene for *M. tuberculosis.* Ottenhoff, T. H. M., *et al.* ..... (A) 609
HLA antigens and neural reversal reactions in Ethiopian borderline tuberculoid leprosy patients. Ottenhoff, T. H. M., *et al.* ..... (O) 261
HLA class II immune response and suppression genes in leprosy. Ottenhoff, T. H. M. and de Vries, R. R. P. ..... (R) 521
HLA class II restricted helper and suppressor clones reactive with *M. leprae.* de Vries, R. R. P., *et al.* ..... (A) 745
Molecular localization and polymorphism of HLA class II restriction determinants defined by *M. leprae*-reactive helper T cell clones from leprosy patients. Ottenhoff, T. H. M., *et al.* ..... (A) 384
The HLA antigens and leprosy in Korea. Kim, S. J., *et al.* ..... (A) 183

Hypersensitivity,
Comparative study of immunizing and delayed hypersensitivity eliciting antigens of *M. leprae, M. tuberculosis, M. vaccae,* and *M. bovis* (BCG). Sinha, S., *et al.* ..... (O) 42
Delayed-type hypersensitivity in human volunteers immunized with a candidate leprosy vaccine. ..... (A) 593
Dissociation between delayed-type hypersensitivity and resistance to pathogenic mycobacteria demonstrated by T-cell clones. Hussein, S., *et al.* ..... (A) 595
Etiological factors in delayed-type hypersensitivity reactions in leprosy. Klenerman, P. ..... (E) 702
Influence of delayed immune reactions on human epidermal keratinocytes. Kaplan, G., *et al.* ..... (A) 178
Study of DTH and resistance in *M. lepraemurium* infection using a T-cell line isolated from mice infected with *M. bovis* (BCG). Hussein, S., *et al.* ..... (A) 595
Suppression of delayed hypersensitivity skin reactions to tuberculin by *M. leprae* antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., *et al.* ..... (A) 600
Suppressor T cells for delayed-type hypersensitivity in susceptible mice infected with *M. lepraemurium.* Richard, L., *et al.* ..... (O) 63
The relationship between delayed type hypersensitivity and protective immunity induced by mycobacterial vaccines in man. Fine, P. E. M., *et al.* ..... (A) 745
The relationship between natural killer cell activity and delayed-type hypersensitivity reaction of 2,4-dinitrochlorbenzene in the spectrum of chronic, intractable pulmonary tuberculosis. Yoneda, T., *et al.* ..... (A) 610
The role of IFN-gamma in the regulation of DTH in human skin. Kaplan, G. and Cohn, Z. A. ..... (A) 785

ICRC bacilli,
Effects of ICRC antileprosy vaccine in healthy subjects. Chaturvedi, R. M., *et al.* ..... (O) 657

IgA,
[Effect of thalidomide on serum levels of immunoglobulins IgM and IgA, rheumatoid factor and isohemagglutinins anti-A and anti-B in patients with lepromatous leprosy: a double-blind study.] Arruda, W. O., *et al.* ..... (A) 378

IgG,
The evolution of IgG and IgM antibodies to phenolic glycolipid-I in armadillos inoculated with *M. leprae.* Vadiee, R., *et al.* ..... (A) 419

IgM,
A dot enzyme immunoassay for detection of IgM antibodies against phenolic glycolipid-I in sera from leprosy patients. Kumar, S., *et al.* ..... (A) 178
[Effect of thalidomide on serum levels of immunoglobulins IgM and IgA, rheumatoid factor and isohemagglutinins anti-A and anti-B in patients with lepromatous leprosy: a double-blind study.] Arruda, W. O., *et al.* ..... (A) 378
The evolution of IgG and IgM antibodies to phenolic glycolipid-I in armadillos inoculated with *M. leprae.* Vadiee, R., *et al.* ..... (A) 419

ILEP,
ILEP Catalogue on Training, 1987. ....(N) 734
XVI General Assembly of ILEP, Edinburgh, July 1986. ....(N) 168

Immune complexes,
Circulating immune complexes in normal and immunosuppressed mice infected with *M. leprae*. Vaishnavi, C., *et al.* ....(A) 604
[Detection of immune complexes in lepromatous leprosy. I. Appraisal of precipitation technique with polyethylene glycol.] Valdes-Portela, A. ....(A) 592
Effect of preformed immune complexes on the course of *M. leprae* infection in normal mice. Kaur, S., *et al.* ....(C) 358

Immune responses,
Distribution and turnover of Langerhans cells during delayed immune responses in human skin. Kaplan, G., *et al.* ....(A) 748
Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy. Rao, T. D. and Rao, P. R. ....(O) 36
Humoral immune responses to *M. leprae* in human volunteers vaccinated with killed, armadillo-derived *M. leprae*. Gill, H. K., *et al.* ....(A) 746
Immunosuppression and cellular immunity reactions in leprosy patients treated with a mixture of *M. leprae* and BCG. Rada, E. M., *et al.* ....(O) 646

Immunoglobulins,
Clinical significance of changes in serum proteins, immunoglobulins, and autoantibodies in leprosy. Rawlinson, W. D., *et al.* ....(O) 277
[Effect of thalidomide on serum levels of immunoglobulins IgM and IgA, rheumatoid factor and isohemagglutinins anti-A and anti-B in patients with lepromatous leprosy: a double-blind study.] Arruda, W. O., *et al.* ....(A) 378

Immunology,
An unusual case of untreated lepromatous leprosy with rare bacilli: an immunologic follow-up. Gelber, R. H. and Mohagheghpour, N. ....(C) 353
Application of the mouse foot-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy. Levy, L. ....(S) 823
Biological, chemical, immunological and staining properties of bacteria isolated from tissues of leprosy patients. Cocito, C. and Delville, J. ....(A) 600
Immunologic aspects of leprosy. Ashmalla, L. ....(A) 590
Immunological and biochemical characterization and classification of mycobacterial antigens. Harboe, M. and Wiker, H. G. ....(A) 746
Indo-U.S. Symposium on Immunology & Molecular Biology of Leprosy. ....(N) 165
[Significance of certain biochemical and immunological indices in estimation of activity of limited tuberculosis of the lungs.] Kostina, Z. I., *et al.* ....(A) 763
The immunobiology of leprosy. Kaplan, G. and Cohn, Z. A. ....(A) 177

Immunoperoxidase,
S-100 Protein and immunoperoxidase technique as an aid in the histopathologic diagnosis of leprosy. Fleury, R. N. and Bacchi, C. E. ....(O) 338

Immunosuppression,
A possible role for E-receptor in immunosuppression in leprosy. Muthukkaruppan, V. R. ....(A) 383
ADCC function in *M. leprae* inoculated normal and immunosuppressed mice. Ganguly, N. K., *et al.* ....(A) 390
Circulating immune complexes in normal and immunosuppressed mice infected with *M. leprae*. Vaishnavi, C., *et al.* ....(A) 604
Immunosuppression and cellular immunity reactions in leprosy patients treated with a mixture of *M. leprae* and BCG. Rada, E. M., *et al.* ....(O) 646

Immunotherapy,
Immunotherapy in leprosy: a new approach. Chattopadhyay, S. P. and Gupta, C. M. ..(A) 173

India,
A preliminary report on *M. leprae* in Aurangabad. Kalyankar, S. D., *et al.* ....(A) 605
Bombay Acworth Seminars 1985–1986. ....(N) 363

Dr. Ganapati's leprosy studies recognized. Maniar, J. K. ..... (N) 570
Dr. Thangaraj and Mr. Askew retire. ..... (N) 730
Dropouts during treatment for leprosy. (A study in the ELEP Leprosy Control Project, Dharmapuri District, Tamil Nadu, during 1975–1977). Gopalakrishnan, S. ..... (A) 371
IAL workshop held. ..... (N) 570
Indo-U.S. Symposium on Immunology & Molecular Biology of Leprosy. ..... (N) 165
International Meeting on Voluntary Organizations in Leprosy. ..... (N) 167
KLEP: Karigiri Leprosy Education Programme, South India. ..... (N) 730
Leprosy in eastern region of Rajasthan. Mishra, B., *et al.* ..... (A) 605
Mass vaccination studies initiated. ..... (N) 364
New Director-General of Indian Council of Medical Research. ..... (N) 570
1987 National Awards for the Welfare of the Handicapped. ..... (N) 730
Premananda Memorial Leprosy Hospital opened. ..... (N) 364
Studies on Leprosy in Bombay. Hastings, R. C. ..... (B) 170
Study of autoantibodies in lepromatous leprosy in rural central India. Jain, A. P., *et al.* ..... (A) 175, 590
Western Regional Leprosy Workers' Conference. ..... (N) 167

Inoculation,
ADCC function in *M. leprae* inoculated normal and immunosuppressed mice. Ganguly, N. K., *et al.* ..... (A) 390
Detection of persisting *M. leprae* by inoculation of the neonatally thymectomized rat. Gelber, R. H. and Levy, L. ..... (S) 872
Influence of route of inoculation on anti-*M. lepraemurium* antibody isotopes in murine leprosy. Hoffenbach, A., *et al.* ..... (O) 305
The evolution of IgG and IgM antibodies to phenolic glycolipid-I in armadillos inoculated with *M. leprae.* Vadiee, R., *et al.* ..... (A) 419

Interferon,
A single cell assay for the study of γ-interferon formation in leprosy patients. Lindh, J., *et al.* ..... (A) 382
Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Douvas, G. S., *et al.* ..... (A) 186
Interferon-gamma induces the expression of major histocompatibility complex antigens by *in vitro* cultured murine Schwann cells. Mshana, R. N., *et al.* ..... (A) 781
M. leprae-burdened macrophages are refractory to activation by gamma interferon. Sibley, L. D. and Krahenbuhl, J. L. ..... (A) 386
Quantitative analysis of contrasuppressor T lymphocytes in leprosy; induction of Ia antigens with gamma interferon. Gonzalez-Amaro, R., *et al.* ..... (O) 651
Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Khor, M., *et al.* ..... (A) 763

Interleukin(s),
Assessment of the immune deficit in leprosy patients and the effect of recombinant IL-2 *in vitro.* Locniskar, M., *et al.* ..... (O) 249
Bacillary growth, interleukin-2 production defect, and specific antibody secretion governed by different genetical factors in mice infected subcutaneously with *M. lepraemurium.* Hoffenbach, A. and Bach, M.-A. ..... (A) 390
Deficiency in the biosynthesis of interleukin 2 (IL-2) and functional presence of the IL-2 receptor in lepromatous leprosy. Islas-Rodriguez, A. E., *et al.* ..... (C) 566
Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. Wallis, R. S., *et al.* ..... (A) 188
Effect of interleukin-1 (IL-1) and IL-2 on lymphocytes from patients with leprosy. Rada, E. M., *et al.* ..... (C) 351
Lepromin stimulates interleukin-2 production and interleukin-2 receptor expression *in situ* in lepromatous leprosy patients. Longley, B. J., *et al.* ..... (A) 750
Prevalence and specificity of the enhancing effect of three types of interleukin 2 on T-cell responsiveness in 97 lepromatous leprosy patients of mixed ethnic origin. Barnass, S., *et al.* ..... (A) 379
Soluble serum interleukin 2 receptor levels in leprosy patients. Tung, K. S. K., *et al.* ..... (A) 753

International Journal of Leprosy,
Author Index to Volume 54—1986. ..... (—) 191
Reviewers. ..... (—) 792
Statement of financial condition. ..... (—) 611
Statement of ownership, management, and circulation. ..... (—) 795
Subject Index to Volume 54—1986. ..... (—) 202
The 1986 Journal—a continuing perspective. Hastings, R. C. ..... (—) 140

International Leprosy Association,
Officers and Councillors. ..... (—) 793

International Leprosy Congress,
The 13th International Leprosy Congress, tentative program. ..... (—) 728

Intestine,
[Small intestine transit anomalies in a patient with chronic abdominal pain and treated for leprosy.] Davy, C., *et al.* ..... (A) 371

Isoniazid,
Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Khor, M., *et al.* ..... (A) 763

Italy,
Hansen's disease: a new endemic focus in the Piacenza Province? A description of four diagnosed cases by cutaneous biopsy. Paties, C., *et al.* ..... (A) 393

Japan,
Research Activities of the National Institute for Leprosy Research. Special Issue for the 30th Anniversary. Abe, M., ed. ..... (B) 170
The First Joint THELEP-Sasakawa Memorial Health Foundation Workshop on Experimental Chemotherapy of Leprosy. Grosset, J., *et al.* ..... (S) 807
Twenty-Second Joint Leprosy Research Conference, Bethesda, Maryland, U.S.A., 20–22 July 1987. (U.S.–Japan Cooperative Medical Science Program). ..... (—) 767
Workshop on Experimental Chemotherapy of Leprosy, Osaka, Japan, 11–20 November 1986. ..... (S) 797

Kidney(s),
Histo-functional status of kidney in leprosy. Nigam, P., *et al.* ..... (A) 591

Korea,
The HLA antigens and leprosy in Korea. Kim, S. J., *et al.* ..... (A) 183

Leishmaniasis,
Dapsone in the treatment of cutaneous leishmaniasis. Doga, J., *et al.* ..... (A) 761
Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Douvas, G. S., *et al.* ..... (A) 186

Leonard Wood Memorial,
Leonard Wood Memorial (LWM) seeking Director of Scientific Facility. ..... (N) 571
LWM course offered at Cebu. ..... (N) 365

Lepromatous leprosy,
An HLA-linked gene controls susceptibility to lepromatous leprosy through T cell regulation. Kikuchi, I., *et al.* ..... (A) 749
An unusual case of untreated lepromatous leprosy with rare bacilli: an immunologic follow-up. Gelber, R. H. and Mohagheghpour, N. ..... (C) 353
Antigens of *M. leprae* in urine during treatment of patients with lepromatous leprosy. Olcén, P., *et al.* ..... (A) 384
Application of the mouse foot-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy. Levy, L. ..... (S) 823
Bilateral ulnar nerve abscesses in lepromatous leprosy. Pfaltzgraff, R. E. ..... (C) 553
Chemotherapy trials in the neonatally thymectomized Lewis rat: a model for the study of the therapy of lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 776

Cimetidine inhibits suppressor factor production in Ethiopian lepromatous leprosy patients. Converse, P. J., *et al.* ..... (C) 548
Cold reactive lymphocytotoxic antibodies in patients with tuberculoid and lepromatous leprosy. Nail, S., *et al.* ..... (O) 273
Defective macrophage effector function in lepromatous leprosy. Krahenbuhl, J. L., *et al.* ..... (A) 782
Defective monocyte chemotaxis in active lepromatous leprosy. Schuller-Levis, G., *et al.* ..... (O) 267
Deficiency in the biosynthesis of interleukin 2 (IL-2) and functional presence of the IL-2 receptor in lepromatous leprosy. Islas-Rodriguez, A. E., *et al.* ..... (C) 566
[Detection of immune complexes in lepromatous leprosy. I. Appraisal of precipitation technique with polyethylene glycol.] Valdes-Portela, A. ..... (A) 592
Dr. Nelson *et al.*'s response. Nelson, E. E., *et al.* ..... (C) 551
Effect of prothionamide on the infectivity of lepromatous leprosy. Girdhar, A., *et al.* ..... (A) 739
[Effect of thalidomide on serum levels of immunoglobulins IgM and IgA, rheumatoid factor and isohemagglutinins anti-A and anti-B in patients with lepromatous leprosy: a double-blind study.] Arruda, W. O., *et al.* ..... (A) 378
Evaluation of levamisole, an immunopotentiator, in the treatment of lepromatous leprosy. Kar, H. K., *et al.* ..... (A) 582
Lepromatous leprosy. Miller, J. A., *et al.* ..... (A) 175
Lepromin stimulates interleukin-2 production and interleukin-2 receptor expression *in situ* in lepromatous leprosy patients. Longley, B. J., *et al.* ..... (A) 750
Lepromin-induced suppressor cells in lepromatous leprosy. Nelson, E. E., *et al.* ..... (A) 384
Lymphocyte transformation in lepromatous leprosy: a study of the influence of disease activity and symptom duration. Brown, A. E., *et al.* ..... (A) 379
Myelinated and unmyelinated fibers in sural nerve biopsy of a case with lepromatous leprosy—a quantitative approach. Gibbels, E., *et al.* ..... (O) 333
Oral lesions in lepromatous leprosy. Bucci, F., Jr., *et al.* ..... (A) 742
Prevalence and specificity of the enhancing effect of three types of interleukin 2 on T-cell responsiveness in 97 lepromatous leprosy patients of mixed ethnic origin. Barnass, S., *et al.* ..... (A) 379
Primary visceral Virchowian (lepromatous) hanseniasis. Azulay, R. D. ..... (O) 450
Regulation of cell-mediated immunity in lepromatous leprosy. Kaplan, G. and Cohn, Z. A. ..... (A) 747
Response to Dr. Pfaltzgraff. Gelber, R. H. and Zacharia, A. G. ..... (C) 554
Reversal of T cell unresponsiveness in lepromatous leprosy. Nath, I. ..... (A) 751
Serological reactivity and early detection of leprosy among contacts of lepromatous patients in Cebu, The Philippines. Douglas, J. T., *et al.* ..... (C) 718
Significant enhanced superoxide anion (O_2^-) monocytes of lepromatous leprosy patients stimulated with liposome and suppression by C-reactive protein (CRP). Hokama, Y., *et al.* ..... (A) 746
Studies of *in vitro*-cultivated isolates of *M. leprae* from nodules of lepromatous leprosy patients. Khera, V. R. and Mahadevan, P. R. ..... (A) 405
Study of autoantibodies in lepromatous leprosy in rural central India. Jain, A. P., *et al.* ..... (A) 175, 590
Suppression of delayed hypersensitivity skin reactions to tuberculin by *M. leprae* antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., *et al.* ..... (A) 600
Suppressor response in lepromatous leprosy patients: role of Leu2a cells. Sasiain, M. del C., *et al.* ..... (A) 385
Suppressor T lymphocytes from lepromatous leprosy skin lesions. Modlin, R. L., *et al.* ..... (A) 179
T cell defect in lepromatous leprosy is reversible *in vitro* in the absence of exogenous growth factors. Mohagheghpour, N., *et al.* ..... (A) 383
Tetanus in a case of lepromatous leprosy. Parikh, A. A. and Shah, B. H. ..... (A) 591
[The foamy cells in skin lesions of arrested lepromatous patients.] Zhu, W., *et al.* ..... (A) 754
Ultrasonographic findings in the livers of patients with lepromatous leprosy. Doehring, E., *et al.* ..... (A) 173
Undernutrition in lepromatous leprosy, Part I. Is it associated with poverty or with disease? Rao, K. N., *et al.* ..... (A) 377
Undernutrition in lepromatous leprosy, Part II. Altered levels of serum elements; their

association with the disease and not with food deprivation. Rao, K. N. and Saha, K. ..... (A) 377

Lepromin,
[Behavior of the intradermal reaction with lepromin in patients with sarcoidosis.] Gumaraes Proenca, N., *et al.* ..... (A) 177
Immunohistologic comparison between armadillo-derived leprosin and standard lepromin skin tests in leprosy patients. Narayanan, R. B., *et al.* ..... (A) 598
Lepromin stimulates interleukin-2 production and interleukin-2 receptor expression *in situ* in lepromatous leprosy patients. Longley, B. J., *et al.* ..... (A) 750
Lepromin-induced lymphoproliferative response of experimental leprosy monkeys: regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., *et al.* ..... (A) 751
Lepromin-induced suppressor cells in lepromatous leprosy. Nelson, E. E., *et al.* ..... (A) 384

Lesions,
[Differential diagnosis of leprous lesions in Africans.] Akimov, V. G. ..... (A) 375
Histochemical demonstration of mycobacterial antigen, specific antibody and complement in the lesions of tuberculosis. Ridley, M. J. and Ridley, D. S. ..... (A) 764
[*In situ* characterization of immune cells in the annular lesions of leprosy.] Lee, C. W., *et al.* ..... (A) 597
In situ identification of activated Ta1+ T lymphocytes in human leprosy skin lesions. Shen, J.-Y., *et al.* ..... (O) 494
Leprosy neuropathy; cells expressing MHC class II antigens in the lesion. Mshana, R. N. and Nilsen, R. ..... (A) 407
Oral lesions in lepromatous leprosy. Bucci, F., Jr., *et al.* ..... (A) 742
Suppressor T lymphocytes from lepromatous leprosy skin lesions. Modlin, R. L., *et al.* ..... (A) 179
[The foamy cells in skin lesions of arrested lepromatous patients.] Zhu, W., *et al.* ..... (A) 754
T-lymphocyte clones from leprosy skin lesions. Modlin, R. L., *et al.* ..... (A) 750
Ultrastructural changes in the blood vessel in dermal lesions of leprosy. Mukherjee, A., *et al.* ..... (A) 416
Unusual histological lesions in the eye of a leprosy patient. Zhou, H.-M., *et al.* ..... (O) 507

Levamisole,
Evaluation of levamisole, an immunopotentiator, in the treatment of lepromatous leprosy. Kar, H. K., *et al.* ..... (A) 582
Side effects of levamisole. Arora, S. K., *et al.* ..... (A) 577

Lipid,
Lipid composition of human leprous tissue. Kumar, B., *et al.* ..... (C) 162

Liver,
Ultrasonographic findings in the livers of patients with lepromatous leprosy. Doehring, E., *et al.* ..... (A) 173

Lucio leprosy,
Specific antigen and antibody to *M. leprae* in the cryoprecipitate of a patient with Lucio phenomenon. Drosos, A. A., *et al.* ..... (A) 594

Lymph node(s),
Metastatis of malignant plantar ulcer in lymph nodes in femoral triangle—a case report. Bobhate, S. K., *et al.* ..... (A) 590

Lymphocyte(s),
Arthritis induced by a T-lymphocyte clone that responds to *M. tuberculosis* and to cartilage proteoglycans. van Eden, W., *et al.* ..... (A) 188
Characterization of a factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes. Kerr, M. A., *et al.* ..... (A) 748
Characterization of CD4-positive T-lymphocyte subsets in leprosy granulomas. Rea, T. H. and Modlin, R. L. ..... (A) 786
Cold reactive lymphocytotoxic antibodies in patients with tuberculoid and lepromatous leprosy. Naik, S., *et al.* ..... (O) 273

Effect of interleukin-1 (IL-1) and IL-2 on lymphocytes from patients with leprosy. Rada, E. M., *et al.* ..... (C) 351
In situ identification of activated Ta1+ T lymphocytes in human leprosy skin lesions. Shen, J.-Y., *et al.* ..... (O) 494
In vitro proliferation of lymphocytes from human volunteers vaccinated with armadillo-derived, killed *M. leprae*. Gill, H. K., *et al.* ..... (O) 30
Lepromin-induced lymphoproliferative response of experimental leprosy monkeys: regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., *et al.* ..... (A) 751
Lymphocyte transformation in lepromatous leprosy: a study of the influence of disease activity and symptom duration. Brown, A. E., *et al.* ..... (A) 379
M. leprae-induced lymphoproliferative response of experimental leprosy monkeys; regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., *et al.* ..... (A) 417
M. leprae-specific Lyt-2+ T lymphocytes with cytolytic activity. Chiplunkar, S., *et al.* ..... (A) 380
Quantitative analysis of contrasuppressor T lymphocytes in leprosy; induction of Ia antigens with gamma interferon. Gonzalez-Amaro, R., *et al.* ..... (O) 651
Regulatory role of FcR+ and FcR− monocyte subsets in *M. leprae*-induced lymphoproliferative response *in vitro*. Ohkawa, S., *et al.* ..... (A) 384
[Regulatory subpopulations of T lymphocytes in patients with pulmonary tuberculosis.] Averbakh, M. M., *et al.* ..... (A) 761
[Rosette-forming T lymphocytes of different types in patients with pulmonary tuberculosis.] Petrashenko, A. I. ..... (A) 764
Suppressor T lymphocytes from lepromatous leprosy skin lesions. Modlin, R. L., *et al.* ..... (A) 179
T lymphocytes respond to solid-phase antigen: a novel approach to the molecular analysis of cellular immunity. Young, D. B. and Lamb, J. R. ..... (A) 189
T-lymphocyte clones from leprosy skin lesions. Modlin, R. L., *et al.* ..... (A) 750
Tγ, Tμ and B lymphocytes in erythema nodosum leprosum reactions of leprosy. Rao, T. D. and Rao, P. R. ..... (A) 599
The identification of T cell epitopes in *M. tuberculosis* using human T lymphocyte clones. Lamb, J. R., *et al.* ..... (A) 749
The mechanism of action of the factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes. Hussein, Y. M., *et al.* ..... (A) 747

Macrophage(s),
A novel semi-automated technique for measuring inhibition of intracellular mycobacterial growth by macrophage activating factor. Arden Jones, M. P. and Coates, A. R. M. ..... (A) 185
Comparison of radiometric macrophage assay and fluorescein diacetate/ethidium bromide staining for evaluation of *M. leprae* viability. Harshan, K. V., *et al.* ..... (O) 316
Defective macrophage effector function in lepromatous leprosy. Krahenbuhl, J. L., *et al.* ..... (A) 782
Electron microscopic study of the intracellular fate of *M. leprae* in normal and activated macrophages. Sibley, L. D. and Krahenbuhl, J. L. ..... (A) 411
Functional responses of normal and activated macrophages infected with *M. leprae in vitro*. Sibley, L. D., *et al.* ..... (A) 783
Gamma interferon activates human macrophages to become tumoricidal and leishmonicidal but enhances replication of macrophage-associated mycobacteria. Douvas, G. S., *et al.* ..... (A) 186
Importance of determining viability of *M. leprae* inside macrophages—an *in vitro* method using uracil. Vejare, S. and Mahadevan, P. R. ..... (A) 757
M. leprae-burdened macrophages are refractory to activation by gamma interferon. Sibley, L. D. and Krahenbuhl, J. L. ..... (A) 386
Macrophage chemotaxis in *M. leprae* infected mice. Kumar, B., *et al.* ..... (A) 597
Macrophages infected *in vitro* with live mycobacteria fail to express Ia antigen after stimulation with lymphokine. Mshana, R. N., *et al.* ..... (A) 407
Metabolism of *M. leprae* in macrophages. Ramasesh, N., *et al.* ..... (A) 603
Resistance to *M. lepraemurium* is correlated with the capacity to generate macrophage activating factor(s) in response to mycobacterial antigens *in vitro*. Brett, S. J. and Butler, R. ..... (A) 389

The effect of *in vivo* modulation of macrophage activities on *M. lepraemurium* infection. Ha, D. K. K., *et al.* ..... (A) 181
The *in vitro* microbicidal effects of activated macrophages on *M. leprae*. Ramasesh, N., *et al.* ..... (A) 412
Ultracytochemical studies of lysosomal function in the macrophages of human leprosy—I. Bharadwaj, V. P., *et al.* ..... (O) 328

Malawi,
Histopathological examination of skin biopsies from an epidemiological study of leprosy in Northern Malawi. McDougall, A. C., *et al.* ..... (O) 88
Preliminary evaluation of the affect of WHO-MDT on disabilities in leprosy patients in Malawi (Central Africa). Boerrigter, G. and Ponnighaus, J. M. ..... (A) 578
Ten years' leprosy control work in Malawi (Central Africa)—I. Methods and outcome after treatment. Boerrigter, G. and Ponnighaus, J. M. ..... (A) 182
Ten years' leprosy control work in Malawi (Central Africa)—II. Patterns of endemicity since 1973. Ponnighaus, J. M. and Boerrigter, G. ..... (A) 183

Malaysia,
Autopsy findings in 35 cases of leprosy in Malaysia. Jayalakshmi, P., *et al.* ..... (O) 510

Martinique,
Primary and secondary dapsone resistance of *M. leprae* in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., *et al.* ..... (O) 672

Metabolism,
In vitro studies of phenolic glycolipid-I/^{14}C-palmitate interaction and *M. leprae* metabolism. Harris, E. B., *et al.* ..... (A) 403
[Iodine metabolism in leprosy patients (examination with a method of total body radiometry).] Balybin, E. S. ..... (A) 742
Lipase activity in *M. leprae*—an indicator of metabolic function. Talati, S. and Mohadevan, P. R. ..... (A) 389
Metabolic analyses of *M. leprae*: use in evaluation of *in vitro* culture media and drug activity. Franzblau, S. G. and Harris, E. B. ..... (A) 402
Metabolism in *M. leprae*: possible targets for drug interaction. Wheeler, P. R. ..... (A) 589
Metabolism of *M. leprae* in macrophages. Ramasesh, N., *et al.* ..... (A) 603

Mexico,
Asociacion Mexicana de Accion contra la Lepra. ..... (N) 167
Centro Pascua celebrates 50th anniversary. ..... (N) 570
Sensitivity and specificity of the FLA-ABS test for leprosy in Mexican populations. Amezcua, M. E., *et al.* ..... (O) 286

Mice,
Activities of pefloxacin and ciprofloxacin against *M. leprae* in the mouse. Guelpa-Lauras, C.-C., *et al.* ..... (O) 70
Activity of ofloxacin and pefloxacin against *M. leprae* in mice. Pattyn, S. R. ..... (A) 586
Activity of rifampin in infections of normal mice with *M. leprae*. Grosset, J. H. and Guelpa-Lauras, C.-C. ..... (S) 847
ADCC function in *M. leprae* inoculated normal and immunosuppressed mice. Ganguly, N. K., *et al.* ..... (A) 390
Analysis of idiotypes expressed by anti-mycobacterial mouse monoclonal antibodies using rabbit antisera. Ivanyi, J. and Praputpittaya, K. ..... (A) 747
Application of the mouse foot-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy. Levy, L. ..... (S) 823
Application of the thymectomized-irradiated mouse to the detection of persisting *M. leprae*. Colston, M. J. ..... (S) 859
Attenuated *M. lepraemurium* vaccine nonprotective against *M. intracellulare* infection in mice. Nakanishi, M. ..... (A) 396
Bacillary growth, interleukin-2 production defect, and specific antibody secretion governed by different genetical factors in mice infected subcutaneously with *M. lepraemurium*. Hoffenbach, A. and Bach, M.-A. ..... (A) 390

Chronic *M. avium*-complex infections in athymic (nude) and T-cell depleted (thxb) mice. Collins, F. M., *et al.* ..... (A) 413
Circulating immune complexes in normal and immunosuppressed mice infected with *M. leprae.* Vaishnavi, C., *et al.* ..... (A) 604
Death of *M. lepraemurium* after multiplication in CBA, BALB/c and nude mice. Resnick, M., *et al.* ..... (A) 609
Effect of preformed immune complexes on the course of *M. leprae* infection in normal mice. Kaur, S., *et al.* ..... (C) 358
Immunization of mice with *M. leprae/M. bovis* BCG admixtures: modulation of the acquired response to BCG. Orme, A. M. ..... (O) 293
Immunogenic behaviour of *M. marinum* (SATO) in mice. Srivastava, K. and Singh, N. B. ..... (A) 609
Macrophage chemotaxis in *M. leprae* infected mice. Kumar, B., *et al.* ..... (A) 597
Mouse breeding and husbandry. Colston, M. J. and Levy, L. ..... (S) 819
Multiplication of *M. leprae* in normal mice. Levy, L. ..... (S) 814
[Preliminary observation on the effect of thymic peptide in experimental infection of mice with *M. leprae.*] Wang, H.-Y. ..... (A) 391
Rifabutin and rifapentine compared with rifampin against *M. leprae* in mice. Pattyn, S. R. ..... (A) 373
Study of DTH and resistance in *M. lepraemurium* infection using a T-cell line isolated from mice infected with *M. bovis* (BCG). Hussein, S., *et al.* ..... (A) 595
Suppressor T cells for delayed-type hypersensitivity in susceptible mice infected with *M. lepraemurium.* Richard, L., *et al.* ..... (O) 63
The killing of *M. leprae* in mice by various dietary concentrations of dapsone and rifampin. Gelber, R. H. ..... (A) 390
The normal mouse in experimental chemotherapy. Levy, L. ..... (S) 843

Mice, nude,
Attempts to produce erythema nodosum leprosum in *M. leprae*-infected nude nu/nu mice with monoclonal antibodies. Chehl, S., *et al.* ..... (A) 410
Chronic *M. avium*-complex infections in athymic (nude) and T-cell depleted (thxb) mice. Collins, F. M., *et al.* ..... (A) 413
Death of *M. lepraemurium* after multiplication in CBA, BALB/c and nude mice. Resnick, M., *et al.* ..... (A) 609
Multiplication of *M. leprae* in the nude mouse, and some applications of nude mice to experimental leprosy. McDermott-Lancaster, R. D., *et al.* ..... (S) 889
M. leprae susceptibility of NOD hybrid nude mice. Nakamura, K. and Yogi, Y. ..... (A) 787
The nude mouse—characteristics, breeding and husbandry. McDermott-Lancaster, R. D., *et al.* ..... (S) 885

Mitsuda, reaction,
Ability of the phenolic glycolipid-I antigen of *M. leprae* to elicit a positive Mitsuda response in the armadillo (*Dasypus novemcinctus*). Job, C. K., *et al.* ..... (O) 299
Prevalence and significance of positive Mitsuda reaction in the nine-banded armadillo (*Dasypus novemcinctus*). Job, C. K., *et al.* ..... (O) 685

Monkey(s),
Experimental leprosy in a rhesus monkey: necropsy findings. Baskin, G. B., *et al.* ..... (O) 109
Lepromin-induced lymphoproliferative response of experimental leprosy monkeys: regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., *et al.* ..... (A) 751
M. leprae-induced lymphoproliferative response of experimental leprosy monkeys; regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., *et al.* ..... (A) 417
Naturally acquired leprosy in sooty mangabey monkeys—a second case. Gormus, B. J., *et al.* ..... (A) 417

Monoclonal antibodies,
Analysis of idiotypes expressed by anti-mycobacterial mouse monoclonal antibodies using rabbit antisera. Ivanyi, J. and Praputpittaya, K. ..... (A) 747
Analysis of monoclonal antibodies to *M. leprae* by crossed immunoelectrophoresis. Harboe, M. and Ivanyi, J. ..... (A) 594
Attempts to produce erythema nodosum leprosum in *M. leprae*-infected nude nu/nu mice with monoclonal antibodies. Chehl, S., *et al.* ..... (A) 410

Characterization of mycobacterial species specificity of 14 separate epitopes which reacted with monoclonal antibodies to the 65,000 molecular weight protein molecule of *M. leprae*. Buchanan, T. M., *et al.* ..... (A) 745
Dominant cell wall proteins of *M. leprae* recognized by monoclonal antibodies. Britton, W. J., *et al.* ..... (A) 379
Idiotypic markers of polyclonal B cell activation; public idiotypes shared by monoclonal antibodies derived from patients with systemic lupus erythematosus or leprosy. Mackworth-Young, C., *et al.* ..... (A) 598
Results of World Health Organization-sponsored workshop to characterize antigens recognized by mycobacterium-specific monoclonal antibodies. Engers, H. D., *et al.* ..... (A) 176
Solid phase peptide synthesis of epitopes that react with monoclonal antibodies to the 65,000 dalton protein of *M. leprae*. Anderson, D. C., *et al.* ..... (A) 743
Synthesis of epitopes of monoclonal antibodies to the 65 kD protein of *M. leprae*. Anderson, D. C., *et al.* ..... (A) 406
The detection of subclinical leprosy using a monoclonal based radioimmunoassay. Ashworth, M., *et al.* ..... (A) 176

Multidrug therapy (MDT),

A comparative study of the efficacy of WHO and IAL multidrug therapy regimens for leprosy—an *in vivo* and *in vitro* study. Revankar, C. R., *et al.* ..... (A) 587
Clinical problems in the initiation and assessment of multidrug therapy. Waters, M. F. R., *et al.* ..... (A) 589
[Effect of multibacillary leprosy patients taking multidrug therapy on the population around then.] Miao, Z. and Ziong, S. ..... (A) 740
Experience with multidrug therapy in paucibacillary leprosy. Bhate, R. D., *et al.* ..... (A) 172
Factors influencing clinic attendance during the multidrug therapy of leprosy. Langhorne, P., *et al.* ..... (A) 583
Feasibility of multidrug therapy (MDT) in Hansen's disease in an urban population—Curupaiti State Hospital, Rio de Janeiro, Brazil. Andrade, V. L. G., *et al.* ..... (O) 435
[First year's results of multidrug therapy of leprosy.] (China) Wu, Y. ..... (A) 741
[Multidrug therapy trial for leprosy in Senegal: first results about hepatic tolerance of multibacillary patients—therapeutic proposals.] Millan, J., *et al.* ..... (A) 584
National conference on MDT of leprosy held in Cheng-du. (China) Ye, G. ..... (N) 363
Operational aspects of the implementation of multidrug therapy at ALERT, Ethiopia. Becx-Bleumink, M. ..... (A) 578
[Practical problems of multidrug therapy management in Senegal.] Naudin, J. C., *et al.* ..... (A) 738
Preliminary evaluation of the effect of WHO-MDT on disabilities in leprosy patients in Malawi (Central Africa). Boerrigter, G. and Ponnighaus, J. M. ..... (A) 578
[Problems in applying the practice of multidrug therapy in leprosy in West Africa.] Nebout, M., *et al.* ..... (A) 576
Questions and Answers on the Implementation of Multiple Drug Therapy (MDT) for Leprosy. ..... (B) 737
Recent developments in the field of multidrug therapy and future research chemotherapy of leprosy. Grosset, J. ..... (A) 581
The use of MDT in the three western regions of Nepal. Kalthoff, P. G. ..... (A) 582
[Treatment of leprosy with two multidrug regimens for one year.] Xu, R., *et al.* ..... (A) 741

Murine,

Elastase activity in granulomatous inflammation in experimental murine leprosy. Hsu, P.-S., *et al.* ..... (A) 381
Experimental murine leprosy and its relevance for the study of resistance to mycobacterial infections in man. Lovik, M. ..... (E) 689
Influence of route of inoculation on anti-*M. lepraemurium* antibody isotopes in murine leprosy. Hoffenbach, A., *et al.* ..... (O) 305
Interferon-gamma induces the expression of major histocompatibility complex antigens by *in vitro* cultured murine Schwann cells. Mshana, R. N., *et al.* ..... (A) 781
Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Khor, M., *et al.* ..... (A) 763
Strain-dependent protective effect of adult thymectomy on murine infection by *M. lepraemurium*. Bach, M.-A. and Hoffenbach, A. ..... (A) 757

Mycobacteria, (see also individual species),
A cooperative taxonomic study of mycobacteria isolated from armadillos infected with *M. leprae.* Portaels, F., *et al.* ..... (A) 180
A novel semi-automated technique for measuring inhibition of intracellular mycobacterial growth by macrophage activating factor. Arden Jones, M. P. and Coates, A. R. M. ..... (A) 185
A recombinant 64 kilodalton protein of *M. bovis* bacillus Calmette-Guérin specifically stimulates human T4 clones reactive to mycobacterial antigens. Emmrich, F., *et al.* ..... (A) 594
Analysis of idiotypes expressed by anti-mycobacterial mouse monoclonal antibodies using rabbit antisera. Ivanyi, J. and Praputpittaya, K. ..... (A) 747
Anti-mycobacterial antibodies in saliva. Abe, M., *et al.* ..... (A) 742
Catalases, peroxidases, and superoxide dismutases in *M. leprae* and other mycobacteria studied by crossed immunoelectrophoresis and polyacrylamide gel electrophoresis. Lygren, S. T., *et al.* ..... (A) 388
Characteristics of human T-cell clones from BCG and killed *M. leprae* vaccinated subjects and tuberculosis patients; recognition of recombinant mycobacterial antigens. Mustafa, A. S., *et al.* ..... (A) 750
Characterization of mycobacterial species specificity of 14 separate epitopes which reacted with monoclonal antibodies to the 65,000 molecular weight protein molecule of *M. leprae.* Buchanan, T. M., *et al.* ..... (A) 745
Cloning and expression of mycobacterial plasmid DNA in *Escherichia coli.* Labidi, A., *et al.* ..... (A) 186
Cultivable mycobacteria isolated from 32 newly captured armadillos (*Dasypus novemcinctus*) from Louisiana. (U.S.A.) Portaels, F., *et al.* ..... (A) 788
[Cultivation of tubercle and opportunistic mycobacteria on medium with *N*-alkanes.] Koronelli, T. V. and Fadeeva, N. I. ..... (A) 763
Development of inhibitors of mycobacterial ribonucleotide reductase. Schaper, K.-J., *et al.* ..... (A) 587
Diagnosis and management of mycobacterial infection and disease in persons with human immunodeficiency virus infection. Centers for Disease Control ..... (A) 608
Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. Wallis, R. S., *et al.* ..... (A) 188
Dissociation between delayed-type hypersensitivity and resistance to pathogenic mycobacteria demonstrated by T-cell clones. Hussein, S., *et al.* ..... (A) 595
Enzymes and other biochemically active components of mycobacteria. Draper, P. ..... (A) 755
Experimental murine leprosy and it relevance for the study of resistance to mycobacterial infections in man. Lovik, M. ..... (E) 689
Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Douvas, G. S., *et al.* ..... (A) 186
Histochemical demonstration of mycobacterial antigen, specific antibody and complement in the lesions of tuberculosis. Ridley, M. J. and Ridley, D. S. ..... (A) 764
Immunogenic synthetic peptides against mycobacteria of potential immunodiagnostic and immunoprophylactic value. Patarroyo, M. E., *et al.* ..... (A) 752
Immunological and biochemical characterization and classification of mycobacterial antigens. Harboe, M. and Wiker, H. G. ..... (A) 746
In vitro activity of clofazimine against rapidly growing nonchromogenic mycobacteria. Ausina, V., *et al.* ..... (A) 607
In vitro susceptibility of mycobacteria to ciprofloxacin. Collins, C. H. and Uttley, H. C. ..... (A) 185
Influence of environmental mycobacteria on the prevalence of leprosy clinical type. Lyons, N. F. and Naafs, B. ..... (O) 637
Isolation and restriction endonuclease analysis of mycobacterial DNA. Patel, R., *et al.* ..... (A) 609
Limiting dilution analysis of the human T cell response to mycobacterial antigens from BCG vaccinated individuals and leprosy patients. Brett, S. J., *et al.* ..... (A) 743
Macrophages infected *in vitro* with live mycobacteria fail to express Ia antigen after stimulation with live lymphokine. Mshana, R. N., *et al.* ..... (A) 407
Monitoring of leprosy patients for antibodies to mycobacterial protein, glycolipid and lipopolysaccharide antigens. Levis, W. R., *et al.* ..... (A) 408

Mycobacterial carbohydrate antigens for serologic testing of leprosy. Levis, W. R., *et al.* ..... (A) 775
Mycobacterial infections in AIDS patients with an emphasis on the *M. avium* complex. Young, L. S., *et al.* ..... (A) 765
Mycobacterial plasmids: screening and possible relationship in antibiotic resistance to *M. avium/M. intracellulare.* Franzblau, S. G., *et al.* ..... (A) 602
Mycobacterial wall lipopolysaccharide: aspects of organization and structure. Draper, P. ..... (A) 781
Peptides as potential immunodiagnostic reagents to detect mycobacterial infections. Shinnick, T. M. ..... (A) 753
Possible role of helper and cytolytic T cells in mycobacterial infections. Kaufmann, S. H. E., *et al.* ..... (A) 748
Pyrolysis gas chromatography—mass spectrometry of mycobacterial mycolic acid methyl esters and its application to the identification of *M. leprae.* Kusaka, T. and Mori, T. ..... (A) 387
Resistance to *M. lepraemurium* is correlated with the capacity to generate macrophage activating factor(s) in response to mycobacterial antigens *in vitro.* Brett, S. J. and Butler, R. ..... (A) 389
[Rifampicin effect on L-transformation of mycobacterial population in patients with destructive tuberculosis of lungs.] Karachonsky, M. A., *et al.* ..... (A) 763
The electron-transparent zone in phagocytized *M. avium* and other mycobacteria: formation, persistence, and role in bacterial survival. Frehel, C., *et al.* ..... (A) 762
The influence of killed *M. leprae* and other mycobacteria on opsonized yeast phagocytosis. Cree, I. A. and Beck, J. S. ..... (A) 381
The measurement of adenylate energy charge (AEC) in mycobacteria, including *M. leprae.* Lee, Y. N. and Colston, M. J. ..... (A) 180
The Mycobacteria: A Sourcebook (in two parts). Kubica, G. P. and Wayne, L. G., eds. ..... (B) 369
The relationship between delayed type hypersensitivity and protective immunity induced by mycobacterial vaccines in man. Fine, P. E. M., *et al.* ..... (A) 745
The repertoire of mycobacterial antigens recognized by peripheral blood cells and sera of healthy leprosy patient contacts. Converse, P. J., *et al.* ..... (A) 779

Mycobacterium avium,

Chronic *M. avium*-complex infections in athymic (nude) and T-cell depleted (thxb) mice. Collins, F. M., *et al.* ..... (A) 413
Effect of combined clofazimine and ansamycin therapy on *M. avium-M. intracellulare* bacteremia in patients with AIDS. Masur, H., *et al.* ..... (A) 396
Effect of oral exposure of *M. avium intracellulare* on the protective immunity induced by BCG. Narayanan, S., *et al.* ..... (A) 608
Mycobacterial infections in AIDS patients with an emphasis on the *M. avium* complex. Young, L. S., *et al.* ..... (A) 765
Mycobacterial plasmids: screening and possible relationship in antibiotic resistance to *M. avium/M. intracellulare.* Franzblau, S. G., *et al.* ..... (A) 602
The electron-transparent zone in phagocytized *M. avium* and other mycobacteria: formation, persistence, and role in bacterial survival. Frehel, C., *et al.* ..... (A) 762
Therapeutic implications of inhibition versus killing of *M. avium* complex by antimicrobial agents. Yajko, D. M., *et al.* ..... (A) 765

Mycobacterium bovis,

A recombinant 64 kilodalton protein of *M. bovis* bacillus Calmette-Guérin specifically stimulates human T4 clones reactive to mycobacterial antigens. Emmrich, F., *et al.* ..... (A) 594
Comparative study of immunizing and delayed hypersensitivity eliciting antigens of *M. leprae, M. tuberculosis, M. vaccae,* and *M. bovis* (BCG). Sinha, S., *et al.* ..... (O) 42
Immunization of mice with *M. leprae/M. bovis* BCG admixtures: modulation of the acquired response to BCG. Orme, A. M. ..... (O) 293
MPB59, a widely cross-reacting protein of *M. bovis* BCG. Wiker, H. G., *et al.* ..... (A) 610
Study of DTH and resistance in *M. lepraemurium* infection using a T-cell line isolated from mice infected with *M. bovis* (BCG). Hussein, S., *et al.* ..... (A) 595

The characterization and immunoreactivity of a 70 kD protein common to *M. leprae* and *M. bovis* (BCG). Britton, W. J., *et al.* ..... (A) 744

Mycobacterium chelonei,
Treatment of nonpulmonary infections due to *M. fortuitum* and *M. chelonei* on the basis of *in vitro* susceptibilities. Wallace, R. J., Jr., *et al.* ..... (A) 188

Mycobacterium fortuitum,
Restriction endonuclease mapping and cloning of *M. fortuitum* var. *fortuitum* plasmid pAL5000. Labidi, A., *et al.* ..... (A) 187
Treatment of nonpulmonary infections due to *M. fortuitum* and *M. chelonei* on the basis of *in vitro* susceptibilities. Wallace, R. J., Jr., *et al.* ..... (A) 188

Mycobacterium gordonae,
Purification of the 65 kD protein from *M. gordonae* and use in skin test response to *M. leprae*. Gillis, T. P. and Job, C. K. ..... (O) 54

Mycobacterium intracellulare,
Attenuated *M. lepraemurium* vaccine nonprotective against *M. intracellulare* infection in mice. Nakanishi, M. ..... (A) 396
Effect of combined clofazimine and ansamycin therapy on *M. avium-M. intracellulare* bacteremia in patients with AIDS. Masur, H., *et al.* ..... (A) 396
Mycobacterial plasmids: screening and possible relationship in antibiotic resistance to *M. avium/M. intracellulare*. Franzblau, S. G., *et al.* ..... (A) 602

Mycobacterium leprae,
A cooperative taxonomic study of mycobacteria isolated from armadillos infected with *M. leprae*. Portaels, F., *et al.* ..... (A) 180
A preliminary report on *M. leprae* in Aurangabad. (India) Kalyankar, S. D., *et al.* .... (A) 605
A rapid silver staining method for identification of *M. leprae* in histologic sections. Senba, M., *et al.* ..... (A) 599
Ability of the phenolic glycolipid-I antigen of *M. leprae* to elicit a positive Mitsuda response in the armadillo (*Dasypus novemcinctus*). Job, C. K., *et al.* ..... (O) 299
Accessory cell function of cells isolated from *M. leprae*-induced granulomas. Montree-wasuwat, N., *et al.* ..... (A) 383
Activities of pefloxacin and ciprofloxacin against *M. leprae* in the mouse. Guelpa-Lauras, C.-C., *et al.* ..... (O) 70
Activity of ofloxacin and pefloxacin against *M. leprae* in mice. Pattyn, S. R. ..... (A) 586
Activity of rifampin in infections of normal mice with *M. leprae*. Grosset, J. H. and Guelpa-Lauras, C.-C. ..... (S) 847
Activity of selected beta-lactam antibiotics against *M. leprae*. Shepard, C. C., *et al.* ... (O) 322
ADCC function in *M. leprae* inoculated normal and immunosuppressed mice. Ganguly, N. K., *et al.* ..... (A) 390
Adherence of *M. leprae* to Schwann cells *in vitro*. Itty, B. M., *et al.* ..... (A) 381
Affinity of *M. leprae* with Lewis rat schwannoma cell line (Lewis TC 98). Maeda, M. and Narita, M. ..... (A) 598
An HLA-DR3 immune response gene for *M. leprae* predisposes to tuberculoid leprosy. Ottenhoff, T. H. M. and de Vries, R. R. P. ..... (A) 779
An *in vitro* system using adenosine triphosphate and ^{3}H-thymidine to determine drug sensitivity of *M. leprae*. Dhople, A. M. and Green, K. J. ..... (A) 172
Analysis of monoclonal antibodies to *M. leprae* by crossed immunoelectrophoresis. Harboe, M. and Ivanyi, J. ..... (A) 594
Antibodies to a synthetic analog of phenolic glycolipid-I of *M. leprae* in healthy household contacts of patients with leprosy. Menzel, S., *et al.* ..... (O) 617
Antigens of *M. leprae* in urine during treatment of patients with lepromatous leprosy. Olcén, P., *et al.* ..... (A) 384
Antimycobacterial antibodies in *Dasypus novemcinctus* infected with *M. leprae* and their correlation with the serum levels of lactate dehydrogenase. Rojas-Espinosa, O., *et al.* ..... (A) 391
Appearance of a methoxy mycolate-like component by the acid methanolysis of *M. leprae*. Datta, A. K., *et al.* ..... (O) 680

Application of the thymectomized-irradiated mouse to the detection of persisting *M. leprae*. Colston, M. J. ..... (S) 859
Attempts to produce erythema nodosum leprosum in *M. leprae*-infected nude nu/nu mice with monoclonal antibodies. Chehl, S., *et al.* ..... (A) 410
Beta-lactamase synthesis in *M. leprae*. Prabhakaran, K., *et al.* ..... (A) 587
Biochemical studies on *M. leprae*. Prabhakaran, K., *et al.* ..... (A) 389
Can *M. leprae* enter the body through unbroken epithelium? Job, C. K., *et al.* ..... (C) 722
Catalases, peroxidases, and superoxide dismutases in *M. leprae* and other mycobacteria studied by crossed immunoelectrophoresis and polyacrylamide gel electrophoresis. Lygren, S. T., *et al.* ..... (A) 388
Characteristics of human T-cell clones from BCG and killed *M. leprae* vaccinated subjects and tuberculosis patients; recognition of recombinant mycobacterial antigens. Mustafa, A. S., *et al.* ..... (A) 750
Characterization of antibody-reactive epitopes on the 65-kilodalton protein of *M. leprae*. Buchanan, T. M., *et al.* ..... (A) 594
Characterization of mycobacterial species specificity of 14 separate epitopes which reacted with monoclonal antibodies to the 65,000 molecular weight protein molecule of *M. leprae*. Buchanan, T. M., *et al.* ..... (A) 745
Characterization of the 36 K antigen of *M. leprae*. Klatser, P. R., *et al.* ..... (A) 749
Circulating immune complexes in normal and immunosuppressed mice infected with *M. leprae*. Vaishnavi, C., *et al.* ..... (A) 604
Comparison of radiometric macrophage assay and fluorescein diacetate/ethidium bromide staining for evaluation of *M. leprae* viability. Harshan, K. V., *et al.* ..... (O) 316
Comparative study of immunizing and delayed hypersensitivity eliciting antigens of *M. leprae, M. tuberculosis, M. vaccae,* and *M. bovis* (BCG). Sinha, S., *et al.* ..... (O) 42
Dapsone resistance in *M. leprae*: a genotypic change. Prabhakaran, K., *et al.* ..... (A) 181
Dapsone susceptibility of *M. leprae* before and after 1977. Almeida, J. G. ..... (C) 726
Detection and characterization of antigens of *M. leprae* reacting with sera from leprosy patients. Sathish, M., *et al.* ..... (A) 789
Detection of persisting *M. leprae* by inoculation of the neonatally thymectomized rat. Gelber, R. H. and Levy, L. ..... (S) 872
Detection of trehalose monomycolate in *M. leprae* grown in armadillo tissues. Dhariwal, K. R., *et al.* ..... (A) 387, 755
Dominant cell wall proteins of *M. leprae* recognized by monoclonal antibodies. Britton, W. J., *et al.* ..... (A) 379
Drug susceptibility testing of *M. leprae*. Ji, B. ..... (S) 830
Effect of 2-mercapto-3-hydrazinoquinoxaline (MHQ) on diphenoloxidase and growth of *M. leprae*. Prabhakaran, K., *et al.* ..... (A) 740
Effect of preformed immune complexes on the course of *M. leprae* infection in normal mice. Kaur, S., *et al.* ..... (C) 358
Electron microscopic study of the intracellular fate of *M. leprae* in normal and activated macrophages. Sibley, L. D. and Krahenbuhl, J. L. ..... (A) 411
Events surrounding the recognition of *M. leprae* in nerves. Ridley, M. J., *et al.* ..... (O) 99
Exochelin-mediated iron acquisition by the leprosy bacillus *M. leprae*. Hall, R. M. and Ratledge, C. ..... (A) 387
Expression of major histocompatibility complex class I and class II antigens in human Schwann cell cultures and effects of infection with *M. leprae*. Samuel, N. M., *et al.* ..... (A) 753
Expression of recombinant 65 kD protein of *M. leprae* using the cloning vector pKK223-3. Williams, D. L. and Gillis, T. P. ..... (A) 405
Functional responses of normal and activated macrophages infected with *M. leprae in vitro*. Sibley, L. D., *et al.* ..... (A) 783
Further studies of the killing of *M. leprae* by aminoglycosides: reduced dosage and frequency of administration. Gelber, R. H. ..... (O) 78
[Genetic component of the immune response to *M. leprae* in healthy individuals.] Bottasso, O. A., *et al.* ..... (A) 593
[Histochemical study of reverse reactions in *M. leprae*-infected armadillos.] Juscenko, A. A. and Vishnevetsky, F. E. ..... (A) 757
HLA class II restricted helper and suppressor clones reactive with *M. leprae*. de Vries, R. R. P., *et al.* ..... (A) 745
Host-pathogen interaction—new *in vitro* drug test systems against *M. leprae*; possibilities and limitations. Mahadevan, P. R., *et al.* ..... (A) 583

Humoral immune responses to *M. leprae* in human volunteers vaccinated with killed, armadillo-derived *M. leprae*. Gill, H. K., *et al.* ..... (A) 746
Immunization of mice with *M. leprae/M. bovis* BCG admixtures: modulation of the acquired response to BCG. Orme, A. M. ..... (O) 293
Immunosuppression and cellular immunity reactions in leprosy patients treated with a mixture of *M. leprae* and BCG. Rada, E. M. *et al.* ..... (O) 646
Importance of determining viability of *M. leprae* inside macrophages—an *in vitro* method using uracil. Vejare, S. and Mahadevan, P. R. ..... (A) 757
In vitro proliferation of lymphocytes from human volunteers vaccinated with armadillo-derived, killed *M. leprae*. Gill, H. K., *et al.* ..... (O) 30
In vitro studies of phenolic glycolipid-1/^{14}C-palmitate interaction and *M. leprae* metabolism. Harris, E. B., *et al.* ..... (A) 403
[Incorporation of ^{32}P into the phospholipids of *M. leprae*.] David, H. L., *et al.* ..... (A) 185
Infection of adult trigeminal neurons with *M. leprae in vitro*—a model system. Malaty, R., *et al.* ..... (A) 418
Infection with other experimental animals with *M. leprae*. Colston, M. J. and Levy, L. ..... (S) 896
Influence of prior periodic acid oxidation on the acid-fastness of *M. leprae*. Dhople, A. M. ..... (A) 179
Investigations into cultivation of *M. leprae* in a nasal mucus medium: a preliminary report. Prabhakar, M. C. ..... (C) 561
Investigations into the cultivation of *M. leprae*; a multifactorial approach. Kato, L. ..... (A) 602
Isolation of environment-derived *M. leprae* from soil in Bombay. Kazda, J., *et al.* ..... (A) 603
Limited *in vitro* multiplication of *M. leprae*: application to screening potential antileprosy compounds. Dhople, A. M. and Green, K. J. ..... (A) 601
Lipase activity in *M. leprae*—an indicator of metabolic function. Talati, S. and Mahadevan, P. R. ..... (A) 389
M. leprae antigen-induced suppression of T cell proliferation *in vitro*. Kaplan, G., *et al.* ..... (A) 596
M. leprae susceptibility of NOD hybrid nude mice. Nakamura, K. and Yogi, Y. ..... (A) 787
M. leprae, probably a microbe-dependent microorganism. Kato, L. ..... (A) 361
M. leprae-burdened macrophages are refractory to activation by gamma interferon. Sibley, L. D. and Krahenbuhl, J. L. ..... (A) 386
M. leprae-induced lymphoproliferative response of experimental leprosy monkeys; regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., *et al.* ..... (A) 417
M. leprae-specific Lyt-2+ T lymphocytes with cytolytic activity. Chiplunkar, S., *et al.* ..... (A) 380
Macrophage chemotaxis in *M. leprae* infected mice. Kumar, B., *et al.* ..... (A) 597
Metabolic analyses of *M. leprae*: use in evaluation of *in vitro* culture media and drug activity. Franzblau, S. G. and Harris, E. B. ..... (A) 402
Metabolism in *M. leprae*: possible targets for drug interaction. Wheeler, P. R. ..... (A) 589
Metabolism of *M. leprae* in macrophages. Ramasesh, N., *et al.* ..... (A) 603
Methods for the detection of a specific *M. leprae* antigen in the urine of leprosy patients. Kaldany, R.-R., *et al.* ..... (A) 596
Microbe dependence on *M. leprae*: a possible intracellular relationship with protozoa. Grange, J. M., *et al.* ..... (C) 565
Molecular localization and polymorphism of HLA class II restriction determinants defined by *M. leprae*-reactive helper T cell clones from leprosy patients. Ottenhoff, T. H. M., *et al.* ..... (A) 384
Monitoring of leprosy patients with antibodies to *M. leprae* phenolic glycolipid-I and a synthetic glycoconjugate. Meeker, H. C., *et al.* ..... (A) 409
Multiplication of *M. leprae* in normal mice. Levy, L. ..... (S) 814
Multiplication of *M. leprae* in the nude mouse, and some applications of nude mice to experimental leprosy. McDermott-Lancaster, R. D., *et al.* ..... (S) 889
Orientation staining for the demonstration of *M. leprae* in semithin sections. Luderschmidt, C. ..... (O) 83
Peptidoglycan and arabinogalactan of *M. leprae*. Draper, P., *et al.* ..... (A) 756
Phenolic glycolipid-I of *M. leprae* induces altered monocyte oxidative responses *in vitro*. Holzer, T. J., *et al.* ..... (A) 784
Phenolic glycolipid-I of *M. leprae* induces general suppression of *in vitro* concanavalin A responses unrelated to leprosy type. Prasad, H. K., *et al.* ..... (A) 385

[Preliminary observation on experimental infection with *M. leprae* in hedgehogs (*Erinaceus europaeus* Linne).] Wang, H., *et al.* ..... (A) 182
[Preliminary observation on the effect of thymic peptide in experimental infection of mice with *M. leprae*.] Wang, H.-Y. ..... (A) 391
Preliminary study of a *M. leprae* bacterin vaccine in a human volunteer population in a nonendemic area. Millikan, L. E., *et al.* ..... (A) 383
[Preliminary study of serologic activity of phenolic glycolipid deacetylate of *M. leprae*.] Wu, Q., *et al.* ..... (A) 754
Primary and secondary dapsone resistance of *M. leprae* in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., *et al.* ..... (O) 672
Purification of the 65 kD protein from *M. gordonae* and use in skin test response to *M. leprae*. Gillis, T. P. and Job, C. K. ..... (O) 54
Pyrolysis gas chromatography—mass spectrometry of mycobacterial mycolic acid methyl esters and its application to the identification of *M. leprae*. Kusaka, T. and Mori, T. ..... (A) 387
Regulatory role of FcR+ and FcR− monocyte subsets in *M. leprae*-induced lymphoproliferative response *in vitro*. Ohkawa, S., *et al.* ..... (A) 384
Rifabutin and rifapentine compared with rifampin against *M. leprae* in mice. Pattyn, S. R. ..... (A) 373
Schwann cells and *M. leprae*. Pandya, S. S. ..... (C) 562
Screening of drugs for activity against *M. leprae*. Ji, B., *et al.* ..... (S) 836
Serodiagnosis of leprosy: relationships between antibodies to *M. leprae* phenolic glycolipid-I and protein antigens. Levis, W. R., *et al.* ..... (A) 381
Solid phase peptide synthesis of epitopes that react with monoclonal antibodies to the 65,000 dalton protein of *M. leprae*. Anderson, D. C., *et al.* ..... (A) 743
Specific antigen and antibody to *M. leprae* in the cryoprecipitate of a patient with Lucio phenomenon. Drosos, A. A., *et al.* ..... (A) 594
[Staining of *M. leprae*: comparison between Lepeyssonie and Causse's technique and THELEP's technique to evaluate the bacteriological index.] Baquillon, G., *et al.* ..... (A) 387
Structure of *M. leprae*. Draper, P. ..... (A) 756
Studies of *in vitro*-cultivated isolates of *M. leprae* from nodules of lepromatous leprosy patients. Khera, V. R. and Mahadevan, P. R. ..... (A) 405
Suppression of delayed hypersensitivity skin reactions to tuberculin by *M. leprae* antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., *et al.* ..... (A) 600
Surveillance for *M. leprae* infections in a community of nine-banded armadillos. Stallknecht, D. E., *et al.* ..... (A) 420
Synthesis of epitopes of monoclonal antibodies to the 65 kD protein of *M. leprae*. Anderson, D. C., *et al.* ..... (A) 406
The allyl group for protection in carbohydrate chemistry. Part 19. The coupling of allyl 2,3-di-*O*-methyl-4-*O*-(3,6-di-*O*-methyl-β-D-glucopyranosyl)-α-L-rhamnopyranoside to bovine serum albumin. Preparation of a diagnostic reagent for antibodies to the major glycolipid of *M. leprae* (the leprosy bacillus) in human sera. Gigg, J., *et al.* ..... (A) 745
The carbohydrate-containing antigens of *M. leprae*. Brennan, P. J. ..... (A) 755
The cell wall of *M. leprae*; isolation, composition, and immunogenicity. Brennan, P. J., *et al.* ..... (A) 782
The characterization and immunoreactivity of a 70 kD protein common to *M. leprae* and *M. bovis* (BCG). Britton, W. J., *et al.* ..... (A) 744
The effect of diet on the growth of *M. leprae* in mouse foot pads. Foster, R., *et al.* ..... (A) 403
The evolution of IgG and IgM antibodies to phenolic glycolipid-I in armadillos inoculated with *M. leprae*. Vadiee, R., *et al.* ..... (A) 419
The *in vitro* microbicidal effects of activated macrophages on *M. leprae*. Ramasesh, N., *et al.* ..... (A) 412
The influence of killed *M. leprae* and other mycobacteria on opsonized yeast phagocytosis. Cree, I. A. and Beck, J. S. ..... (A) 381
The killing of *M. leprae* in mice by various dietary concentrations of dapsone and rifampin. Gelber, R. H. ..... (A) 390
The measurement of adenylate energy charge (AEC) in mycobacteria, including *M. leprae*. Lee, Y. N. and Colston, M. J. ..... (A) 180

The use of rodent models in assessing antimicrobial activity against *M. leprae.* Gelber, R. H. ..... (A) 580

Mycobacterium lepraemurium,
Attenuated *M. lepraemurium* vaccine nonprotective against *M. intracellulare* infection in mice. Nakanishi, M. ..... (A) 396
Bacillary growth, interleukin-2 production defect, and specific antibody secretion governed by different genetical factors in mice infected subcutaneously with *M. lepraemurium.* Hoffenbach, A. and Bach, M.-A. ..... (A) 390
Death of *M. lepraemurium* after multiplication in CBA, BALB/c and nude mice. Resnick, M., *et al.* ..... (A) 609
Influence of route of inoculation on anti-*M. lepraemurium* antibody isotopes in murine leprosy. Hoffenbach, A., *et al.* ..... (O) 305
[II. *M. lepraemurium* in cell culture, possibly useful for screening antileprosy drugs.] Ye, S., *et al.* ..... (A) 742
Resistance to *M. lepraemurium* is correlated with the capacity to generate macrophage activating factor(s) in response to mycobacterial antigens *in vitro.* Brett, S. J. and Butler, R. ..... (A) 389
Strain-dependent protective effect of adult thymectomy on murine infection by *M. lepraemurium.* Bach, M.-A. and Hoffenbach, A. ..... (A) 757
Study of DTH and resistance in *M. lepraemurium* infection using a T-cell line isolated from mice infected with *M. bovis* (BCG). Hussein, S., *et al.* ..... (A) 595
Suppressor T cells for delayed-type hypersensitivity in susceptible mice infected with *M. lepraemurium* Richard, L., *et al.* ..... (O) 63
The effect of *in vivo* modulation of macrophage activities on *M. lepraemurium* infection. Ha, D. K. K., *et al.* ..... (A) 181

Mycobacterium marinum,
Immunogenic behaviour of *M. marinum* (SATO) in mice. Srivastava, K. and Singh, N. B. ..... (A) 609

Mycobacterium smegmatis,
Relationship between B-lactamase activity and resistance to B-lactam antiobiotics in *M. smegmatis.* Yabu, K., *et al.* ..... (A) 189

Mycobacterium tuberculosis,
Arthritis induced by a T-lymphocyte clone that responds to *M. tuberculosis* and to cartilage proteoglycans. van Eden, W., *et al.* ..... (A) 188
Comparative study of immunizing and delayed hypersensitivity eliciting antigens of *M. leprae, M. tuberculosis, M. vaccae,* and *M. bovis* (BCG). Sinha, S., *et al.* ..... (O) 42
Evidence for an HLA-DR4-associated immune-response gene for *M. tuberculosis.* Ottenhoff, T. H. M., *et al.* ..... (A) 609
Genes for the major protein antigens of *M. tuberculosis*: the etiologic agents of tuberculosis and leprosy share an immunodominant antigen. Husson, R. N. and Young, R. C. ..... (A) 595
Genetic relatedness among strains of the *M. tuberculosis* complex. Analysis of restriction fragment heterogeneity using cloned DNA probes. Eisenach, K. D., *et al.* ..... (A) 608
The identification of T cell epitopes in *M. tuberculosis* using human T lymphocyte clones. Lamb, J. R., *et al.* ..... (A) 749

Mycobacterium vaccae,
Comparative study of immunizing and delayed hypersensitivity eliciting antigens of *M. leprae, M. tuberculosis, M. vaccae,* and *M. bovis* (BCG). Sinha, S., *et al.* ..... (O) 42

Nepal,
1985–1986 Annual Report—National Leprosy Project. ..... (N) 571
The use of MDT in the three western regions of Nepal. Kalthoff, P. G. ..... (A) 582

Nerve(s),
An ultrastructural study of dermal nerves in early human leprosy. Chandi, S. M. and Chacko, C. J. G. ..... (O) 515
Bilateral ulnar nerve abscesses in lepromatous leprosy. Pfaltzgraff, R. E. ..... (C) 553

Correlating Semmes-Weinstein monofilament mappings with sensory nerve conduction parameters in Hansen's disease patients. Breger, D. ..... (A) 414
Dapsone neuropathy—report of three cases and pathologic features of a motor nerve. Sirsat, A. M., *et al.* ..... (O) 23
Dapsone-induced neuropathy compounds Hansen's disease nerve damage: an electrophysiological study in tuberculoid patients. Sebille, A., *et al.* ..... (O) 16
Evaluation of nerve function deficit, its improvement by nerve decompression or corticosteroid therapy. Shah, A. ..... (A) 176
Events surrounding the recognition of *M. leprae* in nerves. Ridley, M. J., *et al.* ..... (O) 99
HLA antigens and neural reversal reactions in Ethiopian borderline tuberculoid leprosy patients. Ottenhoff, T. H. M., *et al.* ..... (O) 261
Monitoring of patient neural status during drug therapy—preliminary study. Bell-Krotoski, J. ..... (A) 414
Myelinated and unmyelinated fibers in sural nerve biopsy of a case with lepromatous leprosy—a quantitative approach. Gibbels, E., *et al.* ..... (O) 333
Nerve tissue culture: a useful model for the study of nerve damage in Hansen's disease. Antia, N. H. and Mukherjee, R. ..... (A) 176
Sciatic nerve in experimental leprosy. Vaishnavi, C., *et al.* ..... (A) 391
Ulnar nerve abscess in Hansen's disease. Char, G. and Cross, J. N. ..... (A) 375

Netherlands, The,
Amsterdam will host 1988 International Congress for Tropical Medicine and Malaria. ..... (N) 364
XII International Congress for Tropical Medicine and Malaria. ..... (N) 571

Neuritis,
Clinical and histopathologic findings in osteoarticular chronic hypertrophic neuritis and differentiation from leprosy. Li, Z., *et al.* ..... (C) 556
Clinical and histopathological observations in pure neuritic leprosy. Uplekar, M. W. and Antia, N. H. ..... (A) 592
Immunohistochemical studies of leprous neuritis. Nilsen, R., *et al.* ..... (A) 751
Primary polyneuritic leprosy in nonhuman primates. Walsh, G. P., *et al.* ..... (A) 418
[The differentiation of hereditary sensory radicular neuropathy from pure neuritic leprosy.] Zhang, J. and Lu, S. ..... (A) 378

Neuropathy,
Dapsone neuropathy—report of three cases and pathologic features of a motor nerve. Sirsat, A. M., *et al.* ..... (O) 23
Dapsone-induced neuropathy compounds Hansen's disease nerve damage: an electrophysiological study in tuberculoid patients. Sebille, A., *et al.* ..... (O) 16
Dapsone-induced peripheral neuropathy. Ahrens, E. M., *et al.* ..... (A) 607
Leprosy neuropathy; cells expressing MHC class II antigens in the lesion. Mshana, R. N. and Nilsen, R. ..... (A) 407
[Thalidomide induced neuropathy.] Chapon, F., *et al.* ..... (A) 579
[The differentiation of hereditary sensory radicular neuropathy from pure neuritic leprosy.] Zhang, J. and Lu, S. ..... (A) 378
Ulcer border reshaping in the treatment of neuropathic plantar ulcers. Look, J. O. ..... (A) 415

New Caledonia,
Primary and secondary dapsone resistance of *M. leprae* in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., *et al.* ..... (O) 672

Nigeria,
Leprosy in Cross River State, Nigeria. Brightmer, I. ..... (A) 605

Nose,
[A study of the histopathologic changes of the nasal mucosa in patients with leprosy.] Kim, H. B. and Kim, M. Y. ..... (A) 596
Investigations into cultivation of *M. leprae* in a nasal mucus medium: a preliminary report. Prabhakar, M. C. ..... (C) 561
[Reconstruction of the nose after leprosy.] Wintsch, K. ..... (A) 395

Obituaries,
Ambrosoli, Fr. Dr. Joseph. ..... (Ob) 713
Büngeler, Walter. ..... (Ob) 714

Ofloxacin,
Activity of ofloxacin and pefloxacin against *M. leprae* in mice. Pattyn, S. R. .....(A) 586
Effect of ofloxacin on experimental leprosy. Ito, T., *et al.* .....(A) 778

Pakistan,
Leprosy in Pakistan. Pfau, R. and Haq, G. .....(A) 370

Paraguay,
Report of the joint leprosy-tuberculosis project in Paraguay. Alvarenga, A. E. .....(A) 576
[The Paraguay project; a short report on a leprosy/tuberculosis eradication program.] Freerksen, E. .....(A) 182

Pathology,
Dapsone neuropathy—report of three cases and pathologic features of a motor nerve. Sirsat, A. M., *et al.* .....(O) 23
Leprosy: cause, transmission and a new theory of pathogenesis. Reich, C. V. .....(A) 738
Ocular leprosy: a case report and discussion of the pathology. House, P. H. .....(A) 174
[Pathomorphology of leprosy.] Warzok, V. R., *et al.* .....(A) 576
The pathology of leprosy as a reflection of the host parasite relationship. Ridley, D. S. .....(A) 752

Pefloxacin,
Activities of pefloxacin and ciprofloxacin against *M. leprae* in the mouse. Guelpa-Lauras, C.-C., *et al.* .....(O) 70
Activity of ofloxacin and pefloxacin against *M. leprae* in mice. Pattyn, S. R. .....(A) 586

Peroxidase,
Catalases, peroxidases, and superoxide dismutases in *M. leprae* and other mycobacteria studied by crossed immunoelectrophoresis and polyacrylamide gel electrophoresis. Lygren, S. T., *et al.* .....(A) 388

Phagocytes,
The electron-transparent zone in phagocytized *M. avium* and other mycobacteria: formation, persistence, and role in bacterial survival. Frehel, C., *et al.* .....(A) 762
The influence of killed *M. leprae* and other mycobacteria on opsonized yeast phagocytosis. Cree, I. A. and Beck, J. S. .....(A) 381

Pharmacokinetics,
Clinical pharmacokinetics of dapsone. Zuidema, J., *et al.* .....(A) 374
Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Mehta, J., *et al.* .....(A) 584
Pharmacokinetic interaction between dapsone and rifampicin in leprosy patients. Krishna, D. R., *et al.* .....(A) 372
Pharmacokinetics in drug screening. Grosset, J. H. .....(S) 852
Pharmacokinetics of clofazimine in healthy volunteers. Schaad-Lanyi, Z., *et al.* .....(O) 9
The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy. Venkatesan, K., *et al.* .....(A) 373

Phenolic glycolipid,
A dot enzyme immunoassay for detection of IgM antibodies against phenolic glycolipid-I in sera from leprosy patients. Kumar, S., *et al.* .....(A) 178
Ability of the phenolic glycolipid-I antigen of *M. leprae* to elicit a positive Mitsuda response in the armadillo (*Dasypus novemcinctus*). Job, C. K., *et al.* .....(O) 299
Antibodies to a synthetic analog of phenolic glycolipid-I of *M. leprae* in healthy household contacts of patients with leprosy. Menzel, S., *et al.* .....(O) 617
Antibodies to phenolic glycolipid-I during long-term therapy: serial measurements in individual patients. Miller, R. A., *et al.* .....(O) 633
Cellular and humoral immune response to a phenolic glycolipid antigen (PGL-I) in patients with leprosy. Koster, F. T., *et al.* .....(A) 597

In vitro studies of phenolic glycolipid-I/^{14}C-palmitate interaction and *M. leprae* metabolism. Harris, E. B., *et al.* ....(A) 403
Monitoring of leprosy patients with antibodies to *M. leprae* phenolic glycolipid-I and a synthetic glycoconjugate. Meeker, H. C., *et al.* ....(A) 409
Phenolic glycolipid-I of *M. leprae* induces altered monocyte oxidative responses *in vitro*. Holzer, T. J., *et al.* ....(A) 784
Phenolic glycolipid-I of *M. leprae* induces general suppression of *in vitro* concanavalin A responses unrelated to leprosy type. Prasad, H. K., *et al.* ....(A) 385
[Preliminary study of serologic activity of phenolic glycolipid deacetylate of *M. leprae*.] Wu, Q., *et al.* ....(A) 754
Serodiagnosis of leprosy: relationships between antibodies to *M. leprae* phenolic glycolipid-I and protein antigens. Levis, W. R., *et al.* ....(A) 381
Simplification and standardization of serodiagnostic tests for leprosy of phenolic glycolipid-I (PGL-I) antigen. Aguado Sanchez, G., *et al.* ....(A) 743
The evolution of IgG and IgM antibodies to phenolic glycolipid-I in armadillos inoculated with *M. leprae*. Vadiee, R., *et al.* ....(A) 419

Philippines, The,
Leonard Wood Memorial (LWM) seeking Director of Scientific Facility. ....(N) 571
LWM course offered at Cebu. ....(N) 365
Serological reactivity and early detection of leprosy among contacts of lepromatous patients in Cebu, The Philippines. Douglas, J. T., *et al.* ....(C) 718

Phospholipids,
[Incorporation of ^{32}P into the phospholipids of *M. leprae*.] David, H. L., *et al.* ....(A) 185

Phytohemagglutinin,
Phytohemagglutinin as a skin test for the evaluation of immune competence in patients with leprosy and tuberculosis and in controls. Samuel, N. M. and Stanford, J. L. ....(A) 385

Polynesia,
Seroepidemiological study on 724 household contacts of leprosy patients in French Polynesia using disaccharide-octyl-BSA as antigen. Chanteau, S., *et al.* ....(O) 626
Social and demographic aspects of a leprosy epidemic on a Polynesian atoll: implications of pattern. Lieber, M. D. and Lieber, E. B. ....(O) 468

Pregnancy,
Leprosy in pregnancy. Duncan, M. E. ....(A) 174

Protein(s),
A recombinant 64 kilodalton protein of *M. bovis* bacillus Calmette-Guérin specifically stimulates human T4 clones reactive to mycobacterial antigens. Emmrich, F., *et al.* ....(A) 594
Characterization of antibody-reactive epitopes on the 65-kilodalton protein of *M. leprae*. Buchanan, T. M., *et al.* ....(A) 594
Characterization of mycobacterial species specificity of 14 separate epitopes which reacted with monoclonal antibodies to the 65,000 molecular weight protein molecule of *M. leprae*. Buchanan, T. M., *et al.* ....(A) 745
Clinical significance of changes in serum proteins, immunoglobulins, and autoantibodies in leprosy. Rawlinson, W. D., *et al.* ....(O) 277
Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. Wallis, R. S., *et al.* ....(A) 188
Dominant cell wall proteins of *M. leprae* recognized by monoclonal antibodies. Britton, W. J., *et al.* ....(A) 379
Efficient mapping of protein antigenic determinants. Mehra, V., *et al.* ....(A) 382
Expression of recombinant 65 kD protein of *M. leprae* using the cloning vector pKK223-3. Williams, D. L. and Gillis, T. P. ....(A) 405
Genes for the major protein antigens of *M. tuberculosis*: the etiologic agents of tuberculosis and leprosy share an immunodominant antigen. Husson, R. N. and Young, R. C. ....(A) 595
Monitoring of leprosy patients for antibodies to mycobacterial protein, glycolipid and lipopolysaccharide antigens. Levis, W. R., *et al.* ....(A) 408
MPB59, a widely cross-reacting protein of *M. bovis* BCG. Wiker, H. G., *et al.* ....(A) 610

Purification of the 65 kD protein from *M. gordonae* and use in skin test response to *M. leprae*. Gillis, T. P. and Job, C. K. ..... (O) 54
S-100 Protein and immunoperoxidase technique as an aid in the histopathologic diagnosis of leprosy. Fleury, R. N. and Bacchi, C. E. ..... (O) 338
Serodiagnosis of leprosy: relationships between antibodies to *M. leprae* phenolic glycolipid-I and protein antigens. Levis, W. R., *et al.* ..... (A) 381
Significant enhanced superoxide anion (O_2^-) monocytes of lepromatous leprosy patients stimulated with liposome and suppression by C-reactive protein (CRP). Hokama, Y., *et al.* ..... (A) 746
Solid phase peptide synthesis of epitopes that react with monoclonal antibodies to the 65,000 dalton protein of *M. leprae*. Anderson, D. C., *et al.* ..... (A) 743
Studies on serum proteins in leprosy by polyacrylamide gel electrophoresis (PAGE). Patil, S. A., *et al.* ..... (A) 175
Synthesis of epitopes of monoclonal antibodies to the 65 kD protein of *M. leprae*. Anderson, D. C., *et al.* ..... (A) 406
The characterization and immunoreactivity of a 70 kD protein common to *M. leprae* and *M. bovis* (BCG). Britton, W. J., *et al.* ..... (A) 744

Prothionamide,
Effect of prothionamide on the infectivity of lepromatous leprosy. Girdhar, A., *et al.* ..(A) 739
Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages. Jenner, P. J. and Smith, S. E. ..... (A) 581
[Treatment of 24 cases of multibacillary leprosy with DDS, RFP, and PTH.] Zheng, C. ..... (A) 374

Psychosocial,
[On the mental care of leprosy patients.] Tan, D. and Zhang, Z. ..... (A) 761
[Psychosis of leprosy patients from social discrimination and somatic deformities.] Pan, X., *et al.* ..... (A) 760
Psychosocial dimensions of drug default in leprosy. Anandaraj, H. ..... (A) 375

Radioimmunoassay,
The detection of subclinical leprosy using a monoclonal based radioimmunoassay. Ashworth, M., *et al.* ..... (A) 176

Rat(s),
Affinity of *M. leprae* with Lewis rat schwannoma cell line (Lewis TC 98). Maeda, M. and Narita, M. ..... (A) 598
Chemotherapy trials in the neonatally thymectomized Lewis rat: a model for the study of the therapy of lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 776
Detection of persisting *M. leprae* by inoculation of the neonatally thymectomized rat. Gelber, R. H. and Levy, L. ..... (S) 872
The neonatally thymectomized rat as a model of the lepromatous patient. Gelber, R. H. ..... (S) 879

Reaction, leprosy,
An unusual bullous reaction in borderline leprosy. Singh, K. ..... (A) 592
Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy. Rao, T. D. and Rao, P. R. ..... (O) 36
Etiological factors in delayed-type hypersensitivity reactions in leprosy. Klenerman, P. ..... (E) 702
[Histochemical study of reverse reactions in *M. leprae*-infected armadillos.] Juscenko, A. A. and Vishnevetsky, F. E. ..... (A) 757
HLA antigens and neural reversal reactions in Ethiopian borderline tuberculoid leprosy patients. Ottenhoff, T. H. M., *et al.* ..... (O) 261
Immunoprofile of reactions in leprosy. Sehgal, V. N., *et al.* ..... (A) 386
Reversal reaction—management with topical corticosteroids. Srinivas, C. R., *et al.* .... (C) 355
Tγ, Tμ and B lymphocytes in erythema nodosum leprosum reactions of leprosy. Rao, T. D. and Rao, P. R. ..... (A) 599
The "Ellis" and "Ryrie" tests. Naafs, B., *et al.* ..... (A) 591
The histopathology of type I (lepra) and type II (ENL) reactions in leprosy. Sehgal, V. N., *et al.* ..... (A) 179

Type 1 reactions in leprosy—heterogeneity in T-cell functions related to the background leprosy type. Laal, S., *et al.* ..... (O) 481

Rehabilitation,
[A survey of persons living in leprosaria after leprosy cured.] Shu, H., *et al.* ..... (A) 768
Rehabilitation surgery for leprosy handicapped at a rural leprosy colony. Shah, A. and Bhagat, N. ..... (A) 607
Simplified surgical technique for flexible clawed hand rehabilitation. Chevallard, A. J. ..... (C) 160

Relapse(s),
[Inadequate treatment in multibacillary leprosy and incubation times for relapses.] Pattyn, S. R., *et al.* ..... (A) 586
Multiple relapses in borderline leprosy—a case report. Ramachandran, A. and Seshadri, P. S. ..... (A) 591
[Relapse of leprosy among 599 arrested cases in the city of Baoji.] (China) Deng, Y., *et al.* ..... (A) 739
[Relapse of leprosy in Jinju hospital for old-disabled persons.] (China) Liu, W. ..... (A) 740

Rifampin,
Activity of rifampin in infections of normal mice with *M. leprae.* Grosset, J. H. and Guelpa-Lauras, C.-C. ..... (S) 847
Comparison of three regimens containing rifampin for treatment of paucibacillary leprosy patients. Katoch, K., *et al.* ..... (O) 1
Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Mehta, J., *et al.* ..... (A) 584
[Efficacy of combined treatments involving 6 months' administration of rifampin in multibacillary leprosy.] Pattyn, S. R., *et al.* ..... (A) 740
Evaluation of subdermal biodegradable implants incorporating rifampicin as a method of drug delivery in experimental tuberculosis of guinea pigs. Mathur, I. S., *et al.* ..... (A) 604
Pharmacokinetic interaction between dapsone and rifampicin in leprosy patients. Krishna, D. R., *et al.* ..... (A) 372
Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Khor, M., *et al.* ..... (A) 763
Rifabutin and rifapentine compared with rifampin against *M. leprae* in mice. Pattyn, S. R. ..... (A) 373
[Rifampicin effect on L-transformation of mycobacterial population in patients with destructive tuberculosis of the lungs.] Karachunsky, M. A., *et al.* ..... (A) 763
Rifampicin for nontuberculous infections? Gruneberg, R. N., *et al.* ..... (A) 186
[Seven years' follow-up of multibacillary patients treated with RFP or B663 for a short time.] Li, W. and Zhang, Y., *et al.* ..... (A) 372
[Sixty-eight cases of multibacillary leprosy treated with RFP or RFP plus DDS.] Zhou, S. and Zhu, S. ..... (A) 374
T-cell subpopulations in tuberculosis and the effects of rifampicin. Vidhidharm, A., *et al.* ..... (A) 610
The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy. Venkatesan, K., *et al.* ..... (A) 373
The killing of *M. leprae* in mice by various dietary concentrations of dapsone and rifampin. Gelber, R. H. ..... (A) 390
The Malta experience: isoprodian-rifampicin combination treatment for leprosy. Depasquale, G. ..... (A) 579
[Therapeutic effects of rifampicin, clofazimine and dapsone in multibacillary leprosy in the fieldwork—results of a year's treatment.] Li, W., *et al.* ..... (A) 372
[Treatment of 24 cases of multibacillary leprosy with DDS, RFP, and PTH.] Zheng, C. ..... (A) 374
Update on rifampin drug interactions. Baciewicz, A. M., *et al.* ..... (A) 577

Saliva,
Anti-mycobacterial antibodies in saliva. Abe, M., *et al.* ..... (A) 742

Sarcoidosis,
[Behavior of the intradermal reaction with lepromin in patients with sarcoidosis.] Gumaraes Proenca, N., *et al.* ..... (A) 177

Screening,
Limited *in vitro* multiplication of *M. leprae*: application to screening potential antileprosy compounds. Dhople, A. M. and Green, K. J. ..... (A) 601
III. *M. lepraemurium* in cell culture, possibly useful for screening antileprosy drugs.] Ye, S., *et al.* ..... (A) 742
Mass screening in leprosy endemic areas of Turkey; preliminary report. Saylan, T. and Aytekin, A. H. ..... (A) 183
Mycobacterial plasmids: screening and possible relationship in antibiotic resistance to *M. avium/M. intracellulare*. Franzblau, S. G., *et al.* ..... (A) 602
Pharmacokinetics in drug screening. Grosset, J. H. ..... (S) 852
Screening of drugs for activity against *M. leprae*. Ji, B., *et al.* ..... (S) 836

Senegal,
[Clinical and bacteriological evaluation 8 years after triple drug chemotherapy for multibacillary leprosy in Senegal.] Dousset-Faure, I., *et al.* ..... (A) 739
[Multidrug therapy trial for leprosy in Senegal: first results about hepatic tolerance of multibacillary patients—therapeutic proposals.] Millan, J., *et al.* ..... (A) 584
[Practical problems of multidrug therapy management in Senegal.] Naudin, J. C., *et al.* ..... (A) 738
Primary and secondary dapsone resistance of *M. leprae* in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., *et al.* ..... (O) 672

Sensation(s),
An attempt to reduce the loss of pain and touch sensations in leprosy patients. Jain, G. L., *et al.* ..... (A) 175

Sensitivity, drug,
An *in vitro* system using adenosine triphosphate and ^{3}H-thymidine to determine drug sensitivity of *M. leprae*. Dhople, A. M. and Green, K. J. ..... (A) 172

Serodiagnosis,
Gelatin-particle agglutination test for serodiagnosis of leprosy—a new simple test useful for large-scale field study. Izumi, S., *et al.* ..... (A) 790
Serodiagnosis of leprosy: relationships between antibodies to *M. leprae* phenolic glycolipid-I and protein antigens. Levis, W. R., *et al.* ..... (A) 381
Simplification and standardization of serodiagnostic tests for leprosy of phenolic glycolipid-I (PGL-I) antigen. Aguado Sanchez, G., *et al.* ..... (A) 743
Some strategies for developing serodiagnosis of leprosy. Abe, M. ..... (A) 774

Serum,
A dot enzyme immunoassay for detection of IgM antibodies against phenolic glycolipid-I in sera from leprosy patients. Kumar, S., *et al.* ..... (A) 178
Antimycobacterial antibodies in *Dasypus novemcinctus* infected with *M. leprae* and their correlation with the serum levels of lactate dehydrogenase. Rojas-Espinosa, O., *et al.* ..... (A) 391
Binding of dapsone and its analogues to human serum albumin. Karp, W. B., *et al.* ..... (A) 172
Characterization of a factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes. Kerr, M. A., *et al.* ..... (A) 748
Clinical significance of changes in serum proteins, immunoglobulins, and autoantibodies in leprosy. Rawlinson, W. D., *et al.* ..... (O) 277
Detection and characterization of antigens of *M. leprae* reacting with sera from leprosy patients. Sathish, M., *et al.* ..... (A) 789
[Effect of thalidomide on serum levels of immunoglobulins IgM and IgA, rheumatoid factor and isohemagglutinins anti-A and anti-B in patients with lepromatous leprosy: a double-blind study.] Arruda, W. O., *et al.* ..... (A) 378
Serial estimation of serum lactic dehydrogenase & its isoenzymes in an active pulmonary tuberculosis. Zawar, P. B., *et al.* ..... (A) 766
Soluble serum interleukin 2 receptor levels in leprosy patients. Tung, K. S. K., *et al.* ..... (A) 753
Studies on serum proteins in leprosy by polyacrylamide gel electrophoresis (PAGE). Patil, S. A., *et al.* ..... (A) 175
The mechanism of action of the factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes. Hussein, Y. M., *et al.* ..... (A) 747

The repertoire of mycobacterial antigens recognized by peripheral blood cells and sera of healthy leprosy patient contacts. Converse, P. J., *et al.* ....(A) 779
Undernutrition in lepromatous leprosy, Part II. Altered levels of serum elements; their association with the disease and not with food deprivation. Rao, K. N. and Saha, K. ....(A) 377

Skin,
Acid-fast bacilli detected in umbilical cord and skin specimens. Mori, T. ....(A) 786
Distribution and turnover of Langerhans cells during delayed immune responses in human skin. Kaplan, G., *et al.* ....(A) 748
In situ identification of activated Ta1+ T lymphocytes in human leprosy skin lesions. Shen, J.-Y., *et al.* ....(O) 494
Suppression of delayed hypersensitivity skin reactions to tuberculin by *M. leprae* antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., *et al.* ....(A) 600
Suppressor T lymphocytes from lepromatous leprosy skin lesions. Modlin, R. L., *et al.* ....(A) 179
T-lymphocyte clones from leprosy skin lesions. Modlin, R. L., *et al.* ....(A) 750
[The foamy cells in skin lesions of arrested lepromatous patients.] Zhu, W., *et al.* ....(A) 754
The role of IFN-gamma in the regulation of DTH in human skin. Kaplan, G. and Cohn, Z. A. ....(A) 785
[Ultrastructure of Langerhans' cell in the skin of borderline leprosy patients.] Liu, J., *et al.* ....(A) 382

Skin smear(s),
Retrospective analysis of smear examinations from multiple sites in multibacillary leprosy. Bhatia, V. N., *et al.* ....(A) 173
WHO guidelines for skin smears. ....(—) 421

Skin test(s),
Immunohistologic comparison between armadillo-derived leprosin and standard lepromin skin tests in leprosy patients. Narayanan, R. B., *et al.* ....(A) 598
Phytohemagglutinin as a skin test for the evaluation of immune competence in patients with leprosy and tuberculosis and in controls. Samuel, N. M. and Stanford, J. L. ....(A) 385
Purification of the 65 kD protein from *M. gordonae* and use in skin test response to *M. leprae*. Gillis, T. P. and Job, C. K. ....(O) 54

Spain,
XI Ibero-Latin American Congress of Dermatology Leprosy Symposium. Gatti, J. C. ....(N) 731
Fontilles International Courses 1987. ....(N) 365

Sperm,
Antispermatozoal antibodies in leprosy with special reference to their morphological patterns. Gupta, S. C., *et al.* ....(A) 174

Stain(s),
A cold staining method for acid-fast bacilli. Vasanthakumari, R., *et al.* ....(A) 389
A rapid silver staining method for identification of *M. leprae* in histologic sections. Senba, M., *et al.* ....(A) 599
Biological, chemical, immunological and staining properties of bacteria isolated from tissues of leprosy patients. Cocito, C. and Delville, J. ....(A) 600
[Comparative investigation on two modified techniques of acid-fast stain.] Xie, Y. and Dong, X. ....(A) 754
Comparison of radiometric macrophage assay and fluorescein diacetate/ethidium bromide staining for evaluation of *M. leprae* viability. Harshan, K. V., *et al.* ....(O) 316
Orientation staining for the demonstration of *M. leprae* in semithin sections. Luderschmidt, C. ....(O) 83
[Staining of *M. leprae*: comparison between Lepeyssonie and Causse's technique and THELEP's technique to evaluate the bacteriological index.] Baquillon, G., *et al.* ....(A) 387

Subclinical,
The detection of subclinical leprosy using a monoclonal based radioimmunoassay. Ashworth, M., *et al.* ....(A) 176

Sulfone,
Method for detecting sulfones in urine. Jaled, M. M., *et al.* ....(C) 560

Superoxide,
Catalases, peroxidases, and superoxide dismutases in *M. leprae* and other mycobacteria studied by crossed immunoelectrophoresis and polyacrylamide gel electrophoresis. Lygren, S. T., *et al.* ..... (A) 388
Significant enhanced superoxide anion (O_2^-) monocytes of lepromatous leprosy patients stimulated with liposome and suppression by C-reactive protein (CRP). Hokama, Y., *et al.* ..... (A) 746

Suppression,
BCG-induced suppressor T cells optimal conditions for *in vitro* induction and mode of action. Mustafa, A. S. and Godal, T. ..... (A) 187
Cimetidine inhibits suppressor factor production in Ethiopian lepromatous leprosy patients. Converse, P. J., *et al.* ..... (C) 548
HLA class II immune response and suppression genes in leprosy. Ottenhoff, T. H. M. and de Vries, R. R. P. ..... (R) 521
HLA class II restricted helper and suppressor clones reactive with *M. leprae.* de Vries, R. R. P., *et al.* ..... (A) 745
Lepromin-induced suppressor cells in lepromatous leprosy. Nelson, E. E., *et al.* ..... (A) 384
M. leprae antigen-induced suppression of T cell proliferation *in vitro.* Kaplan, G., *et al.* ..... (A) 596
Phenolic glycolipid-I of *M. leprae* induces general suppression of *in vitro* concanavalin A responses unrelated to leprosy type. Prasad, H. K., *et al.* ..... (A) 385
Significant enhanced superoxide anion (O_2^-) monocytes of lepromatous leprosy patients stimulated with liposome and suppression by C-reactive protein (CRP). Hokama, Y., *et al.* ..... (A) 746
Suppression of delayed hypersensitivity skin reactions to tuberculin by *M. leprae* antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., *et al.* ..... (A) 600
Suppressor response in lepromatous leprosy patients: role of Leu2a cells. Sasiain, M. del C., *et al.* ..... (A) 385
Suppressor T cells for delayed-type hypersensitivity in susceptible mice infected with *M. lepraemurium.* Richard, L., *et al.* ..... (O) 63
Suppressor T lymphocytes from lepromatous leprosy skin lesions. Modlin, R. L., *et al.* ..... (A) 179

Surgery,
Biomechanics of tendon transfers. Brand, P. W. ..... (A) 607
[Realistic organization of surgery in countries with endemic leprosy.] Bourrel, P. ..... (A) 184
[Reconstruction of the nose after leprosy.] Wintsch, K. ..... (A) 395
Rehabilitation surgery for leprosy handicapped at a rural leprosy colony. Shah, A. and Bhagat, N. ..... (A) 607
Simplified surgical technique for flexible clawed hand rehabilitation. Chevallard, A. J. ..... (C) 160
Surgical correction of intrinsic minus fingers. Palande, D. D. ..... (A) 606
Surgical correction of thumb with ulnar or ulnar median paralysis. Palande, D. D. ..... (A) 606
Surgical treatment of plantar ulcers in leprosy. Rao, P. T. and Jena, S. K. ..... (A) 395

Switzerland,
Leprosy sample surveys. ..... (N) 168
Training in Leprosy; WHO publication. ..... (N) 168

Tahiti,
Primary and secondary dapsone resistance of *M. leprae* in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., *et al.* ..... (O) 672

Testing,
Drug susceptibility testing of *M. leprae.* Ji, B. ..... (S) 830
Immunodiagnostic tests for leprosy; a need for standards. Ramanathan, V. D. ..... (C) 721
Mycobacterial carbohydrate antigens for serologic testing of leprosy. Levis, W. R., *et al.* ..... (A) 775
The "Ellis" and "Ryrie" tests. Naafs, B., *et al.* ..... (A) 591
The repeatability of testing with Semmes-Weinstein monofilaments. Beli-Krotoski, J. and Tomancik, E. ..... (A) 394

[Testing of the hypothesis of multifactorial type inheritance of predisposition to pulmonary tuberculosis.] Berezousky, B. A., *et al.* ..... (A) 761

Tetanus,
Tetanus in a case of lepromatous leprosy. Parikh, A. A. and Shah, B. H. ..... (A) 591

Thalidomide,
[Effect of thalidomide on serum levels of immunoglobulins IgM and IgA, rheumatoid factor and isohemagglutinins anti-A and anti-B in patients with lepromatous leprosy: a double-blind study.] Arruda, W. O., *et al.* ..... (A) 378
Thalidomide in leprosy—study of 94 cases. Parikh, D. A., *et al.* ..... (A) 585
[Thalidomide induced neuropathy.] Chapon, F., *et al.* ..... (A) 579

The Leprosy Mission (TLM),
Dr. Thangaraj and Mr. Askew retire. ..... (N) 730
The Leprosy Mission (TLM) International 1987 changes. ..... (N) 169

THELEP,
Characteristics of patients in the THELEP trials of chemotherapy of leprosy at Bamako and Chingleput. Subcommittee on Clinical, etc. ..... (A) 588
[Staining of *M. leprae*: comparison between Lepeyssonie and Causse's technique and THELEP's technique to evaluate the bacteriological index.] Baquillon, G., *et al.* ..... (A) 387
The First Joint THELEP-Sasakawa Memorial Health Foundation Workshop on Experimental Chemotherapy of Leprosy. Grosset, J., *et al.* ..... (S) 807
The THELEP controlled clinical drug trials. Subcommittee on Clinical, etc. ..... (S) 864

Therapy, (see also **Chemotherapy**),
A comparative study of the efficacy of WHO and IAL multidrug therapy regimens for leprosy—an *in vivo* and *in vitro* study. Revankar, C. R., *et al.* ..... (A) 587
Antibiotic therapy for leprosy. Jacobson, R. R. ..... (A) 372
Antibodies to phenolic glycolipid-I during long-term therapy: serial measurements in individual patients. Miller, R. A., *et al.* ..... (O) 633
Clinical problems in the initiation and assessment of multidrug therapy. Waters, M. F. R., *et al.* ..... (A) 589
Effect of combined clofazimine and ansamycin therapy on *M. avium-M. intracellulare* bacteremia in patients with AIDS. Masur, H., *et al.* ..... (A) 396
[Effect of multibacillary leprosy patients taking multidrug therapy on the population around them.] Miao, Z. and Ziong, S. ..... (A) 740
Evaluation of nerve function deficit, its improvement by nerve decompression or corticosteroid therapy. Shah, A. ..... (A) 176
Experience with multidrug therapy in paucibacillary leprosy. Bhate, R. D., *et al.* ..... (A) 172
Factors influencing clinic attendance during the multidrug therapy of leprosy. Langhorne, P., *et al.* ..... (A) 583
Feasibility of multidrug therapy (MDT) in Hansen's disease in an urban population—Curupaiti State Hospital, Rio de Janeiro, Brazil. Andrade, V. L. G., *et al.* ..... (O) 435
[First year's results of multidrug therapy of leprosy.] Wu, Y. ..... (A) 741
Implementation of tests for monitoring drug compliance of leprosy out-patients under multi-drug therapy. Balakrishnan, S., *et al.* ..... (A) 577
Methemoglobinemia from dapsone therapy for a suspected brown spider bite. Iserson, K. V. ..... (A) 581
Monitoring of patient neural status during drug therapy—preliminary study. Bell-Krotoski, J. ..... (A) 414
[Multidrug therapy trial for leprosy in Senegal: first results about hepatic tolerance of multibacillary patients—therapeutic proposals.] Millan, J., *et al.* ..... (A) 584
Operational aspects of the implementation of multidrug therapy at ALERT, Ethiopia. Becx-Bleumink, M. ..... (A) 578
[Practical problems of multidrug therapy management in Senegal.] Naudin, J. C., *et al.* ..... (A) 738
[Problems in applying the practice of multidrug therapy in leprosy in West Africa.] Nebout, M., *et al.* ..... (A) 576
Questions and Answers on the Implementation of Multiple Drug Therapy (MDT) for Leprosy. ..... (B) 737

Recent developments in the field of multidrug therapy and future research in chemotherapy of leprosy. Grosset, J. ..... (A) 581
Single bacterial cell mass analysis: a rapid test method in leprosy therapy control. Seydel, U. and Lindner, B. ..... (A) 603

Thymidine,
An *in vitro* system using adenosine triphosphate and ^{3}H-thymidine to determine drug sensitivity of *M. leprae*. Dhople, A. M. and Green, K. J. ..... (A) 172
Thymidine uptake as an indicator of cell ability and *in vitro* growth of *M. leprae*. Dhople, A. M. ..... (A) 402

Tissue(s),
Biological, chemical, immunological and staining properties of bacteria isolated from tissues of leprosy patients. Cocito, C. and Delville, J. ..... (A) 600
Detection of trehalose monomycolate in *M. leprae* grown in armadillo tissues. Dhariwal, K. R., *et al.* ..... (A) 387, 755
Lipid composition of human leprous tissue. Kumar, B., *et al.* ..... (C) 162
Nerve tissue culture: a useful model for the study of nerve damage in Hansen's disease. Antia, N. H. and Mukherjee, R. ..... (A) 176

Training,
ILEP Catalogue on Training, 1987. ..... (N) 734
Teaching of Leprosy. Proceedings of a Symposium Held on the Occasion of the 20th Annual General Meeting of the All Africa Leprosy and Rehabilitation Training Centre (ALERT). Harboe, M., ed. ..... (B) 574
Training in Leprosy; WHO publication. ..... (N) 168

Trial(s),
Application of the mouse foot-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy. Levy, L. ..... (S) 823
Characteristics of patients in the THELEP trials of chemotherapy of leprosy at Bamako and Chingleput. Subcommittee on Clinical, etc. ..... (A) 588
Chemotherapy trials in the neonatally thymectomized Lewis rat: a model for the study of the therapy of lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 776
Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Fox, W. and Kee, T. S. ..... (A) 762
[Multidrug therapy trial for leprosy in Senegal: first results about hepatic tolerance of multibacillary patients—therapeutic proposals.] Millan, J., *et al.* ..... (A) 584
The THELEP controlled clinical drug trials. Subcommittee on Clinical, etc. ..... (S) 864

Tuberculin,
Lack of tuberculin activity of synthetic peptides. Toida, I., *et al.* ..... (A) 188
[Study of new method for the application of tuberculin ointment for cutaneous use in comparison with the Mantoux test.] Levi, D. T., *et al.* ..... (A) 763
Suppression of delayed hypersensitivity skin reactions to tuberculin by *M. leprae* antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., *et al.* ..... (A) 600

Tuberculoid leprosy,
An HLA-DR3 immune response gene for *M. leprae* predisposes to tuberculoid leprosy. Ottenhoff, T. H. M. and de Vries, R. R. P. ..... (A) 779
Cold reactive lymphocytotoxic antibodies in patients with tuberculoid and lepromatous leprosy. Naik, S., *et al.* ..... (O) 273
Dapsone-induced neuropathy compounds Hansen's disease nerve damage: an electrophysiological study in tuberculoid patients. Sebille, A., *et al.* ..... (O) 16
HLA antigens and neural reversal reactions in Ethiopian borderline tuberculoid leprosy patients. Ottenhoff, T. H. M., *et al.* ..... (O) 261
Photoactivated 8-methoxypsoralen in repigmentation of tuberculoid leprosy. Srinivas, C. R., *et al.* ..... (C) 159
Suppression of delayed hypersensitivity skin reactions to tuberculin by *M. leprae* antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., *et al.* ..... (A) 600

Tuberculosis,
[Asymmetry of dermatoglyphical indices and topics of tuberculosis process in the lungs.] Zosimov, A. N. and Khodzitskaya, V. K. ..... (A) 766
Characteristics of human T-cell clones from BCG and killed *M. leprae* vaccinated subjects and tuberculosis patients; recognition of recombinant mycobacterial antigens. Mustafa, A. S., *et al.* ..... (A) 750
[Chlorprothixen efficacy in combined treatment of patients with pulmonary tuberculosis.] Gunich, L. A., *et al.* ..... (A) 762
Evaluation of subdermal biodegradable implants incorporating rifampicin as a method of drug delivery in experimental tuberculosis of guinea pigs. Mathur, I. S., *et al.* ..... (A) 604
Genes for the major protein antigens of *M. tuberculosis*: the etiologic agents of tuberculosis and leprosy share an immunodominant antigen. Husson, R. N. and Young, R. C. ..... (A) 595
Histochemical demonstration of mycobacterial antigen, specific antibody and complement in the lesions of tuberculosis. Ridley, M. J. and Ridley, D. S. ..... (A) 764
Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Fox, W. and Kee, T. S. ..... (A) 762
Management of non-respiratory tuberculosis. Wilkins, E. G. L. and Roberts, C. ..... (A) 765
Phytohemagglutinin as a skin test for the evaluation of immune competence in patients with leprosy and tuberculosis and in controls. Samuel, N. M. and Stanford, J. L. ..... (A) 385
Rationale for the histological spectrum of tuberculosis; a basis for classification. Ridley, D. S. and Ridley, M. J. ..... (A) 764
Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Khor, M., *et al.* ..... (A) 763
[Regulatory subpopulations of T lymphocytes in patients with pulmonary tuberculosis.] Averbakh, M. M., *et al.* ..... (A) 761
Report of the joint leprosy-tuberculosis project in Paraguay. Alvarenga, A. E. ..... (A) 576
[Rifampicin effect on L-transformation of mycobacterial population in patients with destructive tuberculosis of the lungs.] Karachunsky, M. A., *et al.* ..... (A) 763
[Rosette-forming T lymphocytes of different types in patients with pulmonary tuberculosis.] Petrashenko, A. I. ..... (A) 764
Serial estimation of serum lactic dehydrogenase & its isoenzymes in an active pulmonary tuberculosis. Zawar, P. B., *et al.* ..... (A) 766
[Significance of certain biochemical and immunological indices in estimation of activity of limited tuberculosis of the lungs.] Kostina, Z. I., *et al.* ..... (A) 763
[Studies on the tuberculosis infection in a cattle breeding area in sahelian Africa.] Rey, J. L., *et al.* ..... (A) 396
T-cell subpopulations in tuberculosis and the effects of rifampicin. Vidhidharm, A., *et al.* ..... (A) 610
[Testing of the hypothesis of multifactorial type inheritance of predisposition to pulmonary tuberculosis.] Berezousky, B. A., *et al.* ..... (A) 761
[The Paraguay project; a short report on a leprosy/tuberculosis eradication program.] Freerksen, E. ..... (A) 182
The relationship between natural killer cell activity and delayed-type hypersensitivity reaction of 2,4-dinitrochlorbenzene in the spectrum of chronic, intractable pulmonary tuberculosis. Yoneda, T., *et al.* ..... (A) 610

Turkey,
Mass screening in leprosy endemic areas of Turkey; preliminary report. Saylan, T. and Aytekin, A. H. ..... (A) 183

U.K.,
Dr. Thangaraj and Mr. Askew retire from TLM. ..... (N) 730
ILEP Catalogue on Training, 1987. ..... (N) 734
Mr. Neil Winship new Director for LEPRA. ..... (N) 735
OXFAM-LEPRA: Packs of Teaching and Learning Materials for Leprosy; 1982–1986. ..... (N) 367
Robert Cochrane Fund for Leprosy. ..... (N) 571
XVI General Assembly of ILEP, Edinburgh, July 1986. ..... (N) 168
Teaching video on chemotherapy of leprosy available. ..... (N) 736

The Leprosy Mission International's (TLM) teaching and learning materials in leprosy. ..... (N) 365

Ulcer(s),
Metastatis of malignant plantar ulcer in lymph nodes in femoral triangle—a case report. Bobhate, S. K., *et al.* ..... (A) 590
Microflora in the trophic ulcers of the foot in leprosy. Chatterjee, B. D., *et al.* ..... (A) 375
Plantar sensory threshold in the ulcerative foot. Birke, J. A. and Sims, D. S. ..... (A) 184
Reliability of the biothesiometer in measuring plantar vibratory thresholds. Theriot, S., *et al.* ..... (A) 416
Surgical treatment of plantar ulcers in leprosy. Rao, P. T. and Jena, S. K. ..... (A) 395
Ulcer border reshaping in the treatment of neuropathic plantar ulcers. Look, J. O. ..... (A) 415

Ultrastructure, (see also **Electron microscopy**),
An ultrastructural study of dermal nerves in early human leprosy. Chandi, S. M. and Chacko, C. J. G. ..... (O) 515
Ultrastructural changes in the blood vessel in dermal lesions of leprosy. Mukherjee, A., *et al.* ..... (A) 416
[Ultrastructure of Langerhans' cell in the skin of borderline leprosy patients.] Liu, J., *et al.* ..... (A) 382

Urine,
A Spot Test for Dapsone in Urine by Han Huikeshoven. Hastings, R. C. ..... (B) 574
Antigens of *M. leprae* in urine during treatment of patients with lepromatous leprosy. Olcén, P., *et al.* ..... (A) 384
Bedside urinalysis in untreated leprosy patients. Singh, R. G., *et al.* ..... (A) 377
Method for detecting sulfones in urine. Jaled, M. M., *et al.* ..... (C) 560
Methods for the detection of a specific *M. leprae* antigen in the urine of leprosy patients. Kaldany, R.-R., *et al.* ..... (A) 596

U.S.A.,
Cultivable mycobacteria isolated from 32 newly captured armadillos (*Dasypus novemcinctus*) from Louisiana. Portaels, F., *et al.* ..... (A) 788
Dates for 1988 and 1989 seminars at Carville. ..... (N) 571
Dr. Paul Brand honored. ..... (N) 368
Dr. Richard A. Young 1987 Molecular Parasitology Award winner. ..... (N) 736
Leprosy cases for 1986. ..... (N) 368
The Heiser Program for Research in Leprosy 1988. ..... (N) 572
The nationalization of a disease: a paradigm? Soviero, D. J. ..... (A) 370
Treatment clinics for Hansen's disease. ..... (N) 573
Twenty-Second Joint Leprosy Research Conference, Bethesda, Maryland, U.S.A., 20–22 July 1987 (U.S.–Japan Cooperative Medical Science Program). ..... (—) 767

U.S.S.R.,
Academy of Medical Sciences. Juscenko, A. A. ..... (N) 736

Vaccination,
Attenuated *M. lepraemurium* vaccine nonprotective against *M. intracellulare* infection in mice. Nakanishi, M. ..... (A) 396
Characteristics of human T-cell clones from BCG and killed *M. leprae* vaccinated subjects and tuberculosis patients; recognition of recombinant mycobacterial antigens. Mustafa, A. S., *et al.* ..... (A) 750
Delayed-type hypersensitivity in human volunteers immunized with a candidate leprosy vaccine. ..... (A) 593
Effects of ICRC antileprosy vaccine in healthy subjects. Chaturvedi, R. M., *et al.* ..... (O) 657
Humoral immune responses to *M. leprae* in human volunteers vaccinated with killed, armadillo-derived *M. leprae*. Gill, H. K., *et al.* ..... (A) 746
In vitro proliferation of lymphocytes from human volunteers vaccinated with armadillo-derived, killed *M. leprae*. Gill, H. K., *et al.* ..... (O) 30
Limiting dilution analysis of the human T cell response to mycobacterial antigens from BCG vaccinated individuals and leprosy patients. Brett, S. J., *et al.* ..... (A) 743

Mass vaccination studies initiated. (India) ..... (N) 364
[Method of immunization with BCG-M vaccine with reduced antigenic content.] Yablokova, T. B., *et al.* ..... (A) 765
Preliminary study of a *M. leprae* bacterin vaccine in a human volunteer population in a nonendemic area. Millikan, L. E., *et al.* ..... (A) 383
The relationship between delayed type hypersensitivity and protective immunity induced by mycobacterial vaccines in man. Fine, P. E. M., *et al.* ..... (A) 745

World Health Organization (WHO),
A comparative study of the efficacy of WHO and IAL multidrug therapy regimens for leprosy—an *in vivo* and *in vitro* study. Revankar, C. R., *et al.* ..... (A) 587
Disability grading in leprosy; suggested modifications to the WHO disability grading form. Brandsma, J. W., *et al.* ..... (A) 394
Preliminary evaluation of the effect of WHO-MDT on disabilities in leprosy patients in Malawi (Central Africa). Boerrigter, G. and Ponnighaus, J. M. ..... (A) 578
Results of a World Health Organization-sponsored workshop to characterize antigens recognized by mycobacterium-specific monoclonal antibodies. Engers, H. D., *et al.* ..... (A) 176
The First Joint THELEP-Sasakawa Memorial Health Foundation Workshop on Experimental Chemotherapy of Leprosy. Grosset, J., *et al.* ..... (S) 807
Training in Leprosy; WHO publication. ..... (N) 168
WHO guidelines for skin smears. ..... (—) 421
World Health Statistics Quarterly. Maxwell, B. A. ..... (B) 170